Degenotoxification of pharmaceuticals by molecular imprinting and organic solvent nanofiltration by Székely, György
 Degenotoxification of pharmaceuticals by 
molecular imprinting and organic solvent nanofiltration 
 
 
 
 
 
A thesis presented to 
 
the Faculty of Chemistry 
 
at the Technical University of Dortmund 
 
 
 
 
for the degree of 
 
Doctor of Philosophy in Chemistry 
 
(Ph.D. – Dr. rer. nat.) 
 
 
 
 
by 
 
György Székely 
 
born on the 23
rd
 of May, 1986 in Budapest, Hungary 
 
 
 
 
 
 
Supervisors: 
 
PD Dr. Börje Sellergren, Prof. Dr. Ralf Weberskirch (Technical University of Dortmund) 
 
Dr. William Heggie (Hovione FarmaCiencia SA) 
 
 
 
 
 
 
 
August 2012 

Acknowledgements 
 
 
My sincere thanks first and foremost go to my supervisors PD Dr. Börje Sellergren, Prof. Dr. 
Ralf Weberskirch and Dr. William Heggie, who gave me this great opportunity to do my PhD 
studies at the Faculty of Chemistry, Technical University of Dortmund and Chemistry 
Discipline, R&D, Hovione FarmaCiencia SA. They have not only been a great scientific 
advisors and mentors but also gave me intellectual freedom to follow my own ideas 
throughout my PhD research work. 
 
 
I would like to offer my gratitude to Dr. Marco Gil and João Bandarra who have closely 
followed my work along these past years and provided knowledge, feedback and insight from 
a pharmaceutical manufacturing perspective throughout my PhD studies. They have truly 
contributed to narrowing the gap between academic research and industrial needs related to 
my research project. I acknowledge with thanks and appreciation my consultant Dr. Frederico 
Ferreira from the Technical University of Lisbon for his continuous support and availability, 
and of course the abundant late-night meetings throughout my PhD project. 
 
 
Very special thanks go to my ex-colleagues and friends from the Budapest University of 
Technology and Economics, Péter Pogány and József Kupai for their great advice and fruitful 
discussions, but most of all for enriching my life so much in their own way for many years. I 
would like to express my satisfaction about the successful collaboration on molecular 
modeling with Peter. I would like to thank Dr. Sérgio Marques from the Technical University 
of Lisbon for enabling use of the NMR facilities at the IST-UTL center and technical 
assistance with the measurements. Furthermore, I would like to thank to all my colleagues 
both in Dortmund and Hovione for the many interesting and engaging discussions, among 
which special thanks go to Dr. Javier Urraca, Mahadeo Halhalli, Emelie Fritz from Dortmund 
and to Bruno Henriques, Dr. Rui Loureiro and Katalin Kováts from Hovione. I am grateful to 
Carlos Alvarez for sharing his knowledge and experience about design of experiments and for 
the useful discussions. 
Many thanks to Dr. Ecevit Yilmaz and Rüstem Keçili from MIP Technologies Biotage AB for 
their help and support during my technical placement and also making my stay in Sweden 
quite enjoyable! I am grateful to Dr. Andrew Livingston for enabling my secondment in 
Imperial College and to his group for their never-ending advice and the excursions … without 
which I would not have enjoyed as much my time in London! The vibrant and welcoming 
multinational environment of the group was a great help both academically and socially. 
 
 
I wish to acknowledge the financial support of the European Commission under FP7 – Marie 
Curie Actions, contract PITN-GA-2008-214226 [NEMOPUR] for my PhD scholarship. 
Furthermore, I am pleased to thank Hovione as well for giving me the opportunity of carrying 
out most of my research work in its R&D center. The stimulating environment of this 
company has helped immensely in improving my organizational skills and gave me great 
opportunities for networking and broadening my knowledge in various fields, not to mention 
the possibility of being able to express my scientific ideas. 
 
 
At last but not least, I would like to thank my family for their patience and continuous support 
throughout my studies. 
Table of contents 
 
Glossary of the recurrent abbreviations used in this thesis        1 
 
Summary               4 
 
1. Introduction              7 
   1.1. Identification of the problem – genotoxic impurities in pharmaceuticals      7 
      1.1.1. Sulfonic esters and their precursors        11 
      1.1.2. Dialkylsulfates           13 
      1.1.3. Alkyl halides           13 
      1.1.4. Acetamide and thioacetamide         14 
      1.1.5. N,N-dimethylcarbamoyl-chloride         14 
      1.1.6. Aminopyridines           15 
      1.1.7. Ureas            15 
      1.1.8. Aldehydes            16 
   1.2. Design of experiments for the analysis of genotoxic impurities     17 
   1.3. Purification of pharmaceuticals         18 
   1.4. Green process engineering          23 
   1.5. Organic solvent nanofiltration          24 
   1.6. Molecular imprinting           28 
      1.6.1. Concept of molecular imprinting         28 
      1.6.2. Investigation of complexes in the pre-polymerization solution     30 
      1.6.3. Role of NMR and FTIR in molecular recognition studies of MIPs    31 
      1.6.4. In silico approaches to understand molecular imprinting phenomena    33 
 
2. Materials             34 
 
3. Methods             35 
   3.1. DoE approach for GTI quantification         35 
      3.1.1. Instrumentation LC-MS/MS         35 
      3.1.2. Operating conditions LC-MS/MS         35 
      3.1.3. Standard solution and sample preparation       36 
      3.1.4. Design of experiments          36 
      3.1.5. Validation study           37 
   3.2. NMR titrations, continuous variation method and FTIR      38 
   3.3. Solid phase characterization of the scavengers       39 
   3.4. Nanofiltration methods and mathematical framework      41 
   3.5. IPU selective MIP preparation         44 
   3.6. Swelling experiments           45 
   3.7. Bulk rebinding tests           45 
   3.8. Solid phase extraction methods         46 
   3.9. Recrystallization           47 
   3.10. Flash chromatography          48 
 
4. Results and discussion           50 
   4.1. GTI analysis by LC-MS/MS via DoE approach       50 
      4.1.1. DMAP fragmentation and MS risk assessment for DoE      50 
      4.1.2. Determination of the optimal LC-MS/MS method via DoE     52 
      4.1.3. Robustness of the method          57 
      4.1.4. Validation of the method          59 
         4.1.4.1. LOD and LOQ assessment         59 
         4.1.4.2. System precision          60 
         4.1.4.3. Linearity           60 
         4.1.4.4. Repeatability           60 
         4.1.4.5. DMAP recovery in Mometasone furoate       60 
   4.2. Comparison of conventional and nanofiltration API purifications     61 
      4.2.1. Overall process performance comparison        62 
      4.2.2. Stepwise process performance comparison       63 
      4.2.3. Scale-up considerations          67 
      4.2.4. Inventory and cost analysis         71 
      4.2.5. Environmental and economic impact        75 
   4.3. Screening of OSN membranes         78 
      4.3.1. API and GTI rejections and fluxes        78 
      4.3.2. Membrane stability test with peroxide        83 
      4.3.3. Diafiltrations           84 
   4.4. Screening and designing molecularly imprinted scavengers      89 
      4.4.1. In search for IPU selective scavengers – ExploraSep® screening    89 
      4.4.2. Design and characterization of the novel scavengers      90 
      4.4.3. Molecular recognition dependence on deprotonating agents     95 
         4.4.3.1. Geometrical parameters of the pre-polymerization complexes    95 
         4.4.3.2. Effect of the deprotonating agent on the complexation mechanism    99 
         4.4.3.3. Effect of the deprotonating agent on the complexation strength  102 
         4.4.3.4. MIP performance-modification indicators     106 
   4.5. OSN-MIP hybrid process for API degenotoxification    110 
      4.5.1. Stage 1 evaluation: organic solvent nanofiltration    112 
         4.5.1.1. Membrane selection and solvent impact     112 
         4.5.1.2. Organic solvent nano diafiltration      114 
      4.5.2. Stage 2 evaluation: molecularly imprinted polymer phases   115 
         4.5.2.1. IPU removal from APIs by the novel scavengers    115 
         4.5.2.2. Eluent selection: API recovery and MIP regeneration   120 
         4.5.2.3. Robustness of MIP recyclability      122 
      4.5.3. Exploring OSN diafiltration and MIP polishing of the retentate   123 
 
5. Conclusions and future outlook        126 
 
6. Appendix           131 
   6.1. Tables           131 
   6.2. Figures           139 
 
7. Publications resulting from the work carried out in this thesis   144 
   7.1. Articles           144 
   7.2. Patents           145 
   7.3. Posters           145 
   7.4. Lectures          147 
 
8. References           148 
 
 1 
Glossary of the recurrent abbreviations used in this thesis 
 
Δδ chemical shift change 
 solvent flux 
 arbitrary time tolerance constant 
 surface coverage 
AA acetamide 
ABDV 2,2'-azobis(2,4-dimethylvaleronitrile) 
ACR acrolein 
AI accelerating index 
Am membrane area 
Apeak peak area 
API active pharmaceutical ingredients 
AR apparent recovery 
BE 2-bromo-ethanol 
BET Brunauer-Emmett-Teller adsorption theory 
Beta Betamethasone 
BSSE basis set superposition error analysis 
CCF central composite face 
CF,x concentration of solute x in feed 
CHU 1,3-dicyclohexylurea 
CMI capacity modification index 
COST changing one single factor at a time  
CP,x concentration of solute x in permeate 
CR,x concentration of solute x in retentate 
CVM continuous variation method 
D diavolume, dilution ratio 
DCM dichloromethane 
DFT fensity functional theory 
DMAP 4-dimethylaminopyridine 
DMCC N,N-dimethylcarbamoyl-chloride 
DMS dimethylsulfate 
DoE design of experiment 
Ecol collision energy 
Econ cone voltage 
EDMA ethylene glycol dimethacrylate 
EMA European Medicine Agency 
EtMS ethyl methanesulfonate 
EtTS ethyl p-toluenesulfonate 
F flow 
FC flash chromatography 
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FDA Food and Drug Administration 
FF fractional factorial design 
FIA flow injection analysis 
FTE full time equivalent 
FTIR Fourier transform infrared spectroscopy 
G gradient 
GTI genotoxic impurity 
Halo Halobetasole proprionate 
IF imprinting factor 
IPU 1,3-diisopropylurea 
Irb Irbesartan 
K association constant 
KP Keppra 
LA Lacosamide 
LOD limit of detection 
LOQ limit of quantification 
MAA either protonated or deprotonated methacrylate 
MAA
–
 methacrylate anion 
MAAH methacrylic acid 
MEK methyl ethyl ketone 
MeMS methyl methanesulfonate 
Meta Mometasone furoate 
MeTS methyl p-toluenesulfonate 
MIBK methyl iso-butyl ketone 
MIP molecularly imprinted polymer 
MRM multiple reaction monitoring 
MS mass spectrometry 
MsCl methanesulfonyl chloride 
MTBE methyl tert-butyl ether 
Mw molecular weight 
NBO natoral bond orbital analysis 
NIP non-imprinted polymer 
OSN organic solvent nanofiltration 
p pressure 
PDMS polydimethylsiloxane 
PI performance index 
PMP 1,2,2,6,6-pentamethylpiperidine 
Pred Prednisolone 
Q
2
 predictability  
R reproducibility  
R
2
 model fit 
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RC recrystallization 
Rf retention factor 
Roxi Roxithromycin 
RSD relative standard deviation 
Rx membrane rejection of solute x 
S/N signal to noise ratio 
SEM scanning electron microscopy 
Sep separation of peaks 
SIM single ion monitoring 
SPE solid phase extraction 
Suma Sumatriptan 
t time 
T temperature 
TA thioacetamide 
TGA thermogravimetric analysis 
THF tetrahydrofuran 
TLC thin layer chromatography 
TTC threshold of toxicological concern 
V validity of the model 
Vadd volume of fresh solvent added during diafiltration 
VF feed volume 
Vinj injection volume 
VP volume of permeate 
Vpo pore volume 
VR volume of retentate 
VSE spherical equivalent volume  
Vswelling specific swelling volume 
x mole fraction 
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Summary 
 
The thesis discusses molecular imprinting (MI) and organic solvent nanofiltration (OSN) as 
tools for degenotoxification of pharmaceuticals. The manufacturing of active pharmaceutical 
ingredients (APIs) often involves the use of highly reactive reagents, which could remain as 
undesired residues in the final product. Genotoxic impurities (GTIs) represent an accentuated 
class of compounds that can participate in an electrophilic attack on the nucleophilic center(s) 
of the DNA. Pharmaceutical regulatory authorities have recently issued guidelines on the 
control of GTIs. In general, GTIs have severe impact on the product risk assessment and 
hence, degenotoxification of APIs is of great interest to the Pharmaceutical Industry. A 
comparative study of flash chromatography and recrystallization, both conventional API 
purification technologies, versus OSN was performed in order to evaluate the feasibility and 
sustainability of OSN as a potential API purification technology. Solvent recycling, mass and 
carbon intensity and energy consumption were considered. A cost analysis was also carried 
out in order to take into account both environmental and economical aspects during the 
process comparison. OSN was proven to be competitive and hence various solvent resistant 
nanofiltration membranes were screened in THF, MEK and DCM. Eleven GTIs and nine 
APIs of industrial interest were used as model compounds and various diafiltration studies – 
featuring increasing technical difficulties – were carried out. GTIs with higher rejections can 
present significant challenges to OSN. For this reason, the effect of pressure change on solute 
rejection was explored to improve degenotoxification without provoking an increase in API 
loss. Subsequently, 1,3-diisopropylurea (IPU) – representing an OSN case with higher GTI 
rejection – was chosen for further investigation involving MI. Commercially available 
ExploraSep
®
 Plate A with scavengers featuring different hydrophobic and carboxylic acid 
moieties that can possibly bind IPU were screened. Due to the limited performance of the hit 
scavenger, novel scavengers were designed to selectively bind IPU in the presence of APIs. 
The design constituted methacrylic acid (MAA) as functional monomer and ethylene glycol 
dimethacrylate as cross-linker whilst involving the exploitation of 1,2,2,6,6-
pentamethylpiperidine (PMP) as deprotonating agent. The novel imprinted along with the 
corresponding non-imprinted scavengers were successfully tested for degenotoxification in 
the presence of various APIs of different chemical classes. On comparing the effectiveness of 
imprinting and nanofiltration, it was concluded that the scavengers function better at low GTI 
concentrations, whilst OSN at high GTI concentrations. Hence, a synergistic OSN-MI hybrid 
approach was proposed for IPU removal and the recovery of non-specifically bound API by 
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means of selective elution from the scavenger was developed. The effect of the deprotonating 
agent, PMP, both on the self-assembly prior to polymerization and on the molecular 
recognition of imprinted scavengers, was investigated by both experimental (NMR, FTIR) 
and in silico (DFT) tools. The continuous variation method revealed the presence of higher-
order complexes and the appearance of self-association, which were both taken into account 
during the determination of the association constants. The assessment of the impact of the 
deprotonating agent on the molecular recognition behavior of scavengers called for 
introduction of performance-modification indicators such as capacity modification index, 
accelerating index and overall performance index. 
 
Zusammenfassung 
 
In dieser Arbeit wurden das molekulare Prägen (MI) und die Nanofiltration organischer 
Lösungsmittel (OSN) als Werkzeuge für die Entfernung genotoxischer Substanzen aus 
pharmazeutischen Stoffen  untersucht. Die Herstellung von aktiven pharmazeutischen 
Wirkstoffen (APIs) beinhaltet oft die Verwendung von hochreaktiven Reagenzien welche als 
bedenkliche, genotoxische Reststoffe im Endprodukt verbleiben können. Genotoxische 
Verunreiningen (GTIs) stellen hierbei eine Gruppe von Stoffen dar, die elektrophile 
Reaktionen mit nucleophilen Gruppen der DNS eingehen können. In der pharmazeutischen 
Industrie ist das Interesse bezüglich der Entfernung von GTIs von höchster Bedeutung, da 
GTIs gegebnermassen ein erhöhtes Risiko für das pharmazeutische Produkt darstellen. Zwei 
herkömmliche API Aufreinigungstechniken, die Flash Chromatographie und die 
Umkristallisierung wurden in einer Machbarkeitsstudie mit OSN verglichen um deren 
Tragfähigkeit als Aufreiniungsschritt zu ermitteln. Hierbei wurden das Recycling des 
Lösungsmittels, Massenverluste, Kohlenstoffbelastung und Energieverbrauch berücksichtigt. 
Es wurde auch eine Kostenanalyse vorgnommen, um die wirtschaftlichen und 
umweltrelevanten Aspekte der verschiedenen Prozesse zu vergleichen. Dabei hat sich 
ergeben, dass OSN eine gleichwertige Leistung aufzeigt, weswegen die Untersuchung auf 
lösungsmittelresistente Membranen erweitert wurde. Eine Reihe von APIs und dazugehörigen 
GTIs wurden als Modelsubstanzen in verschiedenen Diafiltrationsversuchen untersucht. Dies 
erwies sich als technische Herausforderung, da GTIs ebenfalls von den Membranen 
ausgeschlossen wurden. Um die Entfernung von GTIs zu optimieren und die Verluste von 
API zu verringern, wurde der Einfluss von Druck auf den Ausschluss von gelösten Stoffen 
untersucht. In einer weiteren Studie wurden molekular geprägte Materialien auf ihre 
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Selektivität bezüglich 1,3-Diisoproylurea (IPU) untersucht, da diese einen höheren 
Ausschluss aufweisen. Handelsübliche ExploraSep
®
 Platten A basierend auf selektiv 
bindenden Harzen mit hydrophoben und Carbonsäure-Gruppen wurden auf Bindung zu IPU 
untersucht. Da diese jedoch eine unzureichende Funktionalität aufwiesen, wurden neue Harze 
mit  Methacrylsäure und mit Hilfe eines Deprotonierungsreagenzes synthetisiert. Diese 
neuartigen geprägten Polymere und die entsprechenden nicht-geprägten Kontrollpolymere 
zeigten eine erfolgreiche Entfernung von GTIs von verschieden APIs. Der Vergleich von 
geprägten Polymeren und OSN ergab, dass die geprägten Harze besser bei geringen GTI 
Konzentrationen funktionieren und die OSN Membranen besser bei hohen. Diese Erkenntis 
führte dann zu einer synergistischen Kombination von OSN und MI um IPU zu entfernen und 
unspezifisch gebundenes API in einem selektiven Waschschritt vom Harz zu lösen. Mittels 
NMR wurde der Einfluss des Deprotonierungsreagenzes sowohl auf die Vorpolymerisation 
als auch auf die Wiedererkennungseigenschaften des Harzes untersucht. Es wurde beobachtet, 
dass sich Komplexe höherer Ordnung und auch Selbst-Assoziationen ausbilden, welche dann 
in der Bestimmung der Assoziationskonstanten berücksichtigt wurden. Die Einführung von 
Leistungs-Änderungs-Indikatoren, wie zum Beispiel Kapazitäts-Änderungs-Index, 
Beschleunigungs-Index und Gesamtleistungs-Indikatoren wurden vorgeschlagen. 
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1. Introduction 
 
My PhD research project falls into two areas that, at first glance, appear to be rather different, 
but that are in reality closely related through the common thread of separation science on a 
molecular scale. The major thrust of the work is at the interface of process chemistry and 
material science. In short, the aim was to develop and implement new methodologies for 
pharmaceutical downstream processing, particularly for the removal of genotoxic impurities 
(degenotoxification). Having a synthetic organic chemistry background, I think of systems on 
the molecular level which provided me with a perspective that is different from that of pure 
engineers, with whom I collaborated extensively during the past years. Because efficient 
degenotoxification requires operations on the molecular level, I was able to propose solutions 
to scientific problems that are not on the “radar screen” of these colleagues. Improved 
properties have been gained from the profound molecular scale design. To understand the 
basic principles that govern the recognition of the novel scavengers a thorough investigation 
has been carried out. It is worth mentioning that besides separation science – which is the core 
of the present thesis – both membranes and molecular imprinting are of paramount 
importance on account of many potential applications in diverse fields such as bio- and 
chemisensors
1,2
, targeted delivery of drugs
3
, tools in drug discovery
4
 and catalysis of chemical 
reactions
5,6
. 
 
1.1. Identification of the problem – genotoxic impurities in pharmaceuticals 
 
Cancer is the second cause of death in Western countries, after the circulatory diseases. 
Therefore, nowadays cancer and its prevention are among the most critical health issues. 
According to the World Health Organization (WHO), the worldwide cancer burden is set to 
increase by 50% in 10 years unless further preventive measures are put into practice. 
Therefore, there is an increasing awareness dedicated to potential causes of cancer. Most 
pharmaceutical products are manufactured either by applying a total synthesis approach or 
modification of a naturally occurring product. In both cases a wide range of reactive 
molecules are introduced into the synthetic sequence many of which are genotoxic themselves 
or may form genotoxic compounds that can contaminate the final product reaching patients. 
Thus, pharmaceutical regulatory agencies such as the Food and Drug Administration (FDA) 
and European Medicinal Agency (EMA) have raised concerns on the presence of genotoxic 
impurities (GTIs) in active pharmaceutical ingredient (APIs) that could impact negatively on 
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human health and have issued guidelines controlling their limits in APIs. To address their 
concerns, R&D scientists have to identify GTIs early on during process development, develop 
analytical methods and demonstrate the control of synthetic processes leading to GTIs. The 
objective of the present chapter is to highlight the importance of GTIs in API manufacturing 
and present examples and reagents related to them. As shown in Figure 1, obtained from the 
ISI Web of Science, July 2012, there is an increase in the literature on this topic demonstrated 
by the increasing number of hits on “genotoxicity” and hits on “genotoxic impurity” in 
literature searches
7
. The graph based on the former search shows the overall importance of the 
field of genotoxicity including chemistry, analytical methods, manufacturing, purification, 
diseases, medical aspects, genotoxicity tests, mechanism of action, assessment and 
environment, whilst the latter search shows the increasing attention of GTIs by the industry, 
mainly related to drugs and food. 
 
 
 
Figure 1 – Importance of genotoxicity demonstrated by the increasing 
number of publications on "genotoxicity” and “genotoxic impurity”    
- 
Detailed reviews on the risk assessment
8
, toxicology
9
 and mechanism of action
10
 of such 
compounds can be found in the literature. The book Genotoxic Impurities edited by Teasdale 
provides an exhaustive discussion on the identification and control of such impurities in API 
manufacturing
11
. It should be noted, that compounds categorized as GTIs actually include a 
broad range of unrelated chemicals with very different structures and from very different 
chemical families. These compounds have in common their ability to react with DNA 
resulting in an associated carcinogenic risk. However, from a chemical point of view they do 
not have common chemical-physical properties or chemical structural elements that can 
contribute to easy identification. On the other hand, their presence in the manufacture of APIs 
is not stochastic, since these chemicals often have specific inherent roles in the chemical 
 9 
routes used in API synthesis. In-silico systems such as DEREK can be used for determination 
of structural alerts, however for numerous chemical classes, structural alerts can over-predict 
genotoxicity due to factors such as high molecular weight, hydrophilicity, high reactivity, 
steric hindrance, molecular symmetry, and facile metabolism
12,13
. The mechanism of action of 
genotoxins involves an electrophilic attack on the nucleophilic center(s) of the DNA, these 
being: nitrogen and oxygen atoms of pyrimidine and purine bases and the phosphodiester 
backbone which could, in some circumstances, lead to strand breaks (Figure 2). Bidentate 
genotoxic agents can react with two nucleophilic sites resulting in: (i) one single molecule 
giving a bicyclic or tricyclic system; (ii) involving two different molecules in the same or the 
opposite DNA strand affording inter- or intrastrand cross-linkages respectively or; (iii) linking 
a protein and a DNA strand giving a DNA-protein adduct
4
. Besides the chemical nature of the 
genotoxic agent, the stereospecificity of the reactions also depends on steric factors and 
nucleophilicity, for instance the most nucleophilic sites of the DNA bases are endocyclic 
nitrogens such as N3 and N7 of guanine and adenine, on the contrary, exocyclic oxygens are 
less nucleophilic
14
. 
 
 
 
Figure 2 – Attack of the DNA by genotoxins where the 
arrows indicate the target nucleophilic sites of the DNA bases 
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Impurities, especially genotoxic impurities have been at the centre of increasing regulatory 
and industry attention in the last decade. EMA was the first authority to implement detailed 
guidelines on how such impurities should be controlled shortly followed by the FDA. Both 
authorities agreed on the implementation of the Threshold of Toxicological Concern (TTC) 
which sets a limit of 1.5 g.day-1 for known and potential carcinogens unless experimental 
evidence justifies higher limits. Higher levels can be applied in shorter-term studies during the 
clinical testing of the APIs. The rational behind such low values is to ensure that even if a 
substance was later found to be carcinogenic negligible risk would be maintained
15
. An 
exhaustive effort has to be made by the industry to meet such requirements and since many of 
the potentially genotoxic agents turned out to pose far less risk than originally supposed, the 
TTC approach is considered to be conservative. Nonetheless, GTI thresholds at such low 
levels are here to stay and the industry has been addressing this challenge with a variety of 
control and purification strategies. Regardless of the strategy selected for GTI mitigation, 
before its implementation it is crucial to identify and map the occurrence of the GTI in the 
API manufacture steps. Table 1 provides a list of genotoxic-alerting functional groups 
associated with the various reactions commonly employed today in pharmaceutical 
development and manufacturing
16
. Using this table as starting point, an overview on 
genotoxic impurities, focusing only on individual chemical classes which were experimentally 
investigated in the thesis will follow. The knowledge systematically gathered on GTI 
formation helped in the assessment of both new and alternative synthetic routes and allowed 
us to make a more confident decision to embark on purification strategies. Early realization of 
possible genotoxic contamination of the API improves time lines and safety by avoiding 
wasted effort on processes with no long-term future and in addition directs the focus on the 
relevant purification technology. 
 
Table 1 – Common synthetic transformations related to potential genotoxic alerts 
 
Bond formation 
Alerting group Associated reactions 
C-O C-C C-N AHC
*
 
X X X  Halides & sulfonates Williamson ether synthesis 
X X X X Michael acceptors Michael reaction 
X X X  Epoxides Sharpless asymmetric epoxidation 
X  X X Aldehydes Aldol & Claisen condensation 
X    Haloalkanes Heck, Sonogashira, Kumada, Suzuki 
  X X (Alkyl)aminoaryls common intermediate 
*
aromatic heterocycle   
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1.1.1. Sulfonic esters and their precursors 
 
Sulfonic esters are alkylating agents, which are a class of potentially genotoxic compounds
17
. 
They are called alkylating agents due to their ability per se, or after metabolic activation, of 
adding alkyl residues to the reactive nucleophile sites of the DNA bases. They cover a wide 
range of chemical structures from the simple methyl group to more complex structures 
featuring aromatic systems with various functional groups. Hence, there is a growing concern 
expressed by regulatory authorities in relation to contamination of APIs by these GTIs. 
Usually sulfonic esters are not introduced into the API synthetic route directly, but by 
contamination by side-reactions. Precursors of genotoxic impurities during API synthesis are 
called forgenotoxins. Forgenotoxins of sulfonic esters are alkyl and aryl sulfonic acids and the 
corresponding halides and anhydrides which can all form sulfonic esters. Examples of such 
compounds are mesylates (methanesulfonates), triflates (trifluoromethanesulfonates), 
tosylates (p-toluenesulfonates), besylates (benzenesulfonates) and nosylates (p-
nitrosulfonates). Sulfonic ester impurities are often contaminants of APIs: (i) due to their 
formation in side-reactions between sulfonic acids or halides and alcohols or; (ii) as reactants 
carried over from incomplete reactions. When any of the forgenotoxin is used in an API 
synthesis there is always a possibility of the formation of genotoxic sulfonic esters. In 
particular, reactions containing sulfonic acids, sulfonic halides or sulfonic anhydrides in the 
presence of an alcohol, even if only in residual amounts, have the potential to yield sulfonic 
esters. Therefore, the European Pharmacopoeia production requirement for APIs marketed as 
sulfonic acid salts specifies that is compulsory to demonstrate that in such cases any formed 
ester is removed during the API purification process
8
. Hence, it is crucial for scientists 
working in the field of API manufacturing to be aware of the forgenotoxins and their use in 
drug synthesis. Due to their synthetic versatility sulfonate derivatives are common and useful 
reagents in the pharmaceutical industry especially in reactions where carbonium ion initiation 
is needed. They are widely used as salt forming agents, good leaving groups in nucleophilic 
substitutions reactions, protecting groups and for the resolution of enantiomers. Sulfonic acids 
are common salt forming agents used in the last step of the API synthesis. The conversion of 
an API to a salt enhances its stability and water solubility and helps its isolation as final 
product (Figure 3). Elder et al.
18
 overviewed the utility, safety and regulation of APIs 
formulated as sulfonic acid salts. The potential for the tosylate salt forming agent to react with 
the alcoholic solvent to give a potentially genotoxic alkylating ester is a concern. 
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Figure 3 – Utility of sulfonate salts in API manufacturing 
 
A particular but representative example, in which the formation of GTI has severe impact in 
API supply, is the Viracept case study. In 2007, contamination with genotoxic sulfonate ester, 
ethyl mesylate (EtMS) led to the global recall of this drug
19
. The case was investigated and it 
was established that the main GTI accumulation took place in the final manufacturing step. In 
this step the API salt, nelfinavir mesylate is formed as a soluble product by addition of 
methanesulfonic acid (MsOH) to a suspension of nelfinavir in ethanol. In the final step spray 
drying is used to isolate the dissolved nelfinavir mesylate salt from the ethanolic solution. The 
problem was that during this salt formation acidic conditions, combined with long reaction 
times and elevated temperatures, were used which favors MsOH reaction with ethanol to give 
the corresponding genotoxic ester, the primary source of GTI contamination in the process. 
Additional sources for accumulation of EtMS were also identified, such as supply of MsOH 
already containing some EtMS as impurity, reaction of MsOH with ethanol used to clean 
MSA holding tank and not properly removed before refilling, and cleaning of the spray dryer 
with ethanol, whose vapors could reach the MsOH hold tank through the ventilation system 
contributing again to additional EtMS formation
20
. Therefore, the conclusion of the Viracept 
case study points out that GTI contamination of API can result from a wide range of difficult 
to anticipate sources: pH adjustment problems; charging speed of a chemical to the reaction 
mixture; raw material supplier; pipelines and reagent holder tanks; cleaning procedures; 
drying procedures; prolonged reaction time; elevated temperature; introducing genotoxic 
reagent during the API production (more significant in the final steps). 
 13 
1.1.2. Dialkylsulfates 
 
The most common dialkylsulfates used in the pharmaceutical industry are the methyl and 
ethyl derivatives, the latter having been used as a war gas
21
. Being a strong methylating agent 
dimethyl sulfate (DMS) is used to introduce a methyl group in atoms featuring unshared 
electron pairs, such as oxygen, nitrogen, carbon, sulfur, phosphorus and some metals. 
Comparing with the alkyl halide type methylating agents, DMS is more favorable due the 
higher reaction rate and lower possibility of by-product formation
22
. Usually methylation with 
dimethyl sulfate requires the presence of a base, either: (i) to intensify the reactivity of the 
reaction site (e.g. converting the phenolic hydroxyl group of vanillin to sodium phenolate 
during the first step of Papaverine synthesis) or; (ii) to neutralize the by-products of the 
reaction, monomethyl sulfate (MMS) and sulfuric acid, for example in the case of the 
methylation of aliphatic alcohols. Usually only one of the methyl groups of DMS reacts in the 
methylation reaction because the MMS formed is a much weaker alkylating agent than the 
original DMS. Although, for research purposes – in small scale preparations – there is little 
necessity to use both methyl groups, in manufacturing – large scale production – in cases 
where the substrate is reactive enough to be methylated by MMS (e.g.: the sodium salt of 
mercaptans) it is desirable to utilize both groups if possible. In order to do so the reaction 
conditions are adjusted as follows: (i) increase the reaction temperature and; (ii) apply 
anhydrous conditions and avoid excess base to suppress the competing reactions with water 
and the hydroxide ion. To obtain the best results the base can be introduced to the reaction 
mixture continuously in small portions as the reaction proceeds but limiting this to the extent 
of the acid formed to minimize the competing reaction with the hydroxide ion. Non-aqueous 
solvent-base systems such as DMF/K2CO3 can be used in certain cases. 
 
1.1.3. Alkyl halides 
 
Methyl, ethyl and propyl halides are used widely as industrial alkylating agents. Although the 
mechanism of their toxicity is still not fully understood, they have been shown to directly 
alkylate critical biologically active macromolecules such as proteins and DNA
23
. Geminal, 
vicinal and ω-bifunctional alkyl halides are also directly used in API synthesis of which ω-
alkyl dihalides are common linking agents due to their ability to connect API intermediates 
via consecutive alkylation. It was hypothesized that bifunctional alkanes cause genotoxic 
damage by the glutathione-dependent pathway and consequent formation of toxic 
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methanethiol
24
. Nitrogen and sulfur mustards (e.g. 2,2-dichlorodiethylsulphide) represent a 
special class of alkyl halides and have been used as chemical weapons. They are potential 
alkylating agents and their toxicity is attributed to cross-ling between DNA strands
25
. The 
source of alkyl halide contamination in APIs can be derived not only from direct use of alkyl 
halides, but from side-reactions between alcoholic solvents and hydrogen halides or de- 
quaternization of ammonium salts. APIs may be contaminated with genotoxic alkyl halides 
when a reaction takes place in alcoholic solvent at reflux temperature in the presence of 
hydrogen halides. These reaction conditions may be applied in cyclization, decarboxylation, 
sulfonyl cleavage, N-arylation and API salt formation. Alcoholic hydrogen chloride can also 
be used for ring openings. 
 
1.1.4. Acetamide and thioacetamide 
 
Acetamide (AA) is a known carcinogen, thus the awareness of its formation in API 
manufacturing is crucial
26
. Acetamide is not used directly, but its derivatives such as 2- and 
N-bromoacetamide or trifluoroacetamide are often used as building blocks in drug synthesis. 
These derivatives initially contain acetamide as impurity but also the 2- and N- derivatives 
have potential to form acetamide depending on the reaction conditions. Another source of 
carcinogenic acetamide contamination is the hydrolysis of the widely used solvent acetonitrile 
under acidic or basic conditions at elevated temperature. Acetonitrile is not only used as a 
solvent in the pharmaceutical industry, but also as a reagent in API synthesis. For instance it 
is directly used as a reagent in the synthesis
27
 of Corontin. Thioacetamide (TA) is anticipated 
to be a human carcinogen based on evidence of carcinogenicity in experimental animals
28
. TA 
is an organosulfur compound soluble in water and serves as a source of sulfide ions in the 
synthesis of organic and inorganic compounds, thus often non reacted portions contaminate 
later phases of API synthesis. 
 
1.1.5. N,N-dimethylcarbamoyl-chloride 
 
N,N-dimethylcarbamoyl-chloride (DMCC) is listed under amides in the thesis for the sake of 
simplifying the classification of genotoxic impurities, but note that it is a half acyl chloride, 
half amide of carbonic acid and its reactions are driven by the acyl chloride moiety. DMCC is 
also considered carcinogenic
29
 and it is used as an alkylating agent, similar to the sulfonate 
esters describe above, providing good leaving groups, thus it is used as a chemical 
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intermediate in the production of dyes, pesticides and pharmaceuticals
30
. An example of its 
application in API synthesis is in N-heterocyclic compounds, for example Carbamayepine
31
. 
 
1.1.6. Aminopyridines 
 
Derivatives of aminopyridines are often used as starting material or catalyst during API 
synthesis. During the preparation of glucocorticoids in order to replace the 21-hydroxyl group 
with a chlorine, sulfonyl chlorides are used in a 4-dimethylaminopyiridne (DMAP) catalyzed 
sulfonylation reaction
32
. DMAP has alerting structures for genotoxicity and thus can be 
considered a potentially genotoxic impurity
33,34
. Besides the sulfonylation reactions DMAP is 
also used in acylations
35
, esterifications
36,37
, amino group protections with Boc
38,39
 and 
sylilations
40
.
 
 
1.1.7. Ureas 
 
1,3-diisopropylurea (IPU) and 1,3-dicyclohexylurea (CHU) are the most common impurities 
of the urea chemical class, which are potentially genotoxic impurities
41
. Ureas are the direct 
and unavoidable hydrolyzation product of carbodiimides. Carbodiimides are stabilizing, 
coupling and condensing agents in the preparation of peptides and nucleotides; versatile 
dehydration reagents in organic synthesis
42,43
 and often used to activate carboxylic 
acids towards amide or ester formation
44
. 
 
 
 
Scheme 1 – Formation of 1,3-diisopropylurea from 
dehydrating agent 1,3-diisopropylcarbodiimide      
- 
Reagents such as 1,3-diisopropylcarbodiimide (DIC) and 1,3-dicyclohexylcarbodiimide 
(DCC) are the most important discoveries that helped to drive the field of peptide synthesis
45
 
and probably the most popular of the carbodiimides-type coupling reagents in use today
46
. 
IPU and DCC are considered to be dehydrating agents inasmuch as the results are a loss of 
water from the amino and carboxyl groups involved in the coupling. Carbodiimide mediated 
crosslinking is usually used in the polymerization of polypeptides, and thus widely used in 
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immobilization procedures (e.g., attaching proteins to a carboxylated surface) and in 
immunogen preparation (e.g., attaching a small peptide to a large carrier protein). In this 
reaction, carbodiimides react first with carboxylic acid groups to form an active O-acylisourea 
intermediate, this intermediate is easily displaced by nucleophilic attach from primary amino 
group in the reaction mixture. The primary amine forms an amide bond with the original 
carboxyl group, and the by-product is released as a soluble urea derivative. The O-acylisourea 
intermediate is unstable in aqueous solutions, and its hydrolysis result on regeneration of the 
carboxyl group and release of an N-unsubstituted urea
47
 (Scheme 2). 
 
 
 
Scheme 2 – Use of carbodiimides in API synthesis with urea formation: (A) 
DIC reacts with carboxylic acid group and activates the carboxyl group, 
allowing it to be coupled to the amino group in the reaction mixture; (B) DIC 
is released as a urea derivative after displacement by the nucleophile, R4NH2  
- 
 
1.1.8. Aldehydes 
 
Aldehydes are important molecules used as building block in the production of 
pharmaceuticals, however many of them are inherently genotoxic, and thus when reactions 
are incomplete, their removal is required. Acrolein (ACR) is an unsaturated aldehyde, and 
was selected as a GTI representative of this class. Acrolein is a severe pulmonary irritant and 
lachrymatory agent, causes serious damage to skin, and exposure to it in concentrations of 2 
ppm is immediately harmful. Acrolein was used as a chemical weapon during World War I. 
Studies on rats have shown an increase in cancerous tumors from ingestion (but not from 
inhalation). Also in vitro studies show that acrolein can react directly with DNA and proteins 
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to form stable adducts and that it induces gene mutations in mammalian cells, nevertheless 
ACR is used as reactant during the synthesis of various APIs, e.g. Methionine
48
. 
 
1.2. Design of experiments for the analysis of genotoxic impurities 
 
The pharmaceutical regulatory authorities, such as FDA and EMA periodically issue 
guidelines on the limits of GTIs in APIs. These guidelines make it critical to be able to 
determine ultra low levels of traces impurities and also imply the continuous assessment of 
additional purification steps for the removal of GTIs from the API
49,50
. Prior to the 
investigation of potential degenotoxification methodologies, reliable analytical methods had 
to be developed for the trace analysis of the model impurities, which is illustrated through the 
example of DMAP. Impurity trace determination at ppm levels calls for highly sensitive 
analytical methodologies, which pose tremendous challenges on analytical chemists in the 
pharmaceutical quality control sector. Sun et al. have recently published an article with case 
studies on a systematic method development strategy for the analysis of genotoxic impurities 
considering various factors such as method selection, risk assessment and validation
51
. The 
analysis of potentially genotoxic aminopyridines is required in fields such as environmental 
studies, toxicology and pharmaceutical quality control. Vanhoenacker et al. reported on 
arylamine and aminopyridine analysis both with and without the application of derivatization 
agents in matrices such as vitamin C, bromhexine, ephedrine and penicillin
52
. It is of interest 
to note, that although DMAP is potentially genotoxic, it has been recently suggested as a pre-
column derivatization agent for the analysis of genotoxic alkylation compounds such as alkyl 
halides, sulfonates, azides and aldehydes
53
. The matrices chosen for this study are 
glucocorticoids since the analyte of interest is a widely used catalyst during their synthesis 
and possesses a risk of contamination of the drug products. Recent review by Liu et al. 
provides an industrial perspective with regard to the analysis of various structural classes of 
GTIs that are commonly encountered during pharmaceutical development and 
manufacturing
49
. For further reading the book entitled Genotoxic Impurities edited by A. 
Teasdale, providing an exhaustive discussion on the identification and control of such 
impurities in API manufacturing, is suggested
11
. 
 
Besides obtaining a reliable method for GTI analysis, the objective of the present analytical 
work was to explore the application of (i) design of experiment (DoE) optimization in LC-
MS/MS method development comprising both LC and MS instrumentation in one single DoE 
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stage and (ii) DoE robustness testing. Such an approach addresses the industrial call for a 
quick method development methodology and considers the effect of LC parameters on the MS 
detection. Thorough understanding of a given analytical task is crucial to obtain optimal 
analytical methods. Furthermore, to work efficiently in terms of time and resources, the 
method development has to be performed in a highly organized and conscious manner. Hence, 
in order to fulfill these requirements, design of experiments
54
, quality by design
55
 and design 
space computer modeling
56
 have gained increased attention in pharmaceutical analysis during 
recent years. A review on the quality by design approaches for the control of genotoxic 
impurities can be found in the literature
57
. The development of analytical methods is 
conventionally made by trial and error, changing one single factor at a time (i.e. each factor 
has to be optimized separately, in a consecutive manner) which is often abbreviated as COST. 
While a trained analyst can obtain an acceptable result following this approach it takes 
excessive time and does not allow the analyst to reach really optimum conditions and may 
produce different results from different starting points. DoE is a statistical tool being used in a 
number of fields that can also be useful in analytical method development. It is a systematic 
approach that reduces time, accounts for experimental error and considers interactions 
between variables of the analytical method. Carefully selected sets of experiments using the 
DoE approach – in which all relevant factors are varied simultaneously – ensures that the 
analyst obtains the maximum amount of relevant information. The methodology starts by a 
risk assessment to define the variables to be studied. In the present work variables of both LC 
and MS were considered and the objective was to determine the best ranges to maximize peak 
area (Apeak) and S/N ratio and minimize running time, while still achieving an acceptable 
separation of the analytes. 
 
1.3. Purification of pharmaceuticals 
 
As described in Chapter 1.1 the pharmaceutical regulatory authorities periodically issue 
guidelines on the limits of GTIs in pharmaceutical manufacturing, making the addition of a 
GTI removal step in API purification crucial. GTIs can be successfully reduced below the 
limits set by regulatory authorities following three different strategies. In the first strategy, the 
use and generation of GTIs in the synthetic route is avoided by searching for different 
chemical sequences to reach the same API or intermediate
58
. In very particular cases, this 
strategy can be achieved without significant losses of yield. Examples of redesigning the 
synthetic process specifically to avoid GTIs can be found in the literature, e.g. the synthesis of 
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Zaurategrast Sulfate originally involved the use of methanesulfonic acid, but due to the 
potential risk of generating genotoxic ethyl mesylate it was replaced by an alternative acid
59
. 
In many cases, the use of reagents and intermediates that are reactive and synthetically useful, 
which likely makes them interact with DNA, are often unavoidable. Furthermore, it may not 
be practical to change the synthetic steps during development, particularly when the processes 
are scaled up, to control or reduce GTIs. Therefore, a second strategy to achieve GTI-free 
drug products is based on prevention, focusing on elimination or reduction of GTI 
concentration either before the critical API synthetic step or during the reaction. This can be 
achieved by altering appropriate reaction conditions such as: (i) proportions of reaction 
components; (ii) interchanging of the reaction addition modes; (iii) changing the key starting 
materials; (iv) starting with different intermediates or; (iv) changing functional groups with 
structural alerts.  Furthermore, a deeper Quality by Design (QbD) investigation can contribute 
to a better control of GTIs (Figure 4)
60
. 
 
 
 
Figure 4 – Quality by design strategy for GTI prevention 
 
Nevertheless, in many cases, the API contamination with GTIs is unavoidable, which results 
in extensive analytical and purification process development. For instance, depending on API 
daily dosage, a specification of 70 ppb was set for an especially potent genotoxin in a drug 
candidate
61
. Such ultra low levels in the specifications of APIs pose additional analytical and 
processing difficulties. Therefore, the third strategy involves direct API purification from 
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GTIs. Several workup processes have been proposed to address such issues, including 
crystallization, drying to remove volatiles, washings, resolution, preparative column 
chromatography, fractional distillation, membrane processes, use of resins and scavengers. It 
should be noted, that most of the API purification processes are not GTI-specific, but remove 
other impurities from the crude API as well. However, application of scavengers is a selective 
way for the removal of a GTI. Usually the higher the selectivity of a purification process 
regarding a specific impurity, the lower the API loss and the higher the removal efficiency of 
the impurity in question. However, as other impurities remain in the crude API, the overall 
purity of the API remains low with respect to all the other impurities present. Therefore GTI 
removal from API post reaction streams is of utmost concern for the industry and it is still 
without a consensual effective solution. The difference between point-of-source and end-of-
pipe GTI removal is schematically illustrated in Figure 5. 
 
 
 
Figure 5 – Point-of-source and end-of-pipe GTI removal 
 
Higher removal of impurities can be usually obtained by increasing the number of cycles 
within a given purification technology, e.g. number of extractions, number of 
recrystallizations. However, increasing the number of cycles also leads to undesirable higher 
API loss. Consider an example of an API stream with a contamination of 1 g of GTI for each 
100 g of API, and a purification process in which, for each stage, 80% of the GTI is 
constantly removed with the sacrifice of 3% of the API. To reduce the GTI from a 
concentration of 1 g.L
-1
 in solution (corresponding to an API concentration of 100 g.L
-1
) to 64 
µg.L
-1
 would require 6 cycles, and a cumulative API loss of 17% of the API in the 
purification alone. Therefore, to drive conventional API purifications to reach ultra low GTI 
content, through an increase in the number of cycles, would lead to unacceptable API loss. 
The use of an additional end-of-pipe GTI purification could complement the already existing 
intercalated purification steps
50,62,63
. Nevertheless, the removal efficiencies are usually 
concentration dependent, decreasing at lower GTI concentrations. When reactive GTIs are 
carried forward in the API synthetic sequence they can suffer further reactions, potentially 
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producing different GTIs, and make the respective identification more difficult. In such cases, 
it may be advantageous to follow a point-of-source degenotoxification strategy. For 
implementation of this strategy, identification and mapping of the reactions where GTIs are 
present is crucial. 
 
Conventional purification steps used in API post reaction synthesis include recrystallization, 
extraction, resins, distillations, adsorbents and chromatography. On the contrary, organic 
solvent nanofiltration (OSN) and molecularly imprinted polymers (MIPs) can be perceived as 
advanced techniques proposed recently (Figure 6). As in any separation, the efficiency of the 
separation depends of the differences in chemical and physical properties of the two entities to 
be separate and/or their relative affinities for a selective agent. A brief review of the 
techniques that are discussed in the thesis follows. Note, that these emerging technologies 
being the main topic of the thesis – organic solvent nanofiltration and molecular imprinting – 
are intended to expand the chemists’ and engineers’ toolbox to address API 
degenotoxification and will be discussed in details in chapters 1.4 and 1.5. 
 
 
 
Figure 6 – Conventional (blue) and advanced 
(green) API purification technologies             
- 
Recrystallization is one of the most important isolation and purification process in the fine 
chemical industry, e.g. API manufacturing, due to its ability to give high purity products. 
However, selection of optimal conditions for recrystallization – solvent system, temperatures, 
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time and cooling rate – is challenging and time-consuming64. The API is isolated as a 
crystalline solid phase whilst the impurities remain dissolved in the liquid phase (the mother 
liquors). Crystallization is also broadly used in chiral separations, namely through 
diastereomeric resolutions
65,66
. Solvent(s), temperature and pH of the recrystallization system 
all play an important role in the effectiveness of the purification process
67
. Recrystallization is 
not only a purification process that determines the purity and residual solvent content of the 
API, but also determines the crystalline properties in terms of polymorphic form, crystal 
habit, bulk density and size distribution – all of which affect downstream drying and 
formulation
68,69
. More importantly, the crystalline properties and respective polymorphic 
forms are responsible for drug bioavailability. Therefore, once a route is approved for API 
production, the crystallization step of the final API is usually maintained. Depending on 
process optimization, a significant fraction, up to 30% of the API can remain in the mother 
liquors or be lost through washes of the crystals
70
. API crystals are usually isolated by 
filtration and the impurities can be carried forward with the API stream, sometimes as part of 
the crystal lattice, due to insufficient washing. 
 
Fractional distillation can be used to purify volatile APIs
71
. However, distillation is also 
broadly used for removal of solvents and solvent exchanges, in particular when switching 
from a high boiling point solvent to a lower boiling point solvent. Solvent exchanges from 
high boiling point solvent to lower boiling point solvents or when thermo-sensitive 
compounds are involved can be achieved using OSN
8
. Volatile organic impurities, mainly 
resulting from residual solvents
72,73
 can also be removed through distillation. Most of the 
GTIs considered in the present work – with the exception of acrolein – have low volatility. 
 
Adsorbents such as activated carbon and resins are broadly used to remove impurities from 
APIs
74,75
. Adsorption based separations are based on different affinities of the different 
compounds for the adsorbent. Therefore, high affinity of the GTI combined with lower API 
binding is desirable in this case. Screening of the different commercially available absorbents 
for metallic API impurities has been evaluated using microtubes and microplates
76,77
. Specific 
studies include removing genotoxic formaldehyde using activated carbon containing amine 
groups
78
 and removal of an aldehyde impurity using polystyrene-based sulfonylhydrazine 
resin
79
. Removal of GTIs such as alkyl mesylates and tosylates has also been evaluated using 
different commercially available resins
74
. These adsorbents and resins can be used as 
stationary phases in chromatography. 
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Column chromatography is a typical post reaction work up in organic chemical synthesis to 
remove impurities from APIs. On one hand, sophisticated stationary phases are applied in the 
pharmaceutical industry for chiral purification
80,81
 but on the other hand for API 
degenotoxification standard silica gel has been used of pharmaceutical grade as stationary 
phase
82
. In this technique a solvent, such as ethyl acetate, ether, acetone, dichloromethane and 
mixtures thereof are used as eluents. Polystyrene or methacrylate based commercially 
available adsorbent matrices using aqueous solutions at different pHs and ionic strengths are 
also reported
83
. Particle size, column dimensions and eluent flow and pressure are critical 
parameters. 
 
1.4. Green process engineering 
 
In order to assess the viability of OSN as an API purification technology, a process 
comparison has been carried out in respect to environmental and economic aspects.  
Recrystallization and flash chromatography as conventional techniques were selected for drug 
degenotoxification as conventional purification technologies for the process comparison. 
Process development is considered to be the most important design stage due to its crucial 
effect both on the whole lifecycle of a process and on its performance
84
. Furthermore, the 
major part of the production costs of pharmaceuticals is caused by downstream processing
85
. 
The pharmaceutical industry has been pioneering process optimization concerning the 
optimization of the purification of final product
86
 as well as on introducing green 
metrics
87,88,89,90
 to stimulate process effectiveness that minimize environmental impacts
91
.  
The model compounds selected for the process comparison study were Meta, as a 
representative API, and MeMS and DMAP as impurities. Several related synthetic routes and 
purification processes for Meta can be found in the literature
92,93,94
. As shown in Scheme 3, 
the reagent system to convert the 21-hydroxyl functionality to chloride during manufacturing 
usually comprises of the use of methanesulfonyl chloride (MsCl) and DMAP in 
dichloromethane (DCM)
32,95,96
. As a drawback of this methanesulfonylation reaction step, 
MsCl may form genotoxic MeMS in the presence of methanol and DMAP may also 
contaminate the final product, making this system particularly relevant to be used as model 
system in the current study. The former impurity is a known genotoxin while the latter is a 
potentially genotoxic impurity with two structural alerting functional groups: aromatic and 
alkyl amines
33
. 
 
 24 
 
 
Scheme 3 – Application of MsCl and DMAP during the synthesis of 
glucocorticoids (MsCl can form genotoxic MeMS in the presence of MeOH)  
- 
It is worth mentioning that the solvent of the Meta post-reaction stream is DCM, which is 
categorized as an undesirable solvent in the pharmaceutical industry both by GSK
97,98
 and 
Pfizer
99
. Therefore, the use of DCM in API manufacturing is decreasing, e.g. it has fallen 
from position 3 to 8 in the ranking of process solvents used between 1990 and 2000 in GSK. 
However, due to the excellent solubility properties of DCM, in 2005 DCM still represented 
about 75 mass percentages in contribution to GSK’s process solvents100 emphasizing the 
industrial importance and presence of DCM. Several green metrics are proposed in the 
literature to evaluate green economy of synthetic routes
89,101
 including mass, energy and 
carbon intensity, however literature data on downstream process comparison is scarce
86,102,,103
. 
Recently published papers give an insight to how companies such as GSK pharmaceuticals
87
, 
L´Oréal cosmetics and Repsol refinery
104
 approach green aspects related to processes. The 
present assessment focuses on solvent use, energy consumption and selective agent disposal 
as well as purification performance and costs. Pharmaceutical downstream processes usually 
consume large amount of solvents, hence the effect of a solvent recovery distillation unit both 
on environmental and financial costs is assessed. 
 
1.5. Organic solvent nanofiltration 
 
Degenotoxification by OSN mainly relies on the molecular size difference between the API 
and the GTI, although other properties such as shape and polarity also contribute to their 
rejection. The aim is to achieve high genotoxin removal through the permeate and low API 
loss in the retentate. The main challenge of genotoxin removal by membranes lies in the fact 
that most of them are highly reactive species and thus can attack the polymeric membrane 
framework at molecular level. Additionally, polymeric membranes are usually prepared by 
phase inversion in dipolar aprotic solvents such as dimethylformamide and dimethylsulfoxide, 
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hence similar harsh solvents can easily attack and dissolve the active layer of the membrane. 
The performance of this technique is highly dependent on the membrane selected and on the 
respective rejection curve. There are several commercially available polymeric and ceramic 
membranes that are stable in organic solvents. Examples include Koch SelRO membranes, 
StarMem series developed by W. R. Grace & Co, DuraMem series from Evonik MET, SolSep 
membranes, GMT-oNF-2 from Borsig Membrane Technology GmbH and Inopor or Pervap 
ceramic membranes. The molecular weight cut off (MWCO) is commonly used to 
characterize nanofiltration membranes. The MWCO of a given membrane corresponds to the 
molecular weight of a compound, obtained by interpolation, rejected at 90%. Different 
suppliers use different reference solutes and solvents as standards. Koch typically uses dyes, 
e.g. Sudan IV or glucose in solvents such as acetone and ethyl acetate or water. MET usually 
uses a sequence of linear alkanes dissolved in toluene. 
 
In the last 10 years, the number of commercially available polymeric membranes for OSN 
that are compatible with a broad range of solvents has dramatically increased. At the end of 
the 90s, the available membranes to process solvents were mainly limited to the Koch SelRO 
membranes, StarMem and SolSep Membranes. The Koch SelRO membranes were the first 
commercially available OSN membranes and offered thin film composite (TFC) membranes 
with MWCO of 250, 400 and 700 Da. These membranes are claimed to be stable in alcohols, 
alkanes, alkenes, ketones, ethers, formaldehyde, chlorinated solvents (dichloromethane, 
carbon tetrachloride, trichloroethane, dichloroethane, methylene chloride) and solvents such 
as propylene oxide, nitrobenzene, tetrahydrofuran, acetonitrile, ethyl acetate or dioxane. 
StarMem membranes, patented by W. R. Grace & Co, have been distributed by Membrane 
Extraction Technology (MET), now Evonik MET. These integral skinned polyimide 
membranes were available with MWCO of 200, 220 and 400 Da and are claimed to be stable 
in alcohols, alkanes, aromatics, alkyl ethers, alkyl ketones, and alkyl acetates. New 
generations of membranes with enhanced solvent stability have been developed for polar 
solvents
105
. Recently, Evonik MET, launched a new generation of integral skinned cross 
linked polyimide membranes, the DuraMem series. Compared with StarMem, these 
membranes are claimed to be stable in further solvents such as dimethylformamide and 
tetrahydrofurane and expand the temperature maximum limit form 60 to 100 ºC. They are 
available with MWCO of 150, 200, 300, 500 and 900 Da, thus covering also the gap between 
400 and 1,000 Da
106
. SolSep offers five membranes with MWCO between 300 and 750 
Da
107,108
 and these membranes are claimed to be compatible with alcohols, esters, ketones, 
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aromatics, chlorinated solvents, but more information on these membranes is scarce. 
Polymeric membranes are available as flat sheets and also as spiral-wound elements, thus 
facilitating scale-up. There are also OSN ceramic membranes commercially available from 
Inopor with MWCO between 450 and 750 Da
109
. 
 
The OSN membrane screening study in the thesis focuses on the development of membrane 
purification of APIs from common classes of GTIs. A total of nine APIs from four different 
chemical families namely N-heterocycles, steroids, macrolides and amides were selected as 
model compounds. The API families and their pharmacological importance, as well as their 
molecular structures are summarized in Table A1 in the Appendix. The model GTIs cover 
four chemical classes: sulfonate esters, ureas, aldehydes, and amides. Their structures and 
molecular weights are resumed in Table A2 in the Appendix. The comparison of the 
molecular weights of these compounds are represented in Figure 7, with the majority of the 
GTIs on the Mw lower range (55–225 Da) and API on the upper Mw range 170–840. Thus 
the OSN strategy consists in pushing the GTIs through the membrane, as the APIs are 
retained. The OSN can be operated in diafiltration mode, i.e. adding additional fresh solvent 
to compensate for the solution leaving the system through the permeate. Two OSN 
membranes (Table 2) with MWCO in the range of 250–350 Da were selected, namely SolSep 
NF010206 with a reported rejection of 95% for a 300 Da compound
107
 and GMT-oNF-2 were 
purchased as a flat sheet from SolSep BV and from Borsig Membrane Technology GmbH, 
respectively. Membranes with different MWCO could be selected for specific Mw ranges of 
API and GTI. 
 
Table 2 – Description of GMT-oNF-2 and SolSep NF010206 membranes 
 
 GMT-oNF-2 SolSep NF010206 
Tmax (ºC) 80 120 
pmax (bar) 35 20 
separation 
characteristics 
R(93%) ~327 Da R(95%) ~300 Da 
solvents 
alkanes, aromatics, 
alcohols, ethers, ketones 
alcohols, esters 
type 
silicone polymer-based 
composite type 
not available 
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Figure 7 – Molecular weight of the selected model 
compounds. The dotted line indicates a Mw of 300 Da.   
-  - 
Hybrid processes featuring OSN and adsorbents has been developed for the removal of 
palladium catalysts from post-reaction solutions
110
. The Suzuki post-reaction solution was 
subjected to OSN, the palladium being retained by the membrane whilst the API was 
collected in the permeate. In a consecutive step the genotoxic palladium level was reduced 
further by using commercially available adsorbents. In a similar fashion a hybrid OSN-MIP 
process has been evaluated in the thesis for API degenotoxification. It should be mentioned, 
that besides pharmaceutical purification, control of genotoxins is also an environmental 
concern. Nanofiltration featuring DESAL 51 HL, DESAL 5 DL, UTC-20, UTC-60 
membranes was applied for the removal of genotoxic atrazine – banned as a total herbicide in 
Europe since 1991 – from different water matrices including distilled water, tap water and 
river water
111
. 
 
Since StarMem membranes were first used in large-scale solvent recovery in the MAX-
DEWAXTM lube dewaxing process in 1998
112
, several other applications have been reported 
in both academic studies and industrial applications. These studies used the membranes listed 
above to develop different applications, including solvent recovery
113,114
, purifying 
products
115
, assisting chiral separations
116
, recycling catalyst
110,117,118,119
 and ionic 
liquids
120,121,122,123
 performing solvent exchange operations
124,125
 and developing membrane 
bioreactors
126
. The fundamentals of solute and solvent transport across these membranes have 
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been exhaustively studied and mathematical models have been developed
127,128,129,130,131,132,133
. 
Therefore, it is believed that OSN is becoming a mature technology, soon to be ready to be 
implemented by the pharmaceutical industry to solve challenges such the one targeted in the 
present thesis. A general scheme of OSN based API purification is demonstrated in Figure 8. 
 
 
 
Figure 8 – Scheme of OSN based API purification, with 
potential use of organic reverse osmosis for solvent recycling 
- 
 
1.6. Molecular imprinting 
 
The use of MIPs for separations in the pharmaceutical industry and in bio- and 
pharmaceutical analysis have been previously suggested
134,135
. Exploring the high specificity 
achieved by MIPs, several studies have evaluated their use for chiral separations
136,137,138
. 
Nevertheless, degenotoxification of APIs by means of molecular imprinting is currently being 
evaluated and the first publications on the topic are just recently materializing
62,139,140,141
. A 
possible limitation of the use of molecular imprinting for GTI removal is the need to develop 
specific MIPs for each individual GTI – or groups of GTIs – hence this technique has not 
become widespread at this time. 
 
1.6.1. Concept of molecular imprinting 
 
Molecular imprinting is a versatile technique for the preparation of intelligent materials 
featuring selective recognition behavior towards an analyte
142
. The active sites of the selective 
cavities are formed by monomers which can be specifically functionalized or by simple, 
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commercially available monomers. The most common types of MIPs have specific binding 
sites capable of reversible non-covalent interactions with target species. The formation of 
selective cavities is the result of the coordinating effect of the template molecule resulting 
from complementary functionalities and topographies. 
 
The continuous development of molecular imprinting technology has been ascribed to several 
factors including (i) the wide range of chemical classes utilized as templates from 
acetamide
63
, the simplest and smallest molecule to be imprinted through to the complex 
structures of proteins
143
, and (ii) its diverse applicability to a number of research fields such as 
analytical
144
, biocatalytical
145
 and preparative purification
141,146
 technologies. The most 
important factors affecting the success of imprinting have been recently reviewed
147
 being 
temperature, pressure, type of initiation, magnetic field, solvent, dilution ratio, polymerization 
time and the pre-polymerization complex of which the latter is in focus during the molecular 
imprinting investigation part of the present thesis. 1,3-diisopropylurea (IPU), methacrylic acid 
(MAA), ethylene glycol dimethacrylate (EDMA) and 1,2,2,6,6-pentamethylpiperidine (PMP) 
were used during the preparation of the novel MIPs as potentially genotoxic template, 
functional monomer, cross-linker and base respectively (Figure 9). 
 
Although the ingredients are all relatively simple organic molecules as depicted in Figure 10, 
the IPU-MAA-PMP pre-polymerization complex system is more intricate than it immediately 
seems. The principal interaction of interest among the ingredients is not of a simple acid-base 
nature and the formation of higher-order complexes was also observed by NMR, and for the 
first time in the imprinting field, it has been treated numerically. The latter, high order 
complexes lead to binding site heterogeneity, an important and often unwanted phenomenon 
in molecular imprinting. Exploring these properties is believed to be of significant interest to 
molecular imprinting research as they have consequences on binding site fidelity. 
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Figure 9 – The concept and application of IPU imprinting 
 
 
 
Figure 10 – Structure and atom numbering of the 
complexation system: IPU (A), PMP (B), MAA (C) 
- 
 
1.6.2. Investigation of complexes in the pre-polymerization solution 
 
Investigation of the functional monomer – template complexes in the pre-polymerization 
solution and recognition phenomena of MIPs is of significant importance for a deeper 
understanding of the imprinting phenomena. Due to practical difficulties of molecular scale 
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investigation of MIP suspensions (solid-liquid interface) where the rebinding of the analyte 
takes place, the generally accepted procedure is to study the pre-polymerization solution. The 
basis for this simplification is based on the following. The nature of imprinting can be 
summarized in the statement that the strength and type of interactions between the functional 
monomers and template in the pre-polymerization mixture is preserved in the polymer matrix 
and will determine the recognition behavior of the scavengers so prepared. It is assumed that 
after the self-assembly, the pre-polymerization complexes formed will somehow survive the 
polymerization stage and their structure will be preserved in the scavenger, hence the name: 
molecularly imprinted polymer
148
. Therefore, it is important to investigate the crucial 
interactions between IPU, MAA and PMP in terms of binding strength, binding stoichiometry 
and geometry. DCM and chloroform were chosen as solvents for the present studies because 
(i) they do not interfere significantly with hydrogen bonding, (ii) DCM was used as a porogen 
for MIP preparation and (iii) the degenotoxification of APIs is also carried out in DCM. The 
importance of the cross-linking monomer and the initiator on host-guest complexation in pre-
polymerization systems has been argued
,149
 but for the simplification of the otherwise already 
complicated higher-order complex system, a decision to exclude the cross-linker and the 
initiator from the complexation study was made. 
 
1.6.3. Role of NMR and FTIR in the imprinting field 
 
NMR titration is a relatively common method for the determination of binding constants in 
the field of host-guest chemistry. In most cases due to fast-exchange complexation, NMR 
signals of the complexes and the initial compounds do not appear separately but as their 
average. Several tutorials, educational articles and some computer codes have been published 
on the evaluation of NMR titration data. Most of the articles focus only on 1:1 
complexes
150,151,152
 and the literature is limited on detailed studies of higher order complexes 
such as 1:2 complexes
153,154,155,156,157
. Furthermore, articles dealing with the recognition 
behavior of molecularly imprinted polymers tend to ignore higher order complexes and, even 
in those cases where the experimental data of the continuous variation method showed 
deviation from 1:1 complexes, the binding constant calculation methods were based on the 
assumption of a 1:1 complexes
158,159
. One of the main interests of the complexation study of 
the thesis is to study the strength and formation mechanism of 1:1 and 1:2 pre-polymerization 
complexes. The continuous variation method (CVM) – also called Job plot or Job’s 
method)
150,160
 – can only be applied to obtain the stoichiometry of a complex, without 
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introducing further approximations
161
, in the case of a one-step complexation event. The 
evaluation of NMR titration data in most cases needs non-linear curve fitting methods and 
thus several approaches were proposed to address the challenge of high sensitivity to initial 
parameters. An insightful overview about such approaches was published by Fielding for 1:1 
complexes
162
. The popular graphic methods for determination of association constants 
referred to as the Benesi-Hildebrand (Hanna-Ashbaugh) method
163,164
; the Scatchard (Foster-
Fyfe) method
165
 and the Scott plot
166
 require not just 1:1 complexation but also a pseudo-first 
order reaction, which means that the compound with constant concentration during the 
titration should be in large excess compared to the titrating compound. The Rose-Drago 
method
167,168
 anticipates only 1:1 complexation. NMR calculation methods for 1:2 complexes 
are scarce in the literature
169,170
 and apparently have never been applied in the imprinting 
field. 
 
Self-association of amides is a constraining factor in the interpretation of NMR data. These 
have been investigated by dielectric permittivity measurements, osmometric
171
 and relaxation 
time NMR techniques
172
, infrared spectroscopy
173
 and modeling studies
174
 focusing mainly on 
qualitative aspects. Although self association is rarely considered in the articles dealing with 
NMR titrations, in the present study it is an integral part of the NMR titration data evaluation. 
Given the fact that self association is noteworthy only at higher free IPU concentrations, it has 
an impact mostly at lower total MAA concentrations where the complexation reaction is not 
dominant. 
 
It is worth pointing out the inconsistencies of host-guest denomination in the literature. The 
host and guest are denominated according to chemical aspects. Usually, these denominations 
are used in articles dealing with multidentate ligands (e.g. crown ethers) or molecules that are 
precursors of complex systems (e.g. receptors) and are considered the hosts. This type of 
denomination is not used in studies of lanthanide induced shifts. Some of the articles define 
guest as the compound whose chemical shift is followed during the titration
152,162
 while other 
articles measure the chemical shift of the host whilst varying the guest concentration
150,169
. 
Host-guest denomination is not relevant for 1:1 complexation, however there can be 
ambiguities in the understanding of the difference between 1:2 or 2:1 complexes. In the 
present paper, since the MAA is the precursor of the imprinted scavengers, the IPU and MAA 
are considered to be the guest and the host, respectively. 
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Infrared spectroscopy is only partly applicable in the investigation of the binding properties of 
weak complexes, however it can provide useful information about the vibrations at the 
binding site, thus giving additional proof for the complexation. Hence, the measurement of 
the complex FTIR spectra and the FTIR spectra of the initial compounds were recorded and 
analyzed. 
 
1.6.4. In silico approaches to understand molecular imprinting phenomena 
 
As stated in the disclaimer, the quantum chemical calculations were carried out by Peter 
Pogány (Department of Analytical and Inorganic Chemistry, Budapest University of 
Technology and Economics) as part of a collaboration. Hence, the thesis discusses only the 
most important and relevant findings of his work related to the complexation event in the pre-
polymerization solution. In recent years computational modeling has been developed to the 
point where a broad range of spectroscopic parameters such as vibrational frequencies, 
electronic transition energies and geometric structures can be computed with a high degree of 
accuracy. Parallel to these experimental methods, the interactions between the template and 
the functional monomer or the polymer were explored by simple statistical mechanics
175,176
, 
molecular mechanics (MM) and semiempirical methods
177,178
, density functional theory 
(DFT) and ab initio static methods
179,180,181,182
 coarse grained molecular dynamics (MD)
183
 
and classical MD calculations
149,184
. In the earlier studies the statistical and the MM/classical 
MD studies are predominant and quantum chemical methods have only been applied in recent 
years, resulting from the rapid development in computational power. In silico studies on 
imprinted polymers themselves and not the pre-polymerization solution are scarce due to (i) 
high demand on computation and time because of the complexity of the system, (ii) the need 
for restrictive assumptions leading to the loss of information at molecular scale
183,184
. The ab-
initio and DFT methods are suitable for modeling the chemical interactions between the 
monomers and templates, describing their binding properties and stability. In most of the 
articles this method was chosen for making a functional monomer screening. 
 
The quantum chemical studies use mostly localized atomic orbitals, hence for calculating the 
complex formation energies for systems with weaker bonds (H-bonds, dispersion forces) the 
consideration of Basis Set Superposition Error (BSSE) is inevitable. Since the primary 
interest in the complexation study is the binding characteristics of the template-monomer 
system, which was studied also with NMR, static DFT was chosen to meet these expectations. 
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The effect of solvent is crucial in the complexation process, since it can change the 
interactions for the complex formation (H-bonds, ionic, hydrophobic interaction). The present 
study illustrates how theory can be used as a complement to spectroscopy and rebinding 
studies to enhance the accuracy of deductions. 
 
2. Materials 
 
Active pharmaceutical ingredients Sumatriptan, Prednisolone, Betamethasone, Halobetasole 
propionate, Mometasone furoate and Roxithromycin were provided by Hovione whilst 
Lacosamide and Keppra were kindly provided by UCB and Irbesartan was purchased from 
Jiacheng-Chem Enterprises Ltd. The potentially genotoxic impurities methyl tosylate, 
dimethylsulfate, acetamide, thioacetamide, dimethyl carbamoyl chloride, 1,3-
dicyclohexylurea, acrolein and 2-bromoethanol were purchased from Sigma-Aldrich while 
ethyl tosylate and 1,3-diisopropylurea were purchased from TCI Europe and Hovione, 
respectively. Ingredients for the molecularly imprinted polymers such as methacrylic acid, 
ethylene glycol dimethacrylate and 1,2,2,6,6-pentamethylpiperidine were purchased from 
Sigma-Aldrich. Solvents dichloromethane, methanol, methyl isobutyl ketone, ethylacetate, 
methyl ethyl ketone and tert-butylmethylether were purchased from Merck. Deuterated 
chloroform was purchased from LaborSpirit. Hydrochloric acid, ammonium hydroxide, 4-
dimethylaminopyridine, tetrahydrofuran and 2,2'-azobis(2,4-dimethylvaleronitrile) were 
purchased from Fluka and Wako, respectively. Methanol, TLC aluminium sheets (Silica Gel 
60 F254) and Silica Gel 60 powder was purchased from Merck. Shirasagi DC32 charcoal was 
purchased from Mitsubishi. 
 
Before use, EDMA was first washed with 10% aqueous NaOH, water, brine and then water in 
this order. The EDMA was then dried with MgSO4 and distilled under vacuum. Anhydrous 
solvents used for MIP preparation, rebinding tests, NMR studies were stored over molecular 
sieves under inert atmosphere. HPLC grade water was obtained from a Millipore Milli-Q-
Gradient ultrapure water system (Millipore, Billerica, MA, USA). The other chemicals were 
used as received and were of reagent grade or higher. 
 
SolSep NF010206, GMT-oNF-2, MPF-44 were purchased as flat sheet nanofiltration 
membranes from SolSep, Borsig Membrane Technology and Koch Membrane Systems, 
respectively. 
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3. Methods 
 
3.1. DoE approach for GTI quantification 
 
3.1.1. Instrumentation LC-MS/MS 
 
LC-MS/MS measurements were carried out on High Performance Liquid Chromatograph 
Waters model Alliance 2695 (Milford, MA, USA) equipped with gradient pump, autosampler 
and PDA Waters 2996 UV detector. Triple Quadrupole Mass Spectrometer for Liquid 
Chromatography Micromass model Quattro Micro (Manchester, UK) equipped with an 
electrospray source was employed as the MS detector. A LaPrep P206 VWR International 
LLC valve (Carnaxide, Portugal) was placed between the UV and MS detector as divert valve 
to avoid sending the highly concentrated API to the MS detector. The control of the system 
was carried out on MassLynx V4.1 acquisition software and data collection and processing 
was handled by QuanLynx module. Before use, tuning was carried out by flow injection 
analysis (FIA) in positive electrospray ionization (ESI) mode using Micromass ESI tuning 
mix part #700002646. 
 
3.1.2. Operating conditions LC-MS/MS 
 
Phenomenex Gemini-NX 3m C18 110Å 50x2.00 mm column was used with a flow rate of 
0.5 mL.min
-1
, with detection in the range of 190 to 400 nm. Eluent A was 0.1% formic acid in 
water and eluent B was 0.1% formic acid in acetonitrile. The gradient was linear from 40% to 
70% B in 4 min, followed by 70% B hold for a further 1 min and a re-equilibration period of 
5 min. The column temperature was 25 ºC and injection volume was 26 L. Electrospray in 
positive mode was used with MRM monitoring for m/z 123>107 transition for DMAP. The 
capillary (kV), cone (V), extractor (V), ion energy (V) and collision energy (eV) were 0.2, 35, 
3, 0.3 and 30, respectively. The LM and HM resolutions were 13.5 for both quadrupoles. Ion 
energy for the second quadrupole was 1.5 V. The source temperature, desolvation gas 
temperature (ºC) and gas flow (L.min
-1
) were 120, 500 and 350, respectively. 
 
 
 
 
 36 
3.1.3. Standard solution and sample preparation 
 
20 mg.mL
-1
 concentrated stock solution of DMAP was prepared by dissolving the compound 
in acetonitrile. The 0.2 mg.mL
-1
 diluted stock solution was prepared by diluting 100 L of the 
20 mg.mL
-1
 concentrated stock solution to 10 mL with acetonitrile. The 0.5 g.mL-1 diluted 
stock solution was prepared by diluting 250 L of the 0.2 mg.mL-1 diluted stock solution to 
100 mL with acetonitrile. The working standard solution was prepared by accurately weighing 
about 125 mg of Mometasone furoate into a 25 mL volumetric flask and making up the 
solution to the graduation mark after adding 250 L of the 0.5 g.mL-1 diluted stock solution 
to give 5 ng.mL
-1
 and 5 g.L
-1
 DMAP and Mometasone furoate absolute concentrations 
respectively which correspond to 1 ppm DMAP contamination relative to the drug substance. 
The working standard solutions were shaken to dissolve the API and homogenize the solution 
and were always freshly prepared just prior to injection. The DMAP samples for validation at 
0.01, 0.05, 0.1, 0.5, 1, 2 , 3, 5, 7, 10 ppm concentrations relative to the API were prepared in 
the same manner using the 0.5 g.mL-1 diluted stock solution. DMAP standard solutions are 
prepared in 5 g.L
-1
 Mometasone furoate concentration. Although higher concentrations would 
further increase the DMAP detection limit, in order to prevent possible matrix effects such as 
analytical column overloading – which can cause loss of sensitivity – the 5 g.L-1 concentration 
was maintained throughout the study. 
  
3.1.4. Design of experiments 
 
The software Modde 9.0.0.0 by Umetrics was used to generate the sequence of runs and the 
data collected were investigated using regression analysis. This gave a model – relating the 
changes in the factors to the changes in responses – which indicated the important factors and 
their combination in influencing the responses. All of the five factors were studied 
simultaneously, namely flow, gradient and injection volume as LC factors and cone voltage 
and collision energy as MS factors. The LC-MS/MS method was optimized with respect to 
four responses, namely separation between peaks (i.e. difference between the retention time of 
the API and DMAP), peak area, length of the analysis and the signal to noise ratio (S/N). A 
central composite face (CCF) design – with 26 runs and 3 center points – was created and the 
modeling results using a quadratic model were converted into response contour plots which 
were used to clarify where the best operating conditions are to be expected. After the 
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determination of the analytical method, its robustness around the optimal conditions was 
evaluated applying a fractional factorial (FF) of resolution III with 8 runs and 3 center points 
further taking into account column temperature as well as quadrupole resolution besides the 
five factors previously mentioned. 
 
3.1.5. Validation study 
 
To demonstrate the accuracy of the developed method, validation was performed. The 
assessed parameters during validation were limit of quantification (LOQ), limit of detection 
(LOD), linearity, system precision and DMAP recovery of spiked samples. LOQ was 
established by injecting in the LCMS system various DMAP concentrations ranging between 
0.01-15 ppm and recording their S/N ratios. The lowest concentration corresponding to S/N ≥ 
10 was selected as LOQ and LOD was considered as 3/10 of LOQ, since the adopted criteria 
for this parameter is S/N ≥ 3. To validate these concentrations, two independent sample 
preparations at LOQ and LOD concentrations were carried out and were injected three times. 
The average result (x) is calculated by summing the individual results and dividing this sum 
by the number (n) of individual values as shown in equation 1. The standard deviation (SD) is 
a measure of how precise the average is, i.e. how well the individual numbers agree with each 
other. It is calculated as shown in equation 2. The relative standard deviation (RSD) is defined 
in equation 3 and expressed in percentage and is obtained by multiplying the standard 
deviation by 100 and dividing this product by the average. The suitability of the method was 
assessed by calculating the RSD for the above mentioned consecutive six injections of LOQ 
and 10xLOQ concentration. Linearity was performed by determining the correlation factor for 
a six point calibration curve, ranging between LOQ and 10xLOQ concentrations. DMAP 
recovery in spiked samples was studied at three different concentration levels of the 
calibration curve corresponding to LOQ, 5xLOQ and 20xLOQ. For each concentration level 
independent sample preparations were carried out giving six samples at the LOQ level and 
three at the other two levels. The apparent recovery (AR) is defined in equation 4 and it was 
determined by comparing the concentration of the spiked sample obtained (observed value → 
Qo) with the concentration of the spiking standard (reference value → Qy). The definition of 
these analytical terms follows the recommendation of the International Union of Pure and 
Applied Chemistry
185
. 
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3.2. NMR titrations, continuous variation method and FTIR 
 
The 
1
H NMR spectra were recorded on a Bruker Avance III 400 spectrometer operating at 25 
ºC within a deviation of 0.2 ºC. Chemical shifts () are reported in ppm, with respect to the 
solvent peak of deuterated chloroform being 7.26 ppm
186
.  The following abbreviations are 
used in the discussion: s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet, bs = 
broad singlet.  The solvent was kept under molecular sieves and handled under inert 
atmosphere in order to avoid contamination of the system with water which disrupts the 
intramolecular hydrogen bonds. For the self-association NMR experiments 1 mM, 2.5 mM, 5 
mM, 7.5 mM, 10 mM, 20 mM, 30 mM, 40 mM IPU working solutions were prepared in 
CDCl3. Additionally, three sets of CVM were also performed for obtaining the stoichiometry 
of the complex. During the CVM, the host/guest molar ratio was varied between 0 and 1 
while their total concentration was kept constant at 20 mM. In CVM1 the host was MAA, in 
CVM2 the host was MAA:PMP (1:1),  while in CVM3 the PMP is proportional to IPU and 
not to MAA being MAA:PMP (1:1). Furthermore, four sets of NMR titrations were carried 
out where IPU was titrated with MAA: T1 (5 mM IPU) and T2 (10 mM IPU) were performed 
in the absence of PMP, while T3 (5 mM IPU) and T4 (10 mM IPU) were performed in the 
presence of PMP. In order to study the effect of concentration, the T1 and T3 were performed 
at 5 mM IPU concentration, while T2 and T4 were performed at 10 mM IPU concentrations. 
The solutions were agitated to dissolve the IPU and homogenize the solution and were always 
freshly prepared just prior to analysis. The room temperature Fourier transform infrared 
(FTIR) spectra of 20 mM IPU and corresponding 20 mM IPU:MAA (1:1) complex were 
measured in DCM, in the 4,000-400 cm
-1
 region at a resolution of 4 cm
-1
, using an IRAffinity-
1 spectrophotometer from Shimadzu (model 2011). 
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3.3. Solid phase characterization of the scavengers 
 
Elemental Analysis was performed at the Department of Organic Chemistry, Johannes 
Guttenberg Universität Mainz using a Heraeus CHN-rapid analyzer (Hanau, Germany). The 
percentage by mass of carbon, hydrogen and nitrogen of the polymers were calculated by 
equation 5. 
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     (eq. 5) 
 
where Aw is the standard atomic weight of element C, H or N; Ni is the number of C, H or N 
atoms of the ingredient i in the scavenger; ni is the number of moles of ingredient i and Mwi is 
the molecular weight of ingredient i. Ingredients considered during the calculation were 
MAA, EDMA and 2,2'-azobis(2,4-dimethylvaleronitrile) ABDV. The morphological analyses 
were carried out on a Morphologi G2 Model MOR5110 equipped with a sample dispersing 
unit. Nitrogen sorption measurements were performed on a Quantachrome Autosorb 6B 
(Quantachrome Corporation, Boynton Beach, FL) automatic adsorption instrument. Prior to 
measurements, 100 mg samples were heated at 80 °C under high vacuum (10-5 Pa) for at least 
16 h. The specific surface areas (ASS) were evaluated using the BET method, the specific pore 
volumes (Vpo) were evaluated following the Gurvitch method, and the average pore radius 
(rpo) was evaluated using the Barret-Joyner-Halenda (BJH) theory using the desorption branch 
of the isotherm. The calculations related to the BET theory are as follows: 
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v c P v cv P / P 1
 
 
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is the BET equation where v is the adsorbed gas quantity, P and P0 are the equilibrium and the 
saturation pressure of nitrogen at the temperature of adsorption, vm is the monolayer adsorbed 
gas quantity and c is the BET constant. Total surface area (Atotal) and specific surface area are 
calculated based on equation 7 and 8, respectively. 
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were N is the Avogadro´s number, s is the adsorption cross section of the adsorbing species, 
V is the molar volume of nitrogen gas and a is the mass of nitrogen. The pore volume 
calculated using the BJH equation
187
: 
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where rp is the pore radius, rK is the Kelvin radius, t is the thickness of the film and VK is the 
Kelvin volume. 
 
Fourier transform infrared (FTIR) spectroscopy was performed using a NEXUS FTIR 
spectrometer, with samples prepared in KBr disks. Thermal stability tests of the polymers 
were performed by thermal gravimetric analysis (TGA) Q50 TA instrument. 10 mg samples 
were placed on a platinum pan, which was heated with a heating rate of 10 °C.min
-1
 from 25 
°C to 1,000 °C, under N2 atmosphere and the % mass loss measured along with the respective 
temperature. Microscopy was carried out for visualization of polymeric particles and 
morphology. To estimate the average circularity
I
, spherical equivalent volume
II
, convexity
III
 
and light intensity, mean
IV
 morphological analyses were carried out on a Morphologi G2 
Model MOR5110 equipped with a sample dispersing unit. Each sample was prepared using 
the sample dispersing unit of the equipment applying the following conditions: injection 
pressure: 2 bar, injection time: 0.4 seconds, total cycle time: 2 min, sample size: 5 mg. The 
samples were visualized applying several lenses. 
 
 
 
I
 Circumference of circle of equivalent area divided by the actual perimeter of the particle. A circularity of 0 
corresponds to a cubic shape and 1 to a perfect sphere. 
II
 SE is calculated on the basis of the diameter of a circle with the area of the particle image projected area. 
III
 Convexity is a measure of the surface roughness of a particle and is calculated by dividing the convex hull 
perimeter by the actual particle perimeter. 
IV
 The intensity mean is the average of the pixel grayscale levels ranging from 0 (black) to 255 (white). The 
average number of particles analyzed with morphology is 3378. 
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3.4. Nanofiltration methods and mathematical framework 
 
The METcell Cross-Flow System, purchased from Evonik MET, consists of high-pressure 
filtration cells suitable for reverse osmosis and nanofiltration, an organic solvent compatible 
gear pump and a tank base. A total of 500 mL of solution is circulated between the tank and 
the filtration cells and filtration takes place in cross flow mode. The appropriate pressure is 
insured by a Nitrogen cylinder and a fine tuning pressure gauge. An HPLC pump is connected 
to the tank during diafiltration in order to keep constant the volume of filtration. The 
membranes were preconditioned by filtering ~300 mL pure solvent through each membrane 
piece (52.8 cm
2
), until a constant solvent flux was obtained. Rejections were estimated at 10, 
20 and 30 bar using single solute solutions of API and GTI at concentrations of 10,000 ppm 
for the APIs and 1,000 ppm for the GTIs in the respective solvent (THF, MEK or DCM). 
Exceptions are CHU and Suma solutions in MEK, they were prepared at concentrations of 
500 ppm and 2,000 ppm, respectively due to their lower solubility limits. Feed volumes of 
500 mL were used. Duplicate assays were carried out using the same sheet of membrane to 
estimate each rejection and the values reported are averages of the two values obtained. 
Rejection values (Rx) were always calculated on the basis of the concentrations of compounds 
measured in the feed (CF,x) and in the first 50 mL permeate (CP,x) – based on equation 11 – 
which corresponds to a feed volume decrease of only 10% and thus no significant increase in 
solute concentration is expected on the retentate side during filtrations. Still, retentate 
concentrations (CR,x), were also measured at the end of the filtrations to close the solute mass 
balance. 
 
P,x
X
F,x
C
R 1
C
            (eq. 11) 
 
Rejections were estimated based on bulk concentrations and thus rejections reported are 
apparent parameters that will vary with concentration and hydrodynamics, according with 
several factors, such as the existence of concentration polarization at membrane interface and 
activity constants of solutes. However, following the simplistic approach from the literature, 
rejections were assumed constant during the diafiltration in order to estimate the diafiltration 
performance. During the diafiltration assays, the feed solutions were API and GTI mixtures 
(two solute system) in the selected solvent at concentrations of 10,000 ppm and 1,000 ppm, 
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respectively. The HPLC pump rate was adjusted to add fresh solvent volumes (VADD) to 
compensate the permeate volume (VP) by keeping the retentate volume constant at a value of 
500 mL, equal to the feed volume (VF) over the entire operation. CF,x were measured after 
thoroughly mixing the feed solution in the METcell system using a gear pump, just prior to 
the start of the nanofiltration. The diafiltration was interrupted periodically, at permeation of 
each 500 mL, to take aliquots of the retentate and permeate solutions. Mass balances were 
closed at each step and the API losses and GTI removals were estimated. 
 
As mentioned earlier, in diafiltration operational mode VR is kept constant and thus VP = 
VADD. Therefore, assuming a constant rejection and simple mass balances the concentration of 
the solutes in the permeate and retentate can be calculated as function of the permeate 
volume. Taken into account infinitesimal small amounts of permeate volumes V
i
P and the 
respective concentrations of solute in such permeate volume, as well as retentate 
concentrations at such time period, the following equations are established: 
 
R,t 0 FC C            (eq. 12) 
 iP,x x R,xC 1 R C           (eq. 13) 
i
i F P
F R,x i i
R,x P,x
V V
V C
C C
           (eq. 14) 
 
Considering that (i) the total volume collected at each instant of the diafiltration is actually the 
sum of all the V
i
P that permeates through the membrane until that time, and (ii) the measured 
concentration of the permeate is the result of the solute content in each of the V
i
P elements, 
equation 15 and 16 can be derived in each point: 
 
i
P PV V           (eq. 15) 
i i
P,x P P,xC V C          (eq. 16) 
 
On the other hand, since the volume of retentate is kept constant, the retentate concentration 
can be derived directly as given in equation 17. 
 
i
R,x R,xC C           (eq. 17) 
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The API loss and GTI removal are estimated on the solute concentration in the feed solution 
and in the retentate as given in equation 18 and 19. 
 
R R,API R,API
F F,API F,API
V C C
API loss
V C C

 

       (eq. 18) 
R R,GTI R,GTI
F F,GTI F,GTI
V C C
GTI removal 1 1
V C C

   

      (eq. 19) 
 
Diavolumes (D), reflecting the solvent intensity of the OSN process, are reported based on 
equation 20. 
 
add P
F F
V V
D
V V
            (eq. 20) 
 
The higher the number of diavolumes, the higher the amount of GTI pushed thought the 
membrane, but also the higher the API loss and solvent used in the processes contributing to 
higher solvent consumption. Thus, the number of diavolumes should be selected carefully 
taken into account the required GTI removal by its toxicity limits and economically 
acceptable loss of API. 
 
The calculated values based on the equation system above match the previously established 
analytical expression reported in the literature
188
 as equation 21. 
 
 
 P xR,x F,x F,x x
F
V 1 R
C C exp C exp D 1 R
V
  
       
 
    (eq. 21) 
 
Solvent fluxes () were estimated on the basis of membrane area (Am) and filtration time (t) 
in duplicated experiments as given in equation 22. From a process economics perspective, 
solvent fluxes define a compromise on membrane area to be applied and operation time, 
respective associated costs and logistics. 
 
P
m
V
A t
 

          (eq. 22)  
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3.5. IPU selective MIP preparation 
 
IPU was used as template during the preparation of MIPs, but absent during the preparation of 
control polymers labeled as non-imprinted polymers (NIPs). Table 3 summarizes the 
composition of the different scavengers prepared. MAA (1.2 mmol, 0.102 mL) was dissolved 
in DCM (2.25 mL), which functions both as porogen and solvent. PMP (0.3 mmol, 0.054 mL) 
was added to MIP2 and corresponding NIP2 polymerization mixtures. For the MIP 
preparation, the IPU template (0.3 mmol, 43 mg) was added to the MAA solution and left for 
5 min. EDMA cross-linker (6 mmol, 1.133 mL) and the initiator ABDV (1 weight% of total 
monomers) were added to the polymerization solution, which was purged with a flow of dry 
nitrogen. The polymerization tubes were sealed and the polymerization was initiated by 
placing the tubes in a thermostat at 40 °C. After 12 hours the temperature was increased to 60 
°C for an additional 12 hours to complete the polymerization. The polymerization tubes were 
then broken and the polymers gently mashed using a pestle and mortar. The template was 
thereafter extracted quasi quantitatively in a Soxhlet-apparatus with a solution of 0.1 M HCl 
in methanol for 48 hours. The remaining acid in the polymers was then washed out with 
methanol using a Soxhlet-apparatus during 24 hours. This was followed by further mashing 
and sieving (Resh stainless steel sieves), whereby the 25-50 μm fraction was used to evaluate 
the binding properties of the polymers. The polymers were dried under vacuum in the oven 
overnight at 40 °C. The same fraction was used for the chemical and morphological 
characterization of the scavengers. Quantitative analysis of the washing and extraction steps 
indicated almost complete template removal (>98%). The non-imprinted polymers were 
prepared in the same way as described above, but with the omission of the template molecule 
from the pre-polymerization solution. 
 
Table 3 - Composition of IPU selective scavengers 
 
 composition stoichiometry method comment 
MIP1 IPU/MAA/EDMA 0.1/0.4/2  with IPU 
MIP2 IPU/PMP/MAA/EDMA 0.1/0.1/0.4/2 ABDV with IPU and PMP 
NIP1 MAA/EDMA 0.4/2 40-60°C without IPU not PMP 
NIP2 PMP/MAA/EDMA 0.1/0.4/2  without IPU but with PMP 
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3.6. Swelling experiments 
 
Swelling is measured by allowing a given volume of dry polymer, with a known particle size 
and weight, to equilibrate in a solvent. For comparison purposes the swelling of all scavengers 
was estimated. 100 mg polymer with 25-50 m diameter was placed in narrow vials, each was 
loaded with 2 mL of the following solvents: DCM, MIBK, MeOH and a solution of 0.1 M 
HCl in methanol. The mixtures were stirred and left to stand overnight to reach equilibrium at 
which point the polymer does not absorb more solvent. The bulk volumes of the dry and 
swollen particles were calculated based on the height and diameter of the particle bed in the 
vial, and used to estimate the volume swelling ratio (VSR) as given in equation 23. 
 
swollen
dry
V
VSR
V
          (eq. 23) 
 
Since the weight and the volume of the dry particles are known, an apparent density (dapp) can 
be calculated based on equation 24. 
 
dry
app
dry
m
d
V
           (eq. 24) 
 
Specific swelling volume was calculated from the volume swelling ratio and apparent density 
based on equation 25. 
 
swelling
app
VSR
V
d
          (eq. 25) 
 
3.7. Bulk rebinding tests 
 
Bulk rebinding tests were carried out to (i) evaluate the IPU uptake by the scavengers in the 
presence of APIs and (ii) explore the effect of a deprotonating agent on the capacity and 
kinetics of the binding. Furthermore, a polymer titration was performed in a bulk rebinding 
test format in order to establish the optimal IPU/MIP ratio. All the assays were carried out in 
duplicates featuring 100 ppm IPU in DCM. 
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In order to evaluate the binding properties of the several scavengers prepared 50 mg of each 
polymer (MIP1, MIP2, NIP1 and NIP2) were placed in independent vials and NIP2 and MIP2 
were preconditioned with 0.1 M PMP solution in DCM. The preconditioning solution was 
removed from the scavengers and the rest of the rinsing DCM was evaporated. 1 mL of 
loading solutions – consisting of 10,000 ppm Meta, Roxi or KP in DCM spiked with 100 ppm 
IPU – were added to each scavenger. The relative concentration of API and GTI aims to 
reflect the industrial scenarios where the API is highly concentrated compared to the IPU 
being present in lower concentrations, which makes selective removal more challenging. 
However, in order to evaluate the selectivity of the polymer, a solution with equimolar 
concentration of IPU (100 ppm, 0.7 mM) and Meta (362 ppm, 0.7 mM) was also loaded to 50 
mg MIP2. During the polymer titration 1 mL of 100 ppm IPU solution in DCM was loaded on 
10, 25, 50, 100, 250, 500 mg of MIP2 both in the presence and absence of PMP. When PMP 
was presence, the MIP2 scavenger was preconditioned as described in the previous paragraph. 
The bulk rebinding mixtures were gently shaken for 24 hours. Samples of the mixtures were 
taken before the addition of the scavengers and after 24 hours. During the kinetic studies, 
samples were also taken from the supernatants at 10 min and at 1, 2, 4 and 8 hours. The 
samples were filtered with Millipore syringe filters in order to remove any floating particles 
before analysis. The DCM was evaporated and the samples were dissolved and diluted using 
the solvent of the LCMS mobile phase. Control experiments were run as described above, but 
replacing the loading solution with DCM. 
 
3.8. Solid phase extraction methods 
 
Solid phase extraction (SPE) experiments were performed on Visiprep DL Vacuum Manifold 
equipped with 3 mL cartridges from Supelco (Germany) that were packed with 50 mg of 
MIP2 polymer between Teflon frits. Disposable liners were used in order to eliminate the 
possibility of cross-contamination when processing a new extraction on the same port. The 
scavengers were preconditioned with 1 mL 0.1 M PMP base in DCM. The mixture was left to 
stand for 5 min and then the preconditioning solution drained and 1 mL solution of the 
compounds of interest loaded on the polymers. The cartridge was sealed and the mixture was 
occasionally stirred during the 24-hour equilibration time. The compounds were selectively 
eluted from the polymers by gradient elution featuring DCM, MeOH and MIBK and the 
eluants were collected in separate vials. The loading solutions and eluants were analyzed by 
LCMS. MIP samples were regenerated by washing with 0.1 M HCl in methanol in a Soxhlet 
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extractor overnight. To confirm that no IPU leaches from the MIP scavenger, 50 mg MIP2 
was weighed in an HPLC vial and 1 mL DCM was added and the mixture was stirred for 24 
hours. The ExploraSep
®
 SPE screening was performed based on this protocol but on the 
ExploraSep
®
 Screening Plate A containing 32 scavengers and the loading solution was 
prepared in acetonitrile:toluene (5:95) and it was loaded to each polymer manually using 
multi-channel pipettes. Vacuum was gently applied to collect all the solutions. The solvent 
was evaporated in a Sigma Vacuum Centrifuge and the residue was taken up in the mobile 
phase of the LC-MS/MS. The free IPU and API content in the supernatants were determined 
by LC-MS/MS. 
 
3.9. Recrystallization 
 
10,000 ppm Meta in DCM was spiked with 1,000 ppm DMAP and MeMS, respectively. A 
comparative study was carried out using in each assay (recrystallization, chromatography and 
nanofiltration) 500 mL crude API solution. The 500 mL feed solution was submitted to 
recrystallization based on WO9800437 patent
92
. Before and after the purification process 
Meta and DMAP were quantified by HPLC and MeMS with GCMS. A 500 mL round-
bottomed flask was pre-calibrated at 50 mL, and 500 mL feed solution was added in two 
portions. The solution was concentrated under reduced pressure to the pre-calibration mark. 
100 mL methanol was added and the solution was heated to 50 ºC, and the mixture was 
concentrated to 50 mL. Precipitation occurred at the end of this step. Further 100 mL 
methanol was added, and the mixture was concentrated to 50 mL. The solution was slowly 
cooled to 23 °C over 1 hour and then cooled further to 10 °C, at which temperature it was 
agitated for 2 hours. The Meta was obtained as a crystalline solid and filtered off and washed 
with 2 x 20 mL methanol cooled to 10 °C. The wet cake was charged into a 500 mL round-
bottomed flask pre-marked at 50 mL. 3 g of Shirasagi DC32 decolorizing charcoal, 100 mL 
methanol and 100 mL DCM were added, and the steroid was dissolved with stirring. The 
solution was heated to 50 ºC and then filtered. The flask and filter paper were rinsed with 2 x 
20 mL DCM and the rinsings were combined with the solution. The combined solution was 
heated to 50 ºC then concentrated under reduced pressure to 50 mL yielding a slurry. 100 mL 
methanol was added and the mixture was concentrated under reduced pressure to 50 mL 
again. It was then cooled slowly to 23 °C over 1 hour and then cooled further to 10 °C, at 
which temperature it was agitated for 2 hours. Meta was obtained as a crystalline solid and 
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filtered off and washed with 2 x 20 mL methanol cooled to 10 °C. Meta was dried in a 
vacuum oven at 70 °C for 24 hours. 
 
3.10. Flash chromatography 
 
For efficient flash chromatographic separation first a thin layer chromatographic (TLC) 
separation was developed to obtain the desired retention factors (Rf) for Meta and the 
impurities i.e. to determine the eluent for flash chromatography. The optimization started with 
the eluent given in the US4472393 patent
93
 and resulted in DCM:EtOAc (95:5) for Meta-
DMAP separation where the Rf values are 0.34 and 0.05 for Meta and DMAP respectively. In 
pure DCM the Rf values for Meta and MeMS are 0.02 and 0.2 respectively, thus for Meta-
MeMS separation a gradient elution was developed as described in Table 4. It should be noted 
that in the original patent chloroform was used instead of DCM, however the latter has one 
less chlorine per molecule and thus a lower environmental and toxic potential impact
189
. 
Additionally, the difference in boiling points of these two solvents is of about 12 ºC, which 
decreases energy requirements when recovering DCM by distillation. Notice, that chloroform 
has been banned in many applications, where the use of DCM is still allowed and since the 
dissolving power properties of these two solvents is in many cases similar, therefore 
replacement of chloroform by DCM is recommended
189
. 
 
Table 4: Gradient elution for the separation of MeMS and Meta 
 
fraction eluent composition eluent volume 
# (DCM:EtOAc) (mL) 
1-12 100:0 600 
13-14 98:2 100 
15-16 95:5 100 
17-18 90:10 100 
19-20 80:20 100 
21-24 50:50 200 
 
Clark Still’s flash chromatographic technique was applied for the purification of the crude 
Meta
83
. 500 mL crude API solution was concentrated to 10% in volume, keeping the API in 
solution, then 10 g silica gel was added and the solvent was evaporated. A chromatography 
column with 50 mm diameter was filled with a slurry of 300 mL silica gel in DCM and the 
API-silica mixture was applied to the top of the column. Pressure was applied with Nitrogen 
to force the solvent through the column and keep a steady eluent flow of 50 mL.min
-1
. 24x50 
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mL fractions were collected, analyzed by TLC and the ones containing mainly Meta were 
merged and the solvent was evaporated. Meta was dried in a vacuum oven at 70 °C for 24 
hours. 
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4. Results and discussion 
 
4.1. GTI analysis by LC-MS/MS via DoE approach 
 
The model system for the present study consists of the potentially genotoxic DMAP impurity 
and Mometasone furoate glucocorticoid. In the absence of toxicological data for the impurity, 
the TTC for genotoxic impurities is used to set limits. Calculation of the limit to be applied 
for DMAP is as follows: the TTC value (1.5 μg.day-1) divided by the maximum daily dose 
(g.day
-1
) and the number of GTIs gives the limit in ppm to be applied to the active 
substance
190
. Notice, that the number of GTIs in this particular case is 2 due to the 
methanesulfonylation reaction step which can lead to the contamination of the API with not 
only DMAP but methyl methanesulfonate as well. Considering the worst case scenario where 
1,000 mg.day
-1
 daily dose is applied, the GTI is required to be controlled at 0.75 ppm relative 
in the API which determines the range in the linearity study during method validation to be 
0.1-10 ppm. This analytical study aims to prove the applicability of DoE in the trace analysis 
of GTIs through the DMAP model impurity in glucocorticoids-type APIs, however the 
methodology can be applied to other type of impurities. 
 
4.1.1. DMAP fragmentation and MS risk assessment for DoE 
 
Trace analysis of potentially genotoxic impurities inevitably calls for high sensitivity 
detection which can be addressed by state-of-the-art instrumentation such as triple quadrupole 
mass spectrometers. Hence, MRM was selected as acquisition mode due to its high sensitivity 
and selectivity over conventional SIM mode. An MS detector featuring a triple quadrupole is 
capable of eliminating overwhelming background interference from the sample matrix which 
is referred to as MRM. Firstly, the target ion is selected and then further fragmented, allowing 
for a high degree of selectivity in which only the target ions from the potentially genotoxic 
impurity are detected. Although MRM acquisition results in a somewhat lower signal, the S/N 
ratio significantly improves due to the decrease in background interference and hence leads to 
much better sensitivity. Being a base, DMAP is easily protonated to give a quaternary 
ammonium cation, thus formic acid was added to the mobile phase as ionization agent to form 
the protonated species. 
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A Flow Injection Analysis (FIA) was carried out using a 50 ng.mL
-1
 DMAP solution in which 
the initial electrospray source conditions were determined for the DoE LCMS method 
development approach and [DMAP+H]
+  
m/z 123 was successfully detected and selected as 
parent ion for MRM experiment and then fragmented in the product ion scan analysis. The 
FIA experiment was also used as part of the DoE risk assessment. For the successful 
application of DoE, it is crucial to get a response in each run, hence the operating range of the 
MS variables had to be chosen with care. During FIA the MS variables were varied and the 
product ion m/z 107 was acquired in order to establish the range of the variables where still 
acceptable analyte response can be detected. The quick manual tuning during FIA led to the 
establishment of the collision energy and cone voltage ranges as 20-40 eV, 20–50 V 
respectively.  To address the industrial need for quick method development the number of 
DoE runs was limited thus the main MS parameters were chosen as DoE variables and the 
parameters were tuned during the FIA. Furthermore the product ion scan revealed ion m/z 107 
as most favorable fragment thus transition 123>107 was selected for monitoring in MRM 
mode. DMAP mass spectra are displayed in Figure 11. 
 
 
 
Figure 11 - Mass spectra of DMAP acquired at 20 and 60 collision energy (eV) 
 
In Figure 12 the structures of the neutral fragment species are indicated above or below the 
arrows which show the resulting charged fragments and their m/z. DMAP, as an 
aminopyridine derivative shows both the aniline and pyridine type fragmentation routes. 
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Interestingly non-derivatized aminopyridines display fragmentation chemistry similar to 
aniline rather than pyridine, i.e. metastable HNC loss rather than stable neutral species 
HCN
191
. It was observed during product ion acquisition that varying the applied collision 
energy favors different fragmentation routes, hence 20 eV and 60 eV were chosen as 
representative collision energies to illustrate all the observed ions on fragmentation of m/z 
123. DMAP can fragment directly in various ways giving rise to MS
2
 product ions m/z 27, 79, 
94, 96, 107 and 108, which are obtained when 20 eV collision energy is applied. On the other 
hand 60 eV favors the formation of MS
3
 m/z 28, 66, 79 and 92. The observed 107>28 
transition gives rise to neutral pyridine which is protonated in the collision cell due to high 
residence time. The protonated pyridine m/z 80 further fragments to aziridene- and 
cyclopropene type species as depicted in Figure 12. 
 
 
 
Figure 12 - Proposed fragmentation pathway of [DMAP+H]
+
 
 
4.1.2. Determination of the optimal LC-MS/MS method via DoE 
 
The problems of a complex system such as LC-MS/MS influenced by many factors are 
handled more efficiently by DoE than the conventional COST approach thus the use of DoE 
for LCMS method development is proposed. The optimization of an analytical technique by 
the proposed approach is to determine which factors and combination of factors will result in 
optimal operating conditions. Note that prior to conducting any experiment, the analyst has to 
specify some input conditions: the number of factors and their ranges, the number of 
responses and the experimental objectives. The first step was to carry out a risk assessment to 
define the variables of the analytical method that could have impact on specific responses. As 
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described in chapter 4.1.1, 123>107 transition was selected to be monitored by the MS 
detector and during its determination the DoE ranges of the related MS factors were also 
established. The ranges of the LC factors and the analytical column were chosen based on the 
knowledge of experienced analysts and prior knowledge on the chromatographic behavior of 
glucocorticoids. The ranges of the variables chosen for the method development and the 
responses as well as their relation to the LCMS instrument are given in Figure 13. 
 
 
 
Figure 13 – Chosen factors with their ranges (blue bubbles), responses 
(green bubbles) and their relation to LC-MS/MS where the dimensions for 
F, G, Vinj, Ecol, Econ are mL.min
-1
, % eluent B, L, eV and V respectively.     
- 
DoE is applicable to three types of problem solving: screening, optimization and robustness 
testing
192
. Optimization is more complex than screening (searching for relevant factors and 
identifying their ranges), thus optimization designs require more experiments per factor while 
the screening designs require few experiments in relation to the number of factors. Typically 
the first approach when using DoE is a screening method where a linear model is fitted. In 
this particular case a quadratic model was chosen as it could better fit the results without 
increasing the number of runs too much.  Using the software Modde, a Central Composite 
Face (CCF) design with 26 runs and 3 center points was created to support such a model. The 
advantage of this approach is that it includes quadratic terms as well as interactions between 
variables. The LC factors chosen for the DoE study includes flow, gradient and injection 
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volume while cone voltage and collision energy were chosen as MS parameters. These factors 
were varied systematically in the defined ranges around the center-point experiment. The 
benefit of the described DoE approach is that it allows the simultaneous study of both the LC 
and MS factors rather than varying them in two, consecutive designs. This way the 
interactions between the LC and MS parameters are being considered. As for any analytical 
method development prior to conducting any experiments, the analyst has to specify the initial 
conditions. It has been decided to fix the column, the solvent and ionization agent of the 
eluent, while the initial MS parameters were identified by direct diffusion of the DMAP 
analyte (see chapter 4.1.1). On the other hand, the standard reference LC operating conditions 
were decided based on the general knowledge of a trained analyst. The runs selected by DoE 
are laid out in a symmetrical fashion around the standard reference experiment namely the 
center-point (Table A3-4 in the Appendix). Figure 14 shows the regression coefficients of the 
quadratic model and their confidence intervals for each response. 
 
 
 
Figure 14 – Regression coefficient plot for the CCF design of method development 
 
The coefficients representing one factor only are called linear terms while those squared are 
called quadratic terms.  They reveal the real effects and importance of each factor. Since the 
response Sep is calculated as the difference between the retention times of the API and 
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DMAP, it shows similar behavior as the response Time itself F, F
2
 and G being the most 
significant terms. Similarly, responses Apeak and S/N also share the most significant terms 
being Ecol
2
 and Vinj. However, the third most relevant term for S/N is F
2
 but, on the contrary, 
for Apeak it is Econ
2
. In other words, the noise of the measurement depends more on the flow 
while the peak area on the cone voltage. The coefficients representing the interactions among 
certain factors are called interaction terms and they show less relevance than the terms 
mentioned. Since the uncertainty of the coefficients is given by the confidence intervals, those 
with much higher uncertainties than the actual values themselves were eliminated leading to a 
better DoE model. In this sense better model means a higher Q
2
 value. Note that however, 
Econ for the variable Apeak has no impact, it was still kept because its squared coefficient 
presents a significant factor. The summary of fit with the obtained model fit (R
2
), 
predictability (Q
2
), validity of the model (V) and reproducibility (R) values of the CCF model 
are shown in Figure 15. 
 
 
 
Figure 15 – Summary of fit for the CCF design of method development 
 
The theoretical optimum value for all descriptive parameter is 1. The fit
 
is over 0.98 for all 
responses, meaning that the model fits the data perfectly. Reproducibility is always higher 
than 0.8, meaning that under the same conditions the variation of all responses at the center 
point, compared to the total variation of the responses, are low. The most important 
descriptive parameter is predictability giving information about how accurately the model can 
predict the responses. The Q
2
 value is higher than 0.7 for all responses, which is considered to 
be very good in DoE models. The validity of the model is good for Sep and Time, acceptable 
for S/N but the negative value for Apeak is caused by almost equal center points. Note, that the 
negative value means that the model error is larger than the replicate error which is only 
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acceptable if the response of center points is almost identical as in our cause. Figure 16 
demonstrates the higher the Vinj and F the higher the Apeak while it reaches a global maximum 
as the MS variables, Econ and Ecol, are varied. The descriptive statistics of the model can be 
found in the Appendix (Table A5). 
 
 
 
Figure 16 – Dependence of Apeak on Econ, Ecol, Vinj and F 
 
After defining the relationship between the variables of the method and the outputs using a 
quadratic model and establishing the design space – which is the ranges of the variables 
giving acceptable results – the optimum point was determined. Data evaluation was done by 
the optimizer function of Modde which is based on a simplex approach. The criteria for the 
responses were systematically aggravated in order to narrow the range of the so-called sweet 
spot where all the previously set criteria are met (Figure A1 in the Appendix). The optimum 
method parameters were determined using the optimizer function of Modde which gave 30 V, 
35 V, 26 L, 0.5 mL.min-1, 70% eluent B for Ecol, Econ, Vinj, F and G respectively. The 
software can automatically calculate the optimum parameters based on the model built on the 
relations among factors determined from the DoE method development runs. The DoE 
approach resulted in a general method for the trace analysis of DMAP which was investigated 
with glucocorticoid matrices such as Meta, Beclometasone Dipropionante, Fluticasone 
Propionate and Holobetasole proprionate resulting in 4.05, 4.47, 4.08, 3.88 min retention time 
respectively. The corresponding chromatograms are presented in Figure 17 where DMAP 
elutes at 0.61 min – detected by MS – and Meta elutes at 4.08. 
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Figure 17 – Chromatogram of DMAP and Meta separation 
 
Given the fact that the retention time of DMAP is always around 0.6 min and the APIs elute 
at least 3 min later, it is concluded that all of the glucocorticoids tested are 
chromatographically separated from the analyte. Since there is no API/DMAP interference the 
method can be used to determine DMAP contents in the above mentioned steroids. 
Additionally, a switch valve was fitted between the UV and MS detectors in order to avoid 
overloading the electrospray source with highly concentrated API solutions by sending the 
eluent to waste after 2 min.  Although the method can be used with various glucocorticoids it 
was validated only for the quantification of DMAP in Mometasone furoate. 
 
4.1.3. Robustness of the method 
 
Demonstrating robustness of a particular analytical method is of high importance in order to 
meet regulatory and manufacturing standards. Although FDA and EMA as pharmaceutical 
regulatory authorities do not require robustness evaluation, it is implied in the scope of good 
manufacturing practices. Similarly to analytical method development, robustness studies were 
conventionally performed via COST approach providing limited data. However, DoE assisted 
multivariable testing is a newer approach to in depth robustness studies. The aim during the 
robustness study was to determine the sensitivity of the method to small changes in the factor 
settings. In LC-MS/MS such small changes usually correspond to fluctuations in the factors 
occurring due to electrical and mechanical errors and deviations. 
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In addition to the first CCF design used for the LCMS method development, variables such as 
column temperature and quadrupole resolution were considered in the robustness study. The 
rationale behind the expenditure of the number of variables lies in the change of the DoE 
design and objective. The CCF design which was used originally for the method development 
is capable of providing thorough relations between the factors and its purpose is to create a 
model, hence it requires more runs and thus analysis time. On the other hand, the objective of 
a robustness testing is not to build a model but to check the sensitivity of the obtained method 
to parameters that may fluctuate during the analysis, a simpler model can be applied requiring 
smaller number of runs and thus allowing a larger number of variables to be tested while still 
being time-efficient. An FF of resolution III design with 11 runs including 3 center points was 
applied for the evaluation of robustness where the focus is on evaluating the effect of small 
changes in the factors on responses and not in depth interaction analysis (Table A6 in the 
Appendix). A rapid robustness evaluation was achieved by increasing the number of factors in 
a decreased number of runs because of the new FF design. 
 
The regression coefficient plot of the robustness testing indicates the factor induced 
fluctuations of the responses (Figure A2 in the Appendix). Ecol and G have effect on Apeak and 
Sep respectively, while Time is affected by G and F. On the other hand, no factors have 
significant effect on the S/N. Note that in robustness testing only the effect of small changes 
in factors are studied. Assessing Apeak fluctuations, the highest deviation is 23% compared to 
the average of the 3 center points meeting the corporate operating procedures’ criteria of 30%. 
Fluctuations observed in Time resulted in 16% highest deviation. On the other hand, the 
remaining studied factors have negligible influence on the responses due to high 
uncertainty/value ratio. The results show some sensitivity of the attributes to changes in some 
of the variables of the method but the overall results indicate that the obtained method is 
robust. Although it is of interest to note, that contrary to our expectations, the method is not 
sensitive to fluctuation in the injection volume, whilst this was one of the key factors during 
the DoE method optimization. The summary of fit of the FF model (Figure A3 in the 
Appendix) also confirms that the factors have no significant and predictable effect on the 
responses, as the V and Q
2
 for S/N and Sep is low meaning that the model is not capable of 
describing the relationship between these attributes and the LC and MS variables. Note that an 
acceptable model was only built during the robustness testing for Time indicating that the 
relationship between time and the studied factors can be described by a quadratic model. It is 
in correspondence with the coefficient plot (Figure A2 in the Appendix) revealing the relevant 
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factors being F and G. The high variation of predictability among the responses and the low 
model validity values are consistent with the fact that the ideal results of a robustness testing 
model refinement is that no model is encountered. 
 
4.1.4. Validation of the method 
 
Validation of the instrumentation and the methods are additional requirements to ensure their 
intended purposes. The extent of the method validation will vary with the stages of drug 
development, becoming more rigorous as the drug progresses to marketing. Validation should 
cover sensitivity, specificity, accuracy, linearity and precision in order to prove the method is 
capable of its intended use. 
 
4.1.4.1. LOD and LOQ assessment  
 
Analyses of two independent DMAP spiked 5 mg.mL
-1
 Mometasone furoate glucocorticoid 
solutions were carried out to determine detection and quantification limits, thus ensuring that 
API presence in the chromatographic system does not interfere with analyte detection. Note 
that a concentration of 5 g.L
-1
 API constitutes a lesser risk of overloading the 
chromatographic column and a consequent loss of sensitivity. Tested concentration levels of 
0.03 and 0.1 ppm relative to the API (0.15 and 0.5 ng.mL
-1
 respectively) were established as 
LOD and LOQ since S/N results obtained from QuanLynx software successfully meet the 
acceptance criteria for those parameters. Also, the two independent API solutions spiked at 
LOQ level when injected three times each, demonstrate that the method is repeatable at 0.1 
ppm concentration level and can be used as a limit test. The results are presented in Table 5. 
 
Table 5 – LOD and LOQ summary of results 
 
Samples
a
 Apeak S/N
c
 
LOD#1 
n.a.
b
 
4, 4, 4 
LOD#2 3, 4, 4 
LOQ#1 2410,2749,2767 11, 11, 11 
LOQ#2 2988, 2893, 2889 11, 11, 12 
RSD 7% n.a.
b
 
 
a) Independent preparations per concentration level 
b) Not applicable 
c) S/N = Signal to noise ratio 
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4.1.4.2. System precision  
 
An API spiked sample at 1 ppm DMAP was injected six times to evaluate the precision of the 
LC-MS system and the peak areas recorded. An RSD of 0.02% was obtained which is 
considered an acceptable value. 
 
4.1.4.3. Linearity 
 
A range from 0.1 ppm to 10 ppm was considered since the TTC level is about 1 ppm. 
Determining DMAP content accurately above this value is not of great interest for 
pharmaceutical companies so ten times the TTC level was decided as upper range limit for 
academic quantification purposes. For DMAP concentrations above 10 ppm the authors 
suggest to dilute the solution accordingly in order to work within the validated concentration 
range. This parameter was assessed using spiked API solutions at six different concentration 
levels, yielding a correlation factor of r=1.000 (r
2
=0.999). 
 
4.1.4.4. Repeatability 
 
Quantification of six independent spiked sample preparations was carried out at the LOQ 
concentration level to assess the method’s ability to quantify samples in this level. The 
DMAP content for the six preparations was determined by the least squares method. The 
calculated RSD for the six concentrations is 1%, which represents an acceptable value for an 
absolute concentration of 0.5 ng.mL
-1
. 
 
4.1.4.5. DMAP recovery in Mometasone furoate 
 
A total of twelve independent recovery determinations were performed, distributed over three 
concentration levels: LOQ (six preparations), 0.5 ppm (three preparations) and 2 ppm (three 
preparations). Sample quantification was performed by the least squares method. Table 6 
displays obtained AR. Given that the absolute DMAP concentration range is 0.5-10 ng.mL
-1
 
the obtained recoveries are considered acceptable. 
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Table 6 – DMAP recovery in Meta at three different concentration levels 
 
preparation Apeak concentration (ppm) AR (%) 
LOQ#1 2410 0.083 83 
LOQ#2 2749 0.096 96 
LOQ#3 2767 0.096 96 
LOQ#4 2988 0.104 104 
LOQ#5 2893 0.101 101 
LOQ#6 2889 0.101 101 
0.5ppm#1 15618 0.567 113 
0.5ppm#2 15620 0.567 113 
0.5ppm#3 15624 0.567 113 
2ppm#1 52642 1.924 96 
2ppm#2 52616 1.923 96 
2ppm#3 52629 1.923 96 
 
4.2. Comparison of conventional and nanofiltration API purifications 
 
The schemes of the three purification processes including inputs, outputs, sources of energy 
consumption and waste formation are illustrated in Figure 18. 
 
 
 
Figure 18 – Comparison of purification processes under 
investigation: recrystallization (A), flash chromatography 
(B) and organic solvent nanofiltration (C) 
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4.2.1. Overall process performance comparison 
 
Selection of purification technologies for GTI removal from API post reaction solutions is not 
trivial: industrial feasibility, economic and environmental impact, achievable purity grade and 
API loss have to be evaluated individually to make a reasonable decision leading to a viable 
manufacturing process. Degenotoxification of APIs is fundamental to decrease toxicological 
risk to patients. GTI limits in APIs are calculated as follows: the TTC value (1.5 μg.day-1) 
divided by the maximum daily dose (g.day
-1
) gives the limit in mg.dm
-3
 to be applied to the 
active substance
190
. Considering 500 mg.day
-1
 daily dose of Meta the GTI is required to be 
controlled at 3 mg.dm
-3
, relative to the API. Consequently, a post-reaction stream containing 
10 g.L
-1
 Meta and 1 g.L
-1
 GTI requires an impurity removal higher than 99.7%. Since the 
higher the desired purity, the higher the API loss, and compromise between level of purity 
and API loss has to be made for any purification process whilst taking into account the 
threshold limit of impurities. Figure 19 demonstrates API recovery versus GTI removal for 
each process. 
 
 
 
Figure 19 – Process performance comparison for 
two case studies: Meta/DMAP and Meta/MeMs       
- 
Regarding the model GTI, recrystallization shows higher API loss without acceptable 
compensation in the API purity achieved. Despite its drawbacks, such as impurity carryover 
and API loss in the mother liquor and washing solutions, recrystallization is a widely used 
purification process due to the fact that it delivers the API in the desired crystallographic 
form. Regarding the removal of DMAP, flash chromatography shows an ideal, almost 100% 
purification level, at the cost of only a 5% loss of Meta. On the other hand, the same level of 
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GTI removal by OSN incurs significant Meta loss. Notice that 98.5% DMAP removal implies 
a loss of 4.7% Meta at 5 diavolumes. MeMS is a smaller molecule compared to DMAP and 
thus permeates through the membrane slightly easier. Hence, at the same diafiltration 
volumes, whilst the same API recovery is observed, a slightly higher amount of GTI is 
removed by OSN. MeMS removal by OSN provides an efficient route when compared with 
chromatography. About 4.5% of the API is lost during the removal of 98.9% of MeMS at 5 
diavolumes and further purification up to virtually 99.9% GTI removal is achieved with a loss 
of 6.3% API showing the robustness of this simple technique. Recrystallization is one of the 
oldest and common processes employed in pharmaceutical industry for API purification. 
Although in the current study the performance of this technique seems inferior, one should 
note that recrystallization is easily scalable and has the advantage of presenting the API in the 
required crystallographic form. In order to highlight the different operational steps of the 
processes to be compared and map API loss as well as GTI removal, the data obtained at each 
particular step, process performance, solvent and energy used, as well as key process costs are 
described in details in the following chapters. 
 
4.2.2. Stepwise process performance comparison 
 
A detailed discussion and analysis of each step of the experimental trials follows. Flash 
chromatography was performed collecting fractions of 50 cm
3
 of eluent. Removal of DMAP 
from crude Meta proved to be straightforward with an isocratic elution described in the 
experimental section of the thesis. Notice that silica gel has a slightly acidic nature which 
causes partial protonation of the basic DMAP, hence its retention on the stationary phase is 
very high (Rf = 0.05). Meta is not detected in the first 300 cm
3
 (fraction 1 to 6). 95% being 
continuously eluted without contamination by DMAP in the following 1200 cm
3
 (fractions 7 
to 30) as monitored by TFC and confirmed by HPLC-UV quantification. A higher EtOAc 
content in the eluent facilitates the elution rate of Meta resulting in lower operational time and 
solvent consumption but this option was rejected since DMAP leakage was observed 
contaminating the API and thus severely affecting purification efficiency. MeMS and Meta 
show reciprocal affinity for the stationary phases with a faster elution rate for MeMS (Rf = 
0.2) than Meta (0.02) in pure DCM. Therefore, a gradient elution (Table 4) was applied with 
initial elution with 600 dm
3
 pure DCM to elute MeMS first (fractions 1-13), followed by 
progressive increase of EtOAc to recover Meta. Results of the MeMS removal and 
corresponding Meta loss are shown in Figure 20A. Most of Meta was recovered in fractions 
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16-26 representing 90.1% of the total applied to the column. Note that these fractions 
correspond to the part of elution gradient where EtOAc content is higher than 5%. 
Intermediate fractions with eluent containing EtOAc between 0 and 5% (fractions 14 and 15) 
feature Meta with low MeMS contamination. Accordingly, fractions 14 and 15 were also 
combined with the main stream (fractions 16-26), thus the MeMS-Meta case study involves 
two analyses values: fractions 16-26 and 14-26. By collecting fraction 14-26 it is possible to 
remove 98.4% of MeMs at a cost of 9.9% API loss. Alternatively, if fractions 16-26 are 
collected up to 100% GTI removal (below LOD) can be achievable at a cost of 11.9% API 
loss, which is not significantly higher than when fractions 14-15 are included. Therefore, 
concerning further analyses, this study focuses on the best scenarios with 100% removal of 
both for MeMs and DMAP. 
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(A) Flash chromatography (B) Recrystallization (C) Organic solvent nanofiltration 
   
   
 
Figure 20 – Experimental evaluation of Meta and MeMs and/or DMAP separations. Distribution of API and GTI is shown in top panels (A) in groups 
of fraction for flash chromatography, (B) crystallization and adsorption stage in recrystallization process and (C) in function of diavolume in OSN. 
API recovery versus GTI removal for each stages are shown in bottom panels. 
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The recrystallization procedure – illustrated in Figure 18 – includes three main stages: (i) first 
recrystallization from methanol, (2) charcoal adsorption and (3) second recrystallization. 
Firstly, the API precipitates during distillation assisted solvent exchange from DCM to 
methanol enriching the mother liquor in the impurity. In the second step charcoal adsorbs the 
impurity and the API remains dissolved in the DCM:MeOH solution. Altogether four 
distillations are required during the two solvent exchanges from DCM to methanol. In order 
to consequently map both GTI removal and API loss during each steps, the amounts were 
quantified in the mother liquors, crystalline solids and charcoal filtrate as illustrated in Figure 
20B. The amount of API and GTI leaving the system through the adsorption to charcoal was 
estimated by component mass balance. Mass balances for crystallization close within 2.5% 
for both API and GTI. The largest fraction of API loss was observed in the first 
recrystallization, representing 9% and accounting for half (53%) of the total API loss over the 
3 steps. API loss on charcoal and second recrystallization accounts for about one quarter (19-
27%) each of total API loss. Although GTI removal cannot be assigned preferentially to any 
of the steps, it can be concluded that DMAP has a higher affinity to charcoal than MeMs, 
similar to that previously observation with adsorption on silica gel. 
 
Discrimination of API and GTI during purification by diafiltration featuring nanofiltration 
membranes is mainly based on their molecular size, and consequently membrane rejections of 
these species are different. The nanofiltration membrane chosen for the present application is 
GMT-oNF-2 showing good stability in DCM.  The flux across the membrane was determined 
for different applied pressures between 5 and 45 bar, with incremental steps of 5 bar. A linear 
relation of flux with pressure, with a correlation factor of 0.97 was found up to 30 bar of 
applied pressure, corresponding to a membrane permeability for DCM of 4.7 L.m
2
.h
-1
.bar
-1
. 
Experimental DCM fluxes through the membrane were 55 L.m
2
.h
-1
. The membrane rejections 
obtained at 10 and 20 bar, presented in Table 7, show that the API, with a molecular weight of 
521.44 g.mol
-1
 is effectively retained by the membrane as both GTIs, DMAP and MeMs, 
respectively, with molecular weight of 122.16 and 110.14 g.mol
-1
, cross the membrane easily. 
Since the difference in the rejection of Meta at 20 and 10 bar is negligible, but higher amounts 
of GTI crosses the membrane at 10 bar, the latter pressure was selected for experimental 
evaluation of diafiltration. Since MeMS is only a slightly smaller molecule than DMAP, its 
average rejection is not significantly lower than DMAP rejection. Note that not only 
molecular size rules solute transport through membranes but other factors such as membrane 
solute interactions and polarity may also play important roles. The results represented in 
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Figure 20C show that the higher the number of diavolumes, the higher the API loss, but on 
the contrary the increments in GTI removal become less significant. On the basis of GTI 
removal versus API recovery (Figure 20 – bottom panels) one can consider two scenarios 
concerning diavolume selection. GTI removals superior to 98.5 or 99.5% can be achieved at 
the cost of lower than 5% or 7% API loss at diavolumes of 5 and 7, respectively. Despite the 
higher purity of API achieved, higher diavolumes not only lead to higher API loss but also 
increases the solvent consumption and operation time. To be consistent with the flash 
chromatographic study, a diavolume of 7, representing the purest API, was selected for 
further analysis. 
 
Table 7 – Rejection of DMAP and MeMS impurities and Meta drug substance 
 
 rejection (%) 
 10 bar 20 bar 
MeMs 13.0±0.1 15.0±1.1 
DMAP 15.1±0.3 16.5±0.4 
Meta 99.0±0.1 99.1±0.1 
 
4.2.3. Scale-up considerations 
 
The experimental trials at a laboratorial scale were performed using 500 cm
3
 solutions with 
API and GTI concentrations of 10 mg.dm
-3
 and 2 mg.dm
-3
, respectively. In order to provide 
an environmental and economic analysis, an inventory of materials and energy of the different 
steps was prepared for the different processes (chapter 4.2.4). Furthermore, the assumptions 
and estimations applied to elaborate inventory in a scale-up scenario are also included in 
Table A7 which can be found in the Appendix. Scale-up was calculated for a factor of 2,000, 
maintaining API and GTI concentrations, corresponding to average steroid batches of 1 m
3
 
featuring 10 kg of API. Production of 10 batches per annum was considered, satisfying a 
demand of about 100 kg API. 
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(A) Flash chromatography (B) Recrystallization (C) Organic solvent nanofiltration 
  
 
 
Main equipment: (i) E-2 is the silica gel column, active carbon column or OSN membrane housing for flash chromatography, recrystallization 
and OSN process respectively; (ii) E-1 vessel with jacket and stirrer, E-3 filter, E-4 dryer, E-5 distillation column; and (iii) C-1 condenser of the 
stirred vessel, C-2 condenser of the dryer, C-3 condenser of the distillation column, B-1 boiler of the distillation column. Tanks: A-1, auxiliary 
tank for API feed, A-2 auxiliary tank for approved DCM, A-2A auxiliary tank for approved EtOAc or MeOH, A-3 auxiliary tank for waste 
solvent to be recycled or disposed, A-3A auxiliary tank for diluted pure API, A-4 auxiliary tank for DCM to be approved, A-4A auxiliary tank 
for EtOAc or MeOH to be approved (A-3A is only required for Flash Chromatography. A-2, A-4 are not required for the OSN process). Pumps: 
(i) P3 is a centrifugal pump for solvent elution through silica and charcoal columns for flash chromatography and recrystallization process, but a 
high pressure pump in OSN; (ii) P-2 pneumatic diaphragm pump for slurry transportation, P5 Vacuum for filtration P-1, P4, P4A, P6, P7 and 
P7A are centrifugal pump for solvent transportation. (P4A and P7A are not required for OSN process) 
 
Figure 21 – Idealized process diagram for the three processes 
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Figure 21 represents the process scheme diagrams of the envisaged processes. The multi-
propose reactor E-1 is comprised of a vessel with jacket and stirrer and coupled with a 
condenser C-1 in all of the processes, allowing an internal loop for removal of solvent from 
API solutions by distillation. This is required since both flash chromatography and 
recrystallization require a reduction of 90% of the volume of DCM. The slurry obtained is fed 
to the main process, i.e the silica column E-2 for flash chromatography or remains in reactor 
E-1 for solvent exchange (DCM → methanol) for recrystallization. Note, that at the end of 
each process, including OSN, the purified API solution is fed to E-1 for concentration by 
distilled to 90% in volume in order to obtain a slurry that can be sent to E-3 for filtration. The 
wet cake obtained is dried in E-4. The specific assumptions for the main steps of each process 
which take place in E-1 and E-2, are discussed below. Note, that the scale-up data is only 
indicative, with the objective of rational selection of the best purification process in terms of 
sustainability and green aspects. The scale-up of the process would require experimental 
justification and adjustment of parameters once the lead process has been selected. 
 
At a lab scale, increase of scale for Flash Chromatography is usually performed by increasing 
column diameter while maintaining both its height and the linear elution solvent velocity. 
However, such an approach can only be followed to a certain extent without compromising 
homogeneous plug flow through the column at large diameters.  Ideally the column diameter 
should remain below 63 cm. Therefore, for a significantly large scale-up it is inevitable that 
the column high increases. The higher the column, the higher the contact time between the 
solutes and the stationary phase promoting better solute separations, i.e. a higher number of 
theoretical separation plates is verified at the same linear velocity. However, a conservative 
approach was taken in which a potential increase in number of theoretical plates was not 
considered and a silica to API ratio of 1.1 was applied.  The ratio of column height to 
diameter was kept at a value of about 3.1, corresponding to a column diameter and height of 
63 cm and 2 m respectively. A linear velocity of 2.55 cm.min
-1
 was considered regardless of 
the scale, corresponding to a flow rate of about 475 m
3
.hour
-1
. Solvent volumes and fractions 
enriched in API or discharging GTI were directly scaled up by a factor of 2,000. Figure 21A 
illustrates a process scheme for the chromatography process. The 100 dm
3
 pre-concentrated 
API solution is loaded onto silica gel column E-2 for purification. The eluent fractions 
comprising pure or GTI contaminated solvent are collected in tank A-3. The eluent fractions 
enriched in the purified API are collected in tank A-3B and then transferred to E-1 in order to 
be concentrated to yield a slurry with a volume of 100 dm
3
 whilst the distilled solvent is 
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collected in tank A-3. The slurry is transferred to filter E-3 using a diaphragm pump and the 
wet cake is manually transferred to E-4 for drying. Tank A-3 contains large amounts of 
solvent and GTI.  
 
Scale-up of the recrystallization is estimated based on volume and masses, using a scale-up 
factor of 2,000 and an assumption of maintaining same performance level. Charcoal to API 
mass ratio is maintained at a value of 0.6 while filters are scaled on the basis of solution 
volume to filter membrane area. Figure 21B represents the process scheme diagram of the 
recrystallization process. The 1 m
3
 API crude solution is loaded to E-1 and solvent exchange I 
(DCM → methanol) is carried out in parallel with the concentration of the solution to 100 dm3 
by distillation at 50 ºC of the solvent in two cycles of addition of fresh methanol to tank E-1 
followed by distillation of the same volume, thus obtaining the API in 100 dm
3
 methanol. In 
recrystallization I the API mixture is cooled down to 10 ºC at a rate of 30 ºC.h
-1
, and 
maintained at 10 ºC for 2 additional hours. The precipitated API is then transferred to filter E-
3 where a further 80 dm
3
 of methanol at 10 ºC is used to wash the crystals beore manually 
transferring to E-1, where a mixture of 400 dm
3
 DCM:MeOH (1:1) is used for complete 
dissolution of the API. The charcoal operation stage is carried out by recalculation of the 
solution obtained at a flow rate of 1.5 m
3
.h
-1
 through charcoal column E-2 and reactor E-1 
during 3 hours (>10 volumes). The charcoal column is washed with a further 80 dm
3
 of fresh 
DCM. Solvent exchange II is carried out by concentration of the solution to 100 dm
3
 by 
distillation at 50 ºC and addition of 100 dm
3
 fresh methanol followed by distillation until the 
original volume is achieved. The mixture is then submitted to recrystallization II, following 
the procedure of recrystallization I where after, the crystals are manually transferred to dryer 
E-4. All the distilled and filtered solvents are collected in tank A-3. 
 
The OSN process scale-up assumes constant ratio of load volume to membrane area, a 
diavolume of 7 and the use of 0.5 m
3
 of solvent for preconditioning/cleaning the membrane 
between batches. An operation time of 7 hours was estimated, corresponding to a membrane 
area of 20 m
2
. Note however that shorter operation times can easily be achieved by increasing 
membrane area, e.g. an increase in membrane area from the 20 to 35 m
2
 l corresponds to an 
operation time of less than 4 hours. Figure 21C represents the OSN process scheme diagram. 
The crude API solution is loaded to tank E-1 and then circulated between tank E-1 and the 
OSN membrane modules E-2. E-1 and E-2 are pressurized to 10 bar using a high pressure 
pump, P-3. The diafiltration is carried out by pumping additional DCM from tank A-2 into the 
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pressurized vessel E-1 while the permeate is collected in tank A-3. At the end of the operation 
the retentate volume is further reduced by distillation and the distilled solvent collected in 
tank A-3, whilst the resulting slurry is transferred to E-3 for filtration and finally, the wet cake 
is manually transferred E-4 dryer. 
 
At the end of each process, the use of an additional 0.5 m
3
 of solvent to clean the vessels E-1, 
E-3 and A-3 and respective connecting pipes is considered. All the solvents removed from the 
main stream – e.g. (i) internal loop distillations from E-1 for volume reduction of initial crude 
API and final purified API solution, as well as API solvent exchange in recrystallization, (ii) 
eluent or permeate solutions containing GTI resulting from the silica column or OSN 
membrane, (iii) solutions from E-3 obtained from filtration of crystals and final slurry 
filtrations in E-3 and wet cake drying trough C-2, and (iv) vessel and pipe washings – are 
collected in tank A-3 to be eventually recycled. At the end of the API purification, pump P-6 
can be used either to transfer solvent for off- or on-site disposal, e.g. by incineration or 
recovery by distillation. An optional distillation unit (E-5/C-3) is suggested with this aim in 
each of the processes. This alternative implies additional capital and operating costs for the 
different processes.  Continuous lines represent pipes connecting equipment used in the main 
process and dotted lines represent pipes connecting equipment only needed when solvent is 
recycled. The effect of solvent recovery on the costs and environmental impact are discussed 
in chapter 4.2.4 and 4.2.5, respectively. 
 
4.2.4. Inventory and cost analysis 
 
Capital costs estimated in the current analysis include (i) main equipment costs based on 
process schemes established in Figure 21 and (ii) indirect capital costs based on multiples of 
main equipment costs as suggested in the literature
193
, which includes additional costs such as 
for assembling piping, instrumentation, electrical installation, process buildings, utilities, 
storage, site development and ancillary buildings (respectively at ratios of 0.4, 0.7, 0.2, 0.1, 
0.15, 0.5, 0.15, 0.5, and 0.15 of total main equipment cost) as well as design, contractors fees 
and contingency (at a ratio of 0.60)
194
. Therefore, the total capital cost can be calculated as 
3.95 times the main equipment costs. The annual capital costs takes into account a 10 year 
amortization period. Operation costs, annual maintenance costs and insurances are then 
calculated as 10%, 5% and 1% of total capital costs. Comparison of capital costs is shown in 
Figure 22. 
 72 
 
 
Figure 22 – Comparison of capital costs 
 
Inputs and outputs of the process are represented in Figure 23. Particular attention is given 
first to solvent and energy consumption with the respective CO2 footprint and waste generated 
and secondly to process time and full time equivalent labor, which is estimated for the three 
alternative processes. 
 
 
 
Figure 23 – Inputs and outputs of the purification 
processes where the blue, green, red and yellow bubbles 
represent the input, process, output and solvent recovery 
respectively (* including E-1/C-1 internal distillation)    
- 
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The selective agent and solvent requirements per batch are shown in Figure 24 where DCM, 
EtOAc and methanol costs are assumed as 998, 1039 and 340 €.m-3. Silica and activated 
carbon costs considered were 31.4 and 18.7 €.kg-1 and membrane cost was 2,000 €.m-2. The 
process generating the largest amount of solid waste is flash chromatography with the 
disposal of 330 kg silica gel per batch (31.4 €.kg-1). On the other hand, recrystallization 
resulting in 6 kg charcoal per batch (18.7 €.kg-1) and the disposal of OSN membrane modules 
every two years are both negligible. The solvent in tank A-3 for disposal or recycle includes 
fresh solvent added during the process and the solvent from the crude API solution (1 m
3
). 
OSN is clearly the most solvent intensive process, recrystallization requiring the lowest 
amount of solvents. As described in Figure 22, the processes include an internal distillation 
stage for API concentration and solvent exchange, which takes place at E-1/C-1. Such 
distillations are energy intensive, thus the amount of solvent distilled at these steps in each of 
the processes is also shown in Figure 24A. 
 
 
 
Figure 24 – Solvent and energy consumption comparison of the processes 
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The energy requirements for heating (steam) and cooling (brine) in the internal distillation 
stage (E-1/C-1), in the condenser C-2, in the cooling ramps of the crystallization (E-1) and for 
the external distillation unit (solvent recovery) were calculated taking into account solvent 
heat capacities and heat of vaporization. The outcome is shown in Figure 24B. Energy 
requirement calculations for pumping and stirring take into account power, time and volumes. 
All the pumps (P-1, P-4, P-4A, P-7 and P-7A) used to fill and empty tanks were assumed to 
be set to a flow rate of 5 m
3
.h
-1
 while P-6 is set to the corresponding distillation flow rate. 
During OSN and flash chromatography the operation time of the diaphragm pump (P-2) and 
vacuum filtration (P-5) is estimated to be 2 hours, while recrystallization calls for 4 hours due 
to the fact that the respective operations are repeated twice. Estimated flow rates of P-3 are 
0.475, 1.5 and 1.1 m
3
.h
-1
 for flash chromatography (5.5 and 7 hours/batch for MeMs and 
DMAP removal, respectively), recrystallization (3 hours/batch for charcoal) and OSN 
processes (7 hours/batch), respectively. The volume of multipurpose reactor E-1 is 1 m
3
 for 
OSN and 0.5 m
3
 for flash chromatography and recrystallization. Stirring times were estimated 
based on filling, emptying and cleaning tank E-1 (3.5 to 5.5 hours), internal loop distillations 
for solution concentration and solvent exchange and main operations (1 to 4.5 hours), and 
main operations (i) two crystallization and charcoal adsorption (about 12 hours) for the 
recrystallization and (ii) membrane preconditioning/cleaning and diafiltration (7 hours) for the 
OSN process.  Additional times considered include 8 hours for final drying of API, 3 hours 
for changing silica and charcoal replacement between each batch and 1 working shift for 
membrane replacement/maintenance every 5 batches (1.6 hours per batch).  
 
Total batch times with and without the option of solvent recovery are considered and are 
shown in Figure 24B. Taking into account, main operation times, which include set up, 
cleaning and shut down times, but not drying time, between 2 and 3 shifts are required. Shifts 
for flash chromatography and OSN process with two FTE are allocated for each shift for 
operational work. Recrystallization, on the other hand, given that it is a more time consuming 
process is given 4 shifts and since these include operations that are more labor intensive, e.g. 
more handling slurries and solids, 4 FTE are allocated for each shift for operational work. 
OSN is more solvent intensive, therefore for additional solvent recovery additional FTEs were 
considered being 2 for the OSN process, but only one for the other two processes. An average 
wage cost of 30,000 € per annum was considered for operators. Total labor costs were 
calculated on the basis of 10 batches per year using the, operating labor mentioned. 
Additional costs for supervision and analytical laboratory costs were calculated as 20% of 
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operating labor costs; plant overheads being calculated as 50% of operating labor costs. Total 
yearly costs for the three processes are represented in Figure 25. 
 
 
 
Figure 25 – Economic comparison of the processes 
 
4.2.5. Environmental and economic impact 
 
The three processes are conceptually quite different, however for cost comparison the variable 
costs, the inventory of inputs and outputs had been organized in four categories: (i) process 
performance indicators related to the API loss and GTI removal; (ii) mass intensity related to 
solvent consumption, discharged materials, selective agent input and solid disposal; and (iii) 
energy intensity and (iv) carbon footprint. Further qualitative analysis was carried out related 
to (v) operation time and labor requirements; and (vi) process complexity and scale-up 
complexity. Process performances are estimated as API loss and GTI removal and are 
illustrated in Figure 19. Note that as scale increases, the fraction of API lost in a 
recrystallization process tend to decrease
195
. The detailed data for the evaluation of mass and 
energy intensity are illustrated in Figure 24. GSK suggests a metric system for assessment 
from 1 to 10 (the higher the better) of the impact of solvent use based on four vectors (i) 
waste, considering solvent recycling, incineration, VOC and biotreatment issues; (ii) 
environmental impact addressing solvent fate and effect on the environment; (iii) health - 
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acute and chronic effects and exposure potential; and (iv) safety, which considers explosivity, 
flammability and operational hazards. According with the GSK methodology
97
, use of 
solvents categorize between 1 and 3 (red flag) is associated with major issues to which 
appropriate control procedures have to be implemented, between 4 to 7 (white flag) some 
issues have been identify and control procedures should be considered, and for values higher 
than 8 there are no issues identified. The mass intensity is dominated by the use of DCM, 
however it would be interesting to have an insight into the mixtures with solvents of lower 
impact. EtOAc and methanol used in flash chromatography and recrystallization are used in 
high enough quantities to alter the weighted average of such impacts. The calculated values 
are presented in Table 8, where it is shown that only in the recrystallization process the use of 
higher fractions of methanol improves both the health vector to a value of 2, which is still 
flagged red, and the environmental impact to a value of 4, in the white flag region. 
 
Table 8 – Solvent impact on waste disposal, environment, health and safety 
 
  Waste Environment Health Safety 
DCM 3 3 1 10 
EtOAc 4 9 7 4 
MeOH 3 8 4 8 
FC-DMAP 3 3 1 10 
FC-MeMS 3 3 1 10 
RC 3 4 2 10 
OSN 3 3 1 10 
 
The batch time required for each process is illustrated in Figure 24B. Note that all the 
processes have an 8 hour final drying step that is low labor intensive. Recrystallization is the 
most time consuming process and given the nature of the separation steps, strategies to 
decrease batch time are more challenging. However, scaling up of this process often results in 
a decrease of API losses and, due to the familiarity that regulator authorities have with API 
crystallization it is often a choice of preference. Scaling up flash chromatography implies a 
larger risk, with probable losses in efficiency. Reduction in the batch time would also be 
difficult without additional equipment or without losses in efficiency of the separation. OSN 
is regarded as a technique easily scaled up on the basis of membrane area. Batch time can be 
reduced by increasing membrane area. However, as OSN uses larger amount of solvents with 
the option of solvent recovery significant amount of time needs to be allocated and additional 
distillation units deployed. 
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Figure 26 – Effect of solvent recycling on the environmental impact of the processes 
 
Figure 26A shows mass intensity vs energy intensity for each of the processes and with 
disposal or recycling of the solvent (a 5% make up of the solvent is considered for each of the 
batches). It is clearly possible to dramatically reduce mass intensity by recycling the solvent 
but at the cost of an increase in energy intensity, particularly for the OSN process, which is 
the process with the highest solvent requirements, and therefore with highest energy 
requirements, when the option of recycling the solvent by distillation is followed. However, 
since mass and energy intensity are not directly comparable, those options were also 
evaluated using an economic and environment metric, cash and CO2 intensity, respectively. In 
the calculations of energy intensity, costs and associated carbon intensity, the source of 
energy was taken into account at 203.7 or 369 kg of CO2 and 27.4 or 93.5 €.MWatth
-1
, for 
steam and electricity, respectively. Solvent incineration is considered for solvent disposal. 
Interestingly, following the option of recycling narrows down process CO2 intensity to a 
range of about 100 kg of CO2 per kg of API (80 to 180 kg-CO2/kg-API), which implies a 
large reduction of CO2 footprint for the OSN process (Figure 26C). Figure 26D shows that the 
cost options for solvent disposal (considering the costs of 1.35 and 3 €.kg-1 of chlorinated 
solid and liquid waste, respectively) and solvent recycle it is fairly similar for flash 
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chromatography and recrystallization but not for OSN. In the case of OSN the option of 
recycling is cheaper than disposal, with a yearly gain of €275,000. The DCM used in the OSN 
(123 ton per year) is about double that used for flash chromatography, and thus well above the 
critical point at which it becomes cost effective to have a DCM in-site recovery unit (directed 
investment cost of €150,000), with savings in solvent and waste treatment costs of €78,000 
and €234,000. These figures are aligned with previous literature, a case study for reducing 
waste by DCM distillation in pharmaceutical processes by Dow Chemical Company
194
, which 
aimed at an initial recycle of 50% of the DCM for a total use of 124 tonnes of DCM, and with 
a final aim of recycling 95%. The projected initial investment was $140,000 and reported 
savings of raw materials and waste treatment costs were €105,000 and €335,000 respectively. 
Overall costs are very much dependent on the total API loss and Figure 26B illustrates 
calculated values for the scenarios considered in the current study assuming an API value of 
100 €.kg-1 using the values described above for the costs of API losses in addition to the GTI 
removal process costs. 
 
4.3. Screening of OSN membranes 
 
4.3.1. API and GTI rejections and fluxes 
 
The solvent fluxes for pure solvent were firstly estimate for pure solvent fluxes at different 
pressures, as resumed in Figure 27. The maximum applied pressures indicated by the 
suppliers were 35 and 20 bar for GMT-oNF-2 and for SolSep NF010206, respectively. In this 
study we did confirm experimentally that Solsep NF010206 membrane was damaged, with 
the flux increasing rapidly, at 30 bar and 40 bar, when permeating THF and MEK, 
respectively. For the permeation of the 300 mL assessed in this experiment, the GMT-oNF-2 
membrane was stable up to 45 bar. Diafiltrations were carried out for longer periods, up to 2 
days at 10 and 20 bar, and both membranes were stable for such periods. 
 
Flux was stable for all the membranes after permeation of the first 50 mL of solvent and 
permeability was calculated from the linear section of the curves obtained between 5 and 25 
bar applied pressure at a value of 3 Lh
-1
m
-2
bar
-1
 for permeation of THF in both membranes 
and MEK in SolSep NF010206. 
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Figure 27 – (A) comparison of solvent fluxes at different pressures, 
(B) changes in solvent flux at 20 bar until steady-state is reached     
- 
 
However the permeability value was 2.1 L.m
-2
.h
-1
.bar
-1
 for permeation of MEK in GMT-oNF-
2. The experimental rejections obtained for the APIs and GTIs in both solvent systems and 
membranes obtained at 10 and 20 bar are resumed as function of compound Mw in Figure 28 
and the values are summarized in Table 9 where the different cases further evaluated by 
diafiltration are highlighted. 
 
 
 
Figure 28 - API and GTI rejections for SolSep NF010206 
in THF and MEK; Borsig GMT-oNF-2 in THF and MEK 
are shown in chart A, B, C and D respectively. 
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Table 9 – Rejections of APIs and GTIs 
 
Membrane SolSep 206 GMT-oNF-2 
Solvent THF MEK THF MEK 
Pressure 
(bar) 
10 20 10 20 10 20 10 20 
ACR 0.6 6.4 2.5 2.9 1.6 2.2 5.2 6.9 
AA 2.2 3.2 0.9 1.3 2.1 2.5 6.3 7.2 
TA 7.7 10.0 14.1 18.8 16.0 17.0 18.2 20.0 
DMCC 3.4 6.4 3.9 5.8 8.5 9.3 7.6 8.7 
EtMS 16.7 17.4 7.0 9.9 20.1 21.2 18.7 31.6 
BE 8.9 12.0 10.7 13.2 12.6 17.1 12.1 19.3 
DMS 11.6 14.1 16.4 26.4 21.4 23.7 13.3 26.5 
IPU 10.4 13.4 31.9 41.9 10.8 14.9 30.3 44.3 
KP 17.4 21.5 45.7 54.0 17.8 25.4 41.0 58.9 
MeTS 23.3 38.4 35.2 48.4 23.9 36.6 49.4 67.3 
EtTS 31.8 55.5 45.9 58.5 33.9 56.5 58.3 79.4 
CHU 65.8 75.4 56.9 66.7 66.2 79.0 77.8 85.8 
LA 80.1 86.5 78.6 82.1 78.0 88.6 84.9 90.2 
Suma 90.0 91.7 93.5 94.4 91.9 95.2 92.2 93.6 
Pred 89.0 91.7 98.2 98.6 95.0 97.0 92.8 95.0 
Beta 96.4 96.6 - - 97.1 98.0 - - 
Irb 97.4 97.7 - - 99.2 99.3 - - 
Halo 99.0 99.3 97.3 98.0 99.0 99.3 97.9 98.9 
Meta 98.9 99.1 99.1 99.3 99.1 99.2 98.4 98.9 
Roxi 99.4 99.6 99.3 99.3 99.8 99.9 99.2 99.5 
         
Case A  GTIs      
Case B  APIs      
Case C         
 
 
There is only a slight increase in rejection, as pressure is increased from 10 bar to 20 bar 
(Figure 29A), which is explained by a decrease in free volume of the active layer due to 
higher compressibility, as consistent with a TFC membrane with a active layer relatively 
thick. This effect is less pronounced in the tails of lower and higher rejections on the MWCO 
curve, but become visible for intermediate rejections: the gap between rejections can be as 
large as the one observed for EtTS. This phenomenon occurred in both membranes and 
solvent systems (e.g. EtTS 58.3% vs. 79.4%, GMT-oNF-2 in MEK or 31.8% vs. 55.5%, 
SolSep NF010206 in THF). MEK promotes lower permeability and higher rejections (Figure 
29B) for GMT-oNF-2 than SolSep NF010206, whereas the same high permeability and 
similar rejections were estimated for both membranes in THF. These results could be 
explained with identical slight swelling degree of the active layer of the membranes in THF, 
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but different ones for MEK, with GMT-oNF-2 swelling less than SolSep NF010206 in this 
solvent, which leads to lower free volumes, higher rejections and lower permeability. Overall, 
rejections in MEK are higher than in THF (Figure 29C) which is the more apolar solvent. 
Further and more detailed studies are required to analyze these results. 
 
 
 
Figure 29 – Rejection comparisons at 10 vs. 20 bar; SolSep NF010206 versus 
GMT-oNF-2 and MEK vs. THF are shown in chart A, B and C respectively. 
 
 
The performance of the two OSN membranes are quite similar, providing similar rejections 
for the same compound in filtrations performed under same conditions (Figure 29B). This 
observation is in accordance with the SEM analyses (Figure 30) that show for both 
membranes an active layer of similar thicknesses (5 m), and most probably of the same 
material, silicone rubber polydimethylsiloxane (PDMS). Further amplifications, within the 
resolution limit of the SEM used do not capture an asymmetric structure of the active layer, 
indicating that most probably, this layer is comprised by a homogenous phase, such as the 
ones obtained using silicone rubber. Still it is interesting to note that in the MEK system, for a 
few compounds with intermediate Mw, there is a shift to lower rejections when SolSep 
membrane is used instead of the GMT-oNF membrane. This information is important for GTI 
removal: the SolSep membrane can provide desirable lower rejections than GMT-oNF. For 
example MeTS, EtTs and CHU have 20% lower rejection in MEK applying SolSep 
membrane compared to GMT-oNF. Notice as well that API retention is similar for both 
membranes. 
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Interestingly, the shape of the MWCO curves is quite different (Figure 28). However, the 
interpolation of the rejection curves obtained with a rejection of 90% is similar for the 2 
membranes and solvent system, at a value of 275 Da; consisting with the estimation of similar 
MWCO estimation (based on 90% rejections), the rejections, at their higher Mw range are 
virtually independent of the solvent used (Figure 29C). In the lower range of rejections, MEK 
promotes predominantly higher rejections for GMT-oNF membrane, which turns more 
challenging to remove the corresponding GTIs (IPU, MeTS, EtTS) when dissolved in MEK.  
 
 
 
 
Figure 30 – SEM images obtained for the membranes: left 
panels (A and C) refers to SolSep NF010206 and right panels (B 
and D) to Borsig Membrane GMT-oNF-2; bottom panels (C and 
D) show amplifications of the top active layer of the membranes     
- 
 
 
 
 
 
5μm 
B A 
C D 
5μm 
5μm 
5μm 
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4.3.2. Membrane stability test with peroxide 
 
An additional concern for membrane users is membrane stability: THF usually contains traces 
of peroxide which can damage the polymeric membrane, promoting pinholes and leakages 
(Figure 31). 
 
 
 
 
 
Figure 31 – A: Flux and rejection at various peroxide 
spiking levels, B: Damaged SolSep membrane after THF 
filtration in the presence of peroxide, C: Intact SolSep 
membrane after THF filtration in the absence of peroxide 
 
The amount of peroxide depends on the purity grade of the solvent, the peroxide content 
increases with time (long and/or inappropriate storage!). Furthermore, API post reaction 
solutions may contain residual peroxide when it was used as an oxidizing agent during API 
C B 
A 
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synthesis, for instance in Beta production
196
. Thus an additional experiment was performed to 
the SolSep membrane. Roxi, the API with the largest molecular weight (and thus rejection) 
was used in this study as a marker during the filtration to check the integrity of the membrane. 
Peroxide free THF was spiked with increasing amounts of peroxide from 0.5 to 25 ppm and 
used to prepare 10,000 ppm Roxi solutions. These solutions were left in contact with the 
membrane for 60 minutes and then solvent flux and Roxi rejections were estimated applying 
20 bar. The results indicate that up to 5 ppm of peroxide the membrane is stable, but it is 
attacked at concentrations of 10 ppm and higher. These effects, flux increase and observable 
differences on the membrane surface, were not present on the GMT-oNF-2 membrane, and 
thus this membrane is apparently stable to peroxide in the concentration range usually present 
in THF. 
 
4.3.3. Diafiltrations 
 
Ideally the rejection of an API and GTI would be 100% and 0% respectively, thus the API 
loss would be zero. In a diafiltration of a given volume of post reaction solution, several 
equivalent volumes of fresh solvent are added and permeate, and one can easily calculate that 
for the ideal case described the GTI removed after permeation (and addition) of 1, 2, 3 and 4 
of equivalent volumes (D=1, 2, 3 and 4), 50%, 75%, 87.5% and 93.75% of the GTI would be 
removed. Unfortunately such ideal case is statistically impossible, since the membrane 
selectivity follows a probability curve. The success of the OSN separation is mainly defined 
by the gap between the rejection values of the API and GTI pairs, which is function of 
molecular size, among other chemical and physical properties. Therefore to probe OSN stage 
feasibility several experimental diafiltration assays were performed (Figure 32). 
 
 85 
 
 
Figure 32 – Diafiltration case studies: resume of input parameters 
 
Table 10 – Diafiltration case studies 
 
Three cases were selected in order to illustrate the opportunities and challenges of the use of 
diafiltration (Figure 32, Table 10), in all the cases an initial GTI/API ratio was set to 10wt%, 
with an API concentration of 10,000 ppm. Case A illustrates a scenario where OSN is 
particularly adequate for the separation, since API and GTI rejections approach the ideal case. 
Different solvent and membrane combinations were selected (SolSep, MEK, 20 bar AA 1.3%, 
Meta 99.2% and GMT-oNF-2, THF, 20 bar Acr 2.2%, Irb 99.3%). Cases B shows how higher 
GTI rejections can present additional challenges to OSN, and how the effect of pressure was 
explored to improve GTI removal, without increasing API loss. Two examples, both using the 
same membrane, solvent and solutes, but two different pressures applied, were selected for 
this case (SolSep, MEK, 20 bar DMS 26.4%, Meta 99.3%and SolSep, MEK, 10 bar DMS 
Cases API vs GTI 
Rejections (%) Conditions: membrane, 
solvent, pressure (bar) API GTI 
Case A: 
Easy 
Irb vs ACR 99.3 2.2 GMT-oNF-2, THF 20 
Meta vs AA 99.2 1.3 SolSep, MEK, 20 
Cases B: 
High GTI 
rejection 
Meta vs DMS 99.1 16.4 SolSep, MEK, 10 
Meta vs DMS 99.3 26.4 SolSep, MEK, 20 
Case C: 
Low API 
rejections 
Suma vs 
DMCC 
95.2 9.3 GMT-oNF-2, THF, 20 
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16.4%, Meta 99.1%). Case C illustrates that a slight decrease in API rejection represents a 
dramatic increase in API loss, limiting the maximum operating dilution (GMT-oNF-2, THF, 
20 bar DMCC 9.3%, Suma 95,2%). 
 
 
 
Figure 33 – Diafiltration results: lines correspond to calculated values based 
on estimated rejections, markers correspond to experimental results. When 
reporting GTI removals or API losses, the corresponding co-dissolved API 
or GTI is indicated in the legend between brackets 
 
The examples within Case A show that is feasible to remove virtually all the GTI (more than 
99.5%) using a diavolume of 5, with API loss below 5% (3.2% and 4.5%). The data are 
initially presented as API loss and GTI removal percentages (Figure 33). However, it is 
actually GTI per API amounts that will dictate drug safety. In the present experimental study, 
model systems with initial concentrations of API were always 10 g.L
-1
 and the GTI 1 g.L
-1
, 
corresponding to initial GTI/API mass ratio of 10 wt%. These are quite high initial GTI/API 
ratios compared with the usual values find in real synthetic routes, usually in the range of 1-
5wt%. It is still worth to report the GTI content present on the final solution and the 
respective final GTI/API ratios (Figure 34). 
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Figure 34 – Resume of diafiltration results obtained in 
the case studies when the number of diavolumes was 5 
 
Notice that in Case B, changing the pressure from 20 to 10 bar, it was possible to decrease to 
more than half the final GTI level in the API. Also in the examples of Case B the rejections of 
GTIs are significantly high which makes GTI removal challenging, even though the API 
rejections are quite high at values of about 99%. Therefore higher numbers of diavolumes 
(above 5) were also tested in order to evaluate if further API purification is feasible without 
significant API loss. The results in Figure 35 show that complete GTI removal, below the 
detection limit of 0.5 ppm, were indeed achieved with API loss of about 9%. 
 
Removal of DMS from a Meta solution has been chosen as an example, which falls in Case B, 
to calculate the effectiveness of OSN in API detoxification. Steroids, such as Meta and Pred, 
are often used to treat dermatologic diseases. These can be used as oral tablets where 5, 30 
and 100 mg per day are generally considered low, moderate and high doses
197
. 
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Figure 35 – Examples of diafiltration at higher numbers of diavolumes, 
effect of pressure: lines correspond to calculated values based on 
theoretical rejections; markers correspond to experimental results         
- 
In the absence of toxicological data for the impurity the TTC for genotoxic impurities should 
be used to set limits. Calculation of the limits to be applied for DMS is as follows: the TTC 
value (1.5 μg.day-1) divided by the maximum daily dose (g.day-1) gives the limit in ppm to be 
applied to the active substance
190
. For diafiltration Case B, where DMS was removed from 
Meta in MEK at 20 bar, the maximum limit of the impurity is calculated and the numbers of 
diavolumes needed to achieve sufficiently pure API and the corresponding API loss are given 
in Table 11. Notice, that regardless the daily dose considered, for the calculated case, taking 
into account the particular conditions used, such as API concentrations and TTC value, the 
allowable concentration range of the impurities is always higher than 5 ppm. 
 
Table 11 – Dependence of diafiltration effectiveness on the API daily dose 
 
  
API daily dose 
(mg.day
-1
) 
Impurity 
limit (ppm) 
Number of 
diavolumes (-) 
API loss (%) 
Low dose 5 300 2 1.8 
Moderate dose 30 50 5 4.6 
High dose 150 10 7 5.5 
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Case C represents a boundary for the application of OSN in degenotoxification of 
pharmaceuticals, in which about 99% of the GTI is removed using a diavolume of 5, but at a 
cost of 20% of API loss, which is a similar value for the phase exchange stage in a 
conventional process. 
 
4.4. Screening and designing molecularly imprinted scavengers 
 
4.4.1. In search for IPU selective scavengers – ExploraSep® screening 
 
The aim of the screening was to rapidly identify a hit scavenger capable of selectively binding 
IPU in the presence of an API. All the scavengers are re-usable when clean solvents are used 
– in the absence of surfactants and proteins – and can be regenerated by an elution step. All 
scavengers found in ExploraSep
®
 plates are commercially available both in pre-packed SPE 
columns and as bulk adsorbents. This has the advantage that once a hit scavenger is found by 
screening (i) optimization of the separation process can be easily assessed and (ii) the scale-up 
for pilot plant and industrial scale is assured. The basic principle behind the ExploraSep
®
 
screening is the cross-reactivity of the scavengers: molecules having similar functional groups 
and framework to the template molecule can also be captured by the binding sites due to 
having a degree of flexibility in their recognition properties
198
. This approach is referred to as 
selectophore concept
199
. The work was carried out at MIP Technologies, part of Biotage AB, 
Sweden
200
. ExploraSep
®
 Screening Plate A was chosen to be screened since its scavengers 
feature different hydrophobic and carboxylic acid moieties that can possibly bind IPU. The 
screening was carried out on a multiwell plate containing 16 MIPs – and the corresponding 
reference NIPs – generated against many different templates and comprising different 
monomer chemistries. Note, that the composition of the scavengers is confidential. The 
binding percentage values of IPU and Meta on Plate A in acetonitrile:toluene (5:95) loading 
solvent are shown in Figure 36A. The selectivity (S) of the scavenger can be calculated based 
on equation 26 and the results are summarized in Figure 36B. 
 
IPU Meta
IPU
B B
S 100
B

            (eq. 26) 
 
where BIPU and BMeta are the binding percentage of IPU and Meta respectively. The highest 
selectivity of IPU over Meta was achieved by the scavenger labeled as EA088 corresponding 
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to 94% IPU binding. Interesting to note that the hit scavenger is a NIP and not a MIP. On the 
other hand, the corresponding MIP – labeled as EA087 – has 15% higher binding of IPU but a 
significant amount of Meta is also bound to the extraction phase (Figure 36). 
 
 
 
Figure 36 – Binding (A) and selectivity (B) of the 
IPU-Meta system on ExploraSep
®
 Screening Plate A 
 
In order to adjust to the current industrial needs a solvent swap was necessary from 
acetonitrile:toluene (5:95) to DCM resulting in 29% IPU and 2% Meta binding on EA088. 
The decreased capacity of the scavenger in DCM called for a specifically designed MIP 
featuring IPU as the template. 
 
4.4.2. Design and characterization of the novel scavengers 
 
Two IPU-imprinted polymers (MIP1-2) and two corresponding non-imprinted polymers 
(NIP1-2) were prepared in the absence (MIP1 and NIP1) and in the presence (MIP2 and 
NIP2) of the deprotonating agent PMP (details in chapter 3.5, Table 3). The model functional 
monomer selected for IPU scavenging is MAA being often used in non-covalent imprinting 
protocols. Usually the non-covalent molecular imprinting protocols are preferred due to the 
relative ease for preparation, template removal and recovery. Particularly, the non-covalent 
strategy involves the self-assembly of the IPU template and the MAA functional monomer via 
non-covalent interactions to form IPU-MAA complexes in DCM, a typical non-polar porogen 
for molecular imprinting. MAA features a carboxylic acid moiety which can act as a host and 
form complexes in two different ways: (i) as an acid it can protonate the target analyte 
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resulting in an ionic interaction or (ii) as a conjugate base it can attract protons from the guest. 
Despite of the fact that MAA has been applied in molecular imprinting as a functional 
monomer since the establishment of the field, up until this point in time, relatively few 
investigations have addressed (i) the mechanisms underlying the molecular recognition of 
methacrylate based MIPs, and (ii) the role of template-MAA complex formation during the 
self-assembly process in the pre-polymerization mixtures. Furthermore, the effect of a 
deprotonating agent on the complexation mechanism and strength has never been thoroughly 
investigated. In the present thesis NMR, FTIR and DFT were applied to study the 
complexation mechanism both in the presence and absence of PMP deprotonating agent. Note 
that the quantum chemical calculations were done by Peter Pogány (Budapest University of 
Technology and Economics) as part of a collaboration. Besides the complexation in the pre-
polymerization solution, the effect of a deprotonating agent on molecular recognition of the 
scavenger itself was also studied and novel indicators are proposed to numerically describe 
the effect on MIP performance. It is interesting to note that Hall et al. used a diaryl substituted 
urea derivative in anion recognition receptors whilst the present work discusses MIPs 
featuring anionic binding sites for scavenging a urea derivative
201
. 
 
The novel IPU imprinted polymers were characterized by elemental micro-analysis, FTIR and 
TGA to gain information on polymer composition and to confirm removal of the target 
molecule. BET was carried out to estimate the pore size distribution of the prepared polymers, 
as well as their specific pore volume and surface area, whereas the polymer particle size and 
shape was characterized by microscopy. The percentage by mass of carbon, hydrogen and 
nitrogen of the solvent extracted polymers determined by elemental analysis, as well as the 
expected values predicted from the feed ratio are given in Table 12 and the corresponding 
calculation is presented in chapter 3.3 under equation 5. Apart from the nitrile containing 
initiator, which when fully incorporated would give a nitrogen content of 0.15%, the only 
source of nitrogen is found in the presumed extractable IPU and PMP, which prior to 
extraction would result in a %N of 1.04.  The nitrogen content is hence informative of the 
extent template removal.  MIP1 and NIP1 exhibit a %N close to 0.15 indicating an effective 
removal of IPU if it is assumed that the initiator was incorporated 100%. This contrasts with 
MIP2 and NIP2 which both display elevated nitrogen content. Interestingly the values 
observed (0.45% and 0.42%) are in close agreement with the presumption that the IPU is 
completely removed whereas PMP is not fully extracted as would be the case where this 
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amine is ionically bound to the carboxylate of the polymer. Additional evidence for the 
presence of PMP in the polymer came from the thermal gravimetric analysis. 
 
Table 12 – Measured percentage by mass of carbon, hydrogen 
and nitrogen of the scavengers. The expected elemental 
composition assuming an exhaustive removal of IPU and PMP 
was as follows: %C=60.31; %H=7.15; %N=0.15. In the case of 
only partial removal of IPU or PMP the following N 
percentage can be expected: %N=0.46 (IPU removed, no PMP 
removed); %N=1.04 (no removal of IPU and PMP). 
 
  Carbon (%) Hydrogen (%) Nitrogen (%) 
MIP1 59.37 6.89 0.19 
MIP2 59.53 7.02 0.45 
NIP1 59.39 6.92 0.15 
NIP2 59.63 6.81 0.42 
 
All the polymers show similar thermograms.  All start to lose mass at 250 ºC, which is closely 
followed by the degradation of the material from 450 ºC onwards. Figure 37 shows the 
thermogram of the scavengers. 
 
 
 
Figure 37 – Thermograms of the scavengers demonstrate 
the presence of a small amount of PMP and methanol, 
driven from the synthetic and washing steps, respectively  
MIP2 
NIP2 
MIP1 
NIP1 
MeOH MeOH PMP 
MeOH 
MeOH PMP 
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A 2% mass loss was observed at 50 ºC presumably due to the adsorbed methanol, carried on 
from the washing step to remove the template.  It is interesting to note that the imprinted 
polymers adsorb slightly more methanol than the non-imprinted polymers. A 5% mass loss, 
with an onset at 150 ºC, was observed for both MIP2 and NIP2 polymers, but not for the 
MIP1 and NIP1, which show no weight loss at that temperature. This result agrees hence with 
the elemental analysis, confirming that, despite the intensive solvent extraction procedure 
after the MIP preparation, the PMP base used in the synthesis of MIP2 and NIP2 is still 
present in the final polymer samples. 
 
Apart from the differences described above, FTIR (Figure 38) and nitrogen sorption analysis 
(Table 13) indicated that the materials were nearly identical in terms of chemical composition 
and dry state morphology. As expected, the typical characteristic peaks of carboxylic acids 
(from the MAA functional monomer) are clearly identified corresponding to the strong and 
broad band for the O–H stretch in the region 3,300-2,500 cm-1, centered at about 3,000 cm-1, 
which are superimposed with sharp C–H stretching bands of the alkyl groups, visible in the 
same region. The carbonyl stretch C=O from the saturated and unsaturated aliphatic esters 
from the EDMA cross-linker and the MAA carboxylic group corresponds to the intense band 
at 1750 cm
-1
.  The typical carboxylate C–O stretch (1300 cm-1) and O–H bends (1430 cm-1, 
950 cm
-1
) were also observed. 
 
 
 
Figure 38 – FTIR spectra of the novel scavengers 
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Table 13 – BET and morphological characterization of the novel scavengers 
 
 
Vpo 
(ccg
-1
) 
ASS 
(m
2
g
-1
) 
rpo (nm) 
VSE 
(m3) 
Circularity 
(-) 
Convexity 
(-) 
Intensity 
(-) 
MIP1 0.969 850 0.193 43.255.25 0.670.24 0.900.11 13415 
MIP2 0.953 855 0.195 40.954.85 0.890.21 0.990.03 10813 
NIP1 0.879 801 0.195 42.943.91 0.740.24 0.950.08 12813 
NIP2 0.922 820 0.196 42.417.06 0.930.21 0.980.058 10717 
 
The nitrogen sorption analysis revealed a mesoporous morphology with an exceptionally high 
specific surface area (ASS) and pore volume (Vpo) by the BET method
202,203
. This permanent 
porosity we anticipated to be important for a broad applicability of the materials in a wide 
range of organic solvents. The properties of the imprinted and non-imprinted polymers are 
shown in Table 13. The specific surface area and pore volume increase in the following order: 
MIP2 > MIP1 > NIP2 > NIP1 but the values are similar, with a respective experimental error 
of 0.04 ccg
-1
 and 25 m
2
g
-1
. Vpo and ASS of about 0.9 ccg
-1
 and 850 m
2
g
-1 
was estimated. The 
shape of isotherms resembled Type II according to IUPAC classification (Figure 39)
204
. The 
high slope and the lack of rounded knee below a relative pressure of 0.4 P/P0 indicates that the 
formation of multilayers after the monolayer is immediate. Hysteresis indicates capillary 
condensation in meso- and macropores and closes at a relative pressure of 0.4 P/P0 (indicating 
the presence of small mesopores). 
 
 
 
Figure 39 – The isotherms observed show a typical BET isotherm for 
a poly(MAA-co-EDMA) based monolith (illustrated through NIP2) 
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The present study does not aim to optimize the morphological properties of the polymer 
particles in terms of their controlled size and shape distribution, but to focus on the molecular 
recognition properties. Hence, simple “bulk” polymerization was applied in the presence of a 
porogen which can result in macroporous materials containing very large pores. Further work, 
such as suspension polymerization
205
 may be applied in subsequent studies to obtain 
monodispersed particles of several microns in diameter. Nevertheless, the particles of the 
polymer scavengers were visualized by microscopy and the resulting images can be seen in 
Figure A4 in the Appendix. The particles were similar with respect to shape and size (Table 
13) with an average circularity around 0.8, an average spherical equivalent volume (VSE) 
around 42 µm
3
, and the majority of the particles with high convexities in a range of 0.9 to 
0.985. The light intensity mean reflects the particle compactness, with less light crossing more 
compact particles. Particles corresponding to MIP2 and NIP2 prepared in the presence of 
PMP were more compact than those prepared in the absence of PMP (MIP1 and MIP1), with 
differences of intensity means in the range of 15-18 % (Figure A5 in the Appendix). 
 
4.4.3. Molecular recognition dependence on deprotonating agents 
 
4.4.3.1. Geometrical parameters of the pre-polymerization complexes 
 
The theoretical calculations of the IPU and MAA showed that the most stable conformers of 
these two compounds are IPU
a
 and trans-MAAH (Figure 40), both for gas phase and 
implicitly treated DCM solution. The latter has already been established by several previous 
articles
206,207
. The difference of the ground state structure and the other two IPU conformers is 
significant with a value of 23 kJ.mol
-1
 in gas phase and 25 kJ.mol
-1
 in DCM for IPU
b
 and 8 
kJ.mol
-1
 in gas phase and 13 kJ.mol
-1
 in DCM for IPU
c
. However the energy difference 
between trans-MAAH and cis-MAAH is only marginal, being 1-2 kJ.mol
-1
. The complexes 
were constructed considering all the sterically different structures. 
 
The observed difference in the stability of the conformers in gas phase and DCM solution is 
insignificant. Figure 41 shows the most stable structures of the complexes in DCM solution. 
The structures of IPU:MAA
–
 (1:1) complex in both gas and liquid phase show high similarity 
(Figure 41B). The only difference in the complex structure is that the MAA
–
 moiety is more 
bent relative to IPU in DCM than in the gas phase, however this causes an energy difference 
of around 1 kJ.mol
-1
. Note that this structure is not symmetric due to the non-symmetric 
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MAA
–
 molecule (C11 and C12 are sp
2
 and sp
3
 carbon atoms respectively – for the numbering 
see Figure 41B). 
 
 
 
Figure 40 – Schematic representation of the initial 
conformers of IPU and MAA for the DFT calculations 
- 
 
  
 
 
Figure 41 – The most stable 
conformers of IPU-MAA 
complexes in DCM with the H-
bond distances given in angstroms: 
(A) 1:1 complex of MAAH and 
IPU, (B) 1:1 complex of MAA
–
 and 
IPU, (C) 1:2 complex of MAAH 
and IPU 
 
 
To explain this phenomenon better NBO analysis was applied. The electrostatic effects were, 
unexpectedly, not important in this asymmetry. Table 14 shows that the symmetry of charges 
A B 
C 
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in IPU did not change with complexation, however N5, N3 and O2 gained some negative 
charge (all together 0.084 e), whilst H4 and H6 lost some charge (0.054 e). Some smaller 
changes of the charges occur on the isopropyl part of the molecule. These charge changes 
show, that significant charge transfer should occur in the system. The charge transfer from the 
IPU N3-H4 bond and the N3 lone pair to MAA
–
 C9-O7 is around 11 kJ.mol
-1
, whilst from 
N5-H6 to C9-O8 it is only 5 kJ.mol
-1
. However the charge transfer in the other direction is 
expected to be much larger due to the lone pairs of O atoms. Two delocalized electron system 
can be found in MAA
–
: O7-C9-C10-C12 and O7-C9-O8. O7 is present in both of these, 
therefore O7 can donate more electrons to H4 of IPU than O8 to H6. This is justified by the 
NBO charge transfer analysis. The N3-H4 bond and the H4 atom receives electrons from O7 
lone pairs, O7-C9  bond and C9-C10 bond, on the contrary the N5-H6 bond and H6 atom 
receives electrons only from the O8 lone pair. The total energy of the charge transfer in the 
first case is 76 kJ.mol
-1
 and in the second case 41 kJ.mol
-1
. The higher charge transfer 
accounts for the shorter bond distance in the complex. The gas and liquid phase structures of 
MAAH:IPU (1:1) complex differ in the mutual position of the MAA sp
2
 and sp
3
 carbons, 
which are reversed in the gas phase in comparison with the structure in DCM, thus making a 
trans-MAAH-IPU
c
 more stable in gas phase compared with the cis-MAAH-IPU
c
 in DCM 
(Figure 41A). However this change also causes an energy difference of 1-2 kJ.mol
-1
. 
 
Table 14 – NBO charges in MAA–, IPUa and 1:1 complex of IPU and MAA– 
 
 MAA
–
 IPU
a
 IPU:MAA
–
 (1:1) 
C1 
– 
0.819 0.818 
O2 -0.752 -0.788 
N3, N5 -0.673 -0.697 
H4, H6 0.405 0.432 
O7 -0.821 
– 
-0.798 
O8 -0.832 -0.802 
C9 0.745 0.755 
C10 -0.107 -0.102 
C11 -0.604 -0.602 
C12 -0.378 -0.376 
 
For IPU:MAA (1:2) complexes, results were obtained only for MAAH. Unexpectedly, the 
charge density in case of two MAA
–
 would be so large, that the 1:2 complex spontaneously 
decomposes, although some higher energy minimum-type structures were found, which can 
be formed and preserved in solution for a limited time. On the other hand, a stable 
IPU:MAAH (1:2) complex was observed and its structure is depicted in Figure 41C. The 
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energy differences between the most stable complex structure observed – featuring one trans-
MAAH and one cis-MAAH conformers – and the less stable structures having two trans-
MAAH and cis-MAAH conformers are 1 kJ.mol
-1
 and 2-3 kJ.mol
-1
 respectively. It is 
interesting to note that the IPU:MAAH (1:2) complex incorporates IPU
b
 conformer while the 
IPU:MAAH (1:1) complex features IPU
c
 conformer. Despite of the fact that IPU
b
 is higher in 
energy than IPU
c
 by a value of 12 kJ.mol
-1
, the former conformer allows a better access to the 
NH and C=O moieties which are the active sites of the complexation. 
 
The FTIR experiments confirmed the existence of these binding sites.  The FTIR spectra of 
the IPU and the complex were both measured and calculated. The observed FTIR spectra can 
be found in the Appendix (Figure A6). Detailed FTIR studies of MAA in halogenated 
solvents can already be found in the literature (see Table A8 in the Appendix)
206,207
. The 
comparison of the calculated and measured spectra of IPU is summarized in Table 15. The 
self-association of IPU was not taken into account in FTIR studies, since at the value 
determined for the association constant (chapter 4.4.3.3) at the measured IPU concentration 
(20 mM) the dimer concentration was around 1% compared to the initial IPU. The FTIR is 
usually insensitive to these trace amounts. The negative or noisy peaks at 706-739, 896 and 
1266 cm
-1
 are assigned to the DCM solvent and the peaks at 2342 and 2359 cm
-1
 correspond 
to the asymmetric stretching vibration of  CO2 present in the air. 
 
The measured and calculated spectra are in a good agreement with an average difference 
between the measured and calculated frequencies of 38.8 cm
-1
. It is worth mentioning that 
consideration of anharmonicity or employing scaling factors could further improve the 
accuracy of calculations, although all the important signals are yet easily assigned. The 
biggest differences are observed in the stretching vibrations of both the CH3 and NH groups. 
In case of the complex in the absence of PMP), mainly the strongest bands of MAA can be 
found in the spectrum of the complex (951, 1204, 1300, 1375, 1454, 1636, 1697, 1730 cm
-1
) 
whilst only some CH vibration bands appear from the IPU (2872 and 2972 cm
-1
). There are 
however three bands which do not appear in either spectrum of the individual compounds 
(1177, 1423, 1541 cm
-1
). The assignment of these bands is summarized in Table 15. All three 
bands which differ in the complex are assigned to characteristical vibrational modes of 
complex NH…O and OH…O vibrations, thus giving a further evidence for the binding along 
with binding site characteristics. 
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Table 15 – Measured and calculated FTIR spectrum of 
both IPU (#1-18) and the complex (#19-21) in absence 
of PMP, different from the MAA and IPU spectra)       
- 
 
# 
measured calculated 
Assignment
b
 
Intensity
a
 
 Intensity 
[cm
-1
] [cm
-1
] [km.mol
-1
] 
1 1128 w 1139 75 δCNC, γC-CH3 
2 1167 m 1178 172 νNC, γC-CH3 
3 1229 s 1247 286 δrCNC 
4 1325 w 1351 16 γCH 
5 1368 m 1382 26 γCH 
6 1385 m 1394 29 δsCH3 
7 1423 w 1413 13 δsCH3 
8 1466 m 1492 47 δasCH3 
9 1524 vs 1549 813 γNH, δNCN 
10 1670 vs 1669 557 νCO, δNCN 
11 2342 m - - νasCO2 
12 2359 s - - νasCO2 
13 2872 w 3013 30 νsyCH3 
14 2932 m 3017 67 νsyCH3 
15 2972 s 3086 147 νasCH3 
16 3046 w 3099 85 νasCH3 
17 3339 w 3397 14 νasNH 
18 3429 m 3411 189 νsyNH 
19 1177 m 1181 83 βNH…O, βNH, νNC 
20 1423 m 1413 150 βOH…O, νNC, δsCH3 
21 1541 m 1509 119 βNH…O, νCO 
 
a
 The abbreviations vs, s, m, w and sh mean very strong, strong, medium, 
weak and shoulder, respectively. The calculated data were obtained at the 
B3LYP/6-311++G** level. 
 
b
 The abbreviations s, as, ν, δ, β, sci, r  mean symmetric, asymmetric, 
stretch, deformation, bend, scissoring and rock, respectively. 
 
4.4.3.2. Effect of the deprotonating agent on the complexation mechanism 
 
PMP is a highly basic tertiary amine (pKa = 11.25)
208
, which can deprotonate MAA forming 
methacrylate anion. First, the continuous variation method (CVM) was applied, where IPU 
mole fraction × Δδ (chemical shift change) is plotted as a function of IPU mole fraction. The 
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points of this curve are proportional to the concentration of the complex assuming solely 1:1 
complexation. The first set of experiments (CVM1) were performed in the absence of PMP 
while two more sets of CVM (CVM2, CVM3) experiments were performed in the presence of 
PMP. In the case of CVM2 PMP was proportional to MAA while in case of CVM3 the PMP 
was proportional to IPU. The results obtained from the three sets of CVM experiments are 
shown in Figure 42. The global maximum of the fitted curves occur at about the same mole 
fraction of IPU for both CVM1 (xIPU = 0.57) and CVM2 (xIPU = 0.59). This corresponds to a 
complex ratio of IPU:MAA (1.33:1) and (1.44:1), respectively. These results show two 
important findings. Firstly, there is no significant difference between the complexation 
mechanism of methacrylic acid and methacrylate anion with IPU. Note, that the binding 
strength can still be different as referred to in chapter 4.4.3.3. Secondly, either in the absence 
or in the presence of PMP the system is more complex than in a one-step complexation event, 
suggesting (i) the formation not only of 1:1 but 1:2 and 2:1 complexes as well as (ii) the self 
association of IPU. Given the proportion of IPU:MAA (1:4) in the pre-polymerization 
solution the presence of IPU:MAA (2:1) complex can be considered as negligible. Hence, the 
present study focuses only on the IPU:MAA of (1:2).   
 
In order to investigate the importance of the amount of deprotonating agent on the 
complexation mechanism, the PMP:MAA ratio was radically perturbed in CVM3. Hence, 
PMP was set to be proportional to IPU (1:1) instead of MAA, the PMP:MAA ratio varied 
throughout experiment CVM3 (Figure 42C). Up until an IPU mole fraction of 0.5 the PMP is 
in excess compared to MAA, resulting in mainly deprotonated MAA, whilst when the IPU 
mole fraction reaches levels of more than 0.5 the MAA is in excess compared to PMP, leading to 
mainly protonated MAA. The continuous variation of the PMP:MAA ratio during CVM3 
leads to an unusual Job plot having a maximum at an IPU mole fraction of 0.7. At low IPU 
mole fractions the shape of the curve is similar to the CVM2 curve. This indicates an acid-
base equilibrium reaction between PMP and MAA. Thus both methacrylic acid and the 
conjugate base are present, forming complexes with IPU, and resulting in anomalous 
behaviors of the chemical shifts. These results indicate that the proper choice of the 
concentration of the deprotonating agent is crucial for the pre-polymerization solution of 
MIPs, since when in excess this can hamper the binding of the target molecule by the 
functional monomer. It is interesting to note, that the H3 and H1 (Figure 10) signals of IPU 
change compared to the other signals. The explanation of this phenomena was aided by DFT 
calculations, since in some non-ground state but minimum-type complex structures the MAA 
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O3 (both as MAAH and MAA
–
) can form weak H-bonds with H3 and H4 of IPU, indicating 
also that the effect is much weaker for H4 than for H3. These structures have energies in the 
range of 20-50 kJ.mol
-1
 above the ground state. 
 
  
 
 
 
 
Figure 42 – Job plot of the IPU-
MAA(-PMP) complex, the blue 
triangles and green squares are 
attributed to the H1 and H3 signals of 
IPU respectively: (A) without PMP 
(CVM1), (B) with PMP concentration 
fixed to MAA (CVM2), (C) with PMP 
concentration fixed to IPU (CVM3)     
-         
 
 
IPU is the observed species for all NMR experiments (titration and CVM) and its H1 and H3 
proton were chosen to be followed throughout the NMR studies. The rational behind the 
selection of the H1 proton is as follows: (i) no peak overlapping occurs throughout the 
titration, (ii) the proton is directly involved in the complexation under investigation. To 
confirm that the observed chemical shifts are due to complexation between IPU and MAA, 
two additional studies were carried out: (i) self-association of IPU; (ii) the effect of PMP on 
the IPU signals in the absence of MAA were assessed. Although the two H1 signals of IPU 
were found to be identical while being titrated with MAA irrespectively of the presence of 
PMP, during the self-association experiments at higher concentrations the H1 signal splits. 
Figure 43 shows the downfield shift (0.201 ppm) and splitting of the H1 signals as well as the 
upfield shift (0.009 ppm) of the H4 doublet. This can be explained by the different behavior 
of the two H1 groups in the dimer as opposed to the IPU-MAA(-PMP) complex. The latter 
contains the flexible MAA structures, while the dimer has only IPU molecules which are 
more rigid due to their two isopropyl groups promoting steric hindrance. Despite of the low 
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solubility of IPU (50 mM in CDCl3) thus making it difficult to reach the saturation of the self-
association curve, the self-association constant was estimated to be 0.485 dm
3
.mol
-1
. As 
predicted, a small association constant was obtained, which is only significant at high IPU 
concentrations or in the presence of low concentrations of MAA, i.e. at the initial points of the 
NMR titrations. Although the H3 signals of IPU continually change during the titration with 
MAA irrespective of the presence of PMP, during the self-association experiments, the H3 
signals did not shift. This observation corresponds with the low value of self-association 
constant. Furthermore, neither the H1 nor the H3 signals shift during the titration of IPU with 
PMP in the absence of MAA, confirming that complexation only occurs in the presence of 
MAA whilst the PMP is present only as a deprotonating agent. 
 
 
 
Figure 43 – Self-association of IPU in the concentration range 
of 1-40 mM in CDCl3 indicating the (i) upfield shift of H4, (ii) 
the downfield shift of H1 as well as its split and (iii) the no-
shift of H3 – the arrows indicate the increase of concentration  
- 
 
4.4.3.3. Effect of the deprotonating agent on the complexation strength 
 
In order to investigate the effect of the deprotonating agent on the binding strength between 
the IPU and the functional monomer, four sets of NMR titrations were carried out both in the 
absence and in the presence of PMP at concentrations of 5 and 10 mM IPU. The observed 
chemical shifts are shown in Figure 44 whilst a typical spectrum indicating all the chemical 
shifts of the system studied can be found in the Appendix (Figure A7). For the calculation of 
the IPU-MAA(-PMP) binding constants, the self-association constant of IPU was considered 
only for the H1 signals, since the H3 signals do not shift due to the self-association of IPU – 
vide supra. In the case where 5 mM IPU was titrated with MAA(-PMP) the fitting was carried 
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out considering only a single-step complexation with the formation of 1:1 complexes. On the 
other hand, when 10 mM IPU was titrated with MAA the IPU:MAA (1:2) complex was also 
considered due to the higher final proportion of MAA/IPU. The association constants and 
chemical shifts of the pure compounds obtained are summarized in Table 16. 
 
 
 
Figure 44 – Measured chemical shifts of H1 (filled signs) and H3 
(empty signs) and the fitted curves (lines) for the NMR titration of IPU-
MAA(-PMP) system where the red rectangular, blue circular and green 
triangular data sets represent titration T2, T1 and T3 respectively where 
T1 (5 mM IPU) and T2 (10 mM IPU) were performed in the absence of 
PMP, while T3 (5 mM IPU) was performed in the presence of PMP.      
- 
According to the conclusions drawn from the Job plot, the IPU-MAA complexation is multi-
step. At higher IPU ratios the IPU:MAA (2:1) complex is dominating, while at higher MAA 
proportions the prevailing complex is IPU:MAA (1:2). Therefore, only 1:1 complexes were 
considered for the calculation of the binding constant where the relative quantities of MAA 
were lower (IPU titrated up to 2 equivalent MAA). As expected, this approach did not result 
in acceptable fitting for the set of NMR titrations where the relative MAA quantities were 
higher (IPU titrated with 5 equivalent MAA). For the latter experiments either 1:2 or 2:1 
complexes were considered to fit the experimental data, both giving similar results. Due to the 
high excess of MAA in the pre-polymerization solution, the results are given only for 
IPU:MAA (1:2). The calculated average values for the association constants and the standard 
deviations are summarized in Table 16. 
 
 
 
 104 
Table 16 – Calculated association constants and observed 
chemical shifts of the H1 of IPU during the titration experiments 
- 
 
 T1 (H1) T1 (H3) T2 (H1) T2 (H3) T3 (H1) T3 (H3) 
1K  555 537 556 482 1144 1133 
2K  - - 1.12 0.78 - - 
IPUδ  3.905 3.847 3.905 3.847 3.905 3.846 
1C
δ  4.423 3.787 4.450 3.785 4.104 3.836 
2C
δ  - - 9.383 3.692 - - 
1K  average 532±35 1138±8 
2K  average - 0.95±0.24 - 
 
However, the addition of PMP results in the formation of methacrylate anion which is 
expected to form a stronger complex with IPU than the free methacrylic acid. The 
expectations are in correspondence with the results of the bulk IPU rebinding studies (see 
chapter 4.5.2.1, Figure 52), where MIP2 (prepared in the presence of PMP) showed 26% 
higher rebinding of IPU than MIP1 (prepared in the absence of PMP). This significant 
improvement of binding is consistent with the results shown in Table 16, indicating that the 
binding constant between IPU and MAA is 2.1 times higher when PMP is used. 
 
In order to prove the importance of considering the higher order complexes and the self-
association, the T1 and T2 NMR data representing the 5 and 10 mM IPU titrations were, in 
addition, evaluated in a conventional fashion. Assumptions are often made in the literature 
during the evaluation of complexation studies of MIPs wherein higher order complexes and 
self-association are neglected
158,159
. Following this approach and the widely applied Rose-
Drago method the calculated K
-1
 is depicted as a function of the chosen set of Δδmax values. 
At different Δδmax values different lines are obtained which have a common intersection point 
giving the value of K
-1
. Association constants of 525 dm
3
.mol
-1
 and 437 dm
3
.mol
-1
 were 
obtained with standard deviations being 195 dm
3
.mol
-1
 and 574 dm
3
.mol
-1
 for the T1 and T2 
datasets, respectively. The Rose-Drago plot can be found in the Appendix (Figure A8). It 
should be noted that (i) the standard deviations are of the same order of magnitude as the 
association constants themselves and (ii) the calculation resulted in a negative association 
constant. Evaluation of this data hence demonstrates that for higher concentrations one has to 
consider self-association as well as higher order complexes. 
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The reactions leading to complex formation were also investigated and the corresponding 
reaction energies are summarized in Table 17. Note that in solution, due to both the existence 
of configurations with close lying energy levels and the presence of thermal perturbation, the 
simultaneous appearance of more complex structures is expected. Hence, the measured 
association constants cannot be assigned to one, well-defined structure. The reaction energies 
related to the formation of the most stable conformers, were calculated for 1:1 and 1:2 
complexes as shown in equation 27-28. The associated Gibbs free energies were calculated 
from the measured association constants as given in equation 29. 
 
       a1ΔE 1:1  = E C  - E IPU  - E trans-MAAH      (eq. 27) 
       a2ΔE 1:2  = E C  - E IPU  - 2×E trans-MAAH     (eq. 28) 
 ΔG = -RTln K          (eq. 29) 
 
Table 17 – Internal energies of complex formation reactions 
and the calculated Gibbs free energies from the measured 
association constant at 25 °C (the values are in kJ.mol
-1
). 
Multiple values are given as without/with BSSE correction.                 
- 
 
 
Gas phase DCM solution Calculated G from K 
MAA
–
 MAAH MAA
–
 MAAH MAA
–
 MAAH 
1:1 -119.5 / -116.2 -59.0 / -55.8 -11.3 / -8.3 -11.3 / -8.2 -17.4 -15.6 
1:2 - -96.4 / -89.9 - -11.2 / -4.9 - -15.5 
 
All the 1:1 complex formation reactions are exothermic, while the second step of the 1:2 
complex formation for MAAH reactions are found to be slightly endothermic in DCM 
solution. As stated previously the calculations refute the formation of the 1:2 complexes of 
MAA
–
 both for solution and gas phase due to observed decomposition thereof. The calculated 
internal energies of the complex formation can be compared to the Gibbs free energies 
calculated from the association constants obtained from the NMR titrations. The implicit 
solvent calculations will decrease the reaction energies significantly as compared to the gas-
phase interaction. This can be explained by the appearance of the solvent which will decrease 
the interaction strength between the parts of the complex
181
. The calculations were in good 
agreement with the Gibbs free energy values calculated from the measured association 
constants confirming the validity of computational investigation of such systems. The 
calculations showed that the formation of 1:2 complex from 1:1 complex in case of MAAH is 
slightly endothermic (E(1:2) – E(1:1) = 0.1 kJ.mol-1) whilst the formation of 1:1 complex 
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is exothermic (E(1:1) = – 11.3 kJ.mol-1), as it was found in the experiments G(1:2) – 
G(1:1) = 0.1 kJ.mol-1, G(1:1) = – 15.6 kJ.mol-1. Interesting to note that the calculations do 
not reveal any energy differences between the IPU complexation with MAA
–
 and MAAH. 
This phenomenon confirms that the IPU complexation with MAA
–
 is strongly affected by the 
presence of PMP. Issues encountered in the presence of PMP were referred to above (NMR 
titrations studies), wherein the choice of the quantity of PMP used in the system is important. 
 
4.4.3.4. MIP performance-modification indicators 
 
The investigation of the impact of PMP was not only performed on the pre-polymerization 
solution (liquid state) but on the scavenger itself as well (liquid-solid surface interface). The 
adsorption isotherm of IPU on MIP2 was assessed both in the presence and in the absence of 
PMP following the polymer titration protocol described in chapter 3.7. Figure 45A 
demonstrates surface coverage () as a function of equilibrium concentration. 
 
 
 
Figure 45 – Adsorption (A) and kinetic (B) isotherms of IPU 
uptake by MIP2 in the presence () and in the absence () of PMP           
- 
In the absence of PMP the adsorption isotherm follows a normal saturation curve as expected 
and results in a maximum surface coverage of 1.283. On the contrary, the presence of PMP 
increases the maximum surface coverage being 1.743 which is in correspondence with the 
NMR and DFT findings, i.e. the imprinted polymer as well as the MAA monomer have higher 
affinity towards IPU in the presence of PMP. It should be noted that PMP gives rise to an 
anomalous isotherm at low equilibrium concentrations which can be explained by the 
participation of the PMP in the complex formation reaction as described in chapter 4.4.3.2. on 
NMR titrations. Figure 45B shows the progress of IPU binding as a function of time. It is 
difficult to directly draw conclusions from the kinetic isotherms since the maximum attainable 
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binding depends on the application of PMP. Hence, the present article introduces three new 
indicators to describe the effect of agents on MIP performance. As defined in equation 30, the 
capacity modification index (CMI) weights the improvement in MIP capacity achieved via 
target-scavenger-agent complexation system and relates it to the original MIP capacity not 
having applied the agent. 
 
w
t
o
t
CMI



          (eq. 30) 
 
where wt  and 
o
t  are the maximum surface coverage obtained in the presence and in the 
absence of the agent, respectively. In certain applications the time needed to reach binding 
equilibrium is of high importance and could have economic impacts on industrial 
applications. Accordingly, a time scale dependent formula is being introduced in equation 31 
designated accelerating index (AI). Its definition is not as straightforward as the definition of 
CMI. To give an example, the increase in the costs will be not the same if the scavenging time 
will increase from 10 minutes to 20 minutes or from 10 h to 20 h. Therefore the following 
formula was suggested: 
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          (eq. 31) 
 
where  is the arbitrary time tolerance constant and tw and t0 are the elapsed times 
corresponding to 90% equilibrium binding in the presence and in the absence of the agent, 
respectively.  expresses the importance of equilibrium time for a given application and its 
restriction is  > t0. The complexity of AI definition justified by the fact that effect without 
the introduction of  the increase from 10 min to 20 min would give the same AI value as the 
increase from 10 h to 20 h although the second case is much less favorable. This can be 
compensated by the right choice of , since above the time tolerance constant the AI increases 
significantly. Table 18 presents the effect of the equilibrium times on AI at a tolerance 
constant value of 1 h. If the equilibrium time is not crucial, a high time tolerance constant is 
chosen (λ → ∞) quenching the effect observed equilibrium time on the accelerating index (AI 
→ 1). On the contrary, when equilibrium time is a crucial application parameter, a low time 
tolerance constant is chosen (λ → 0) intensifying the effect of observed equilibrium time on 
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the accelerating index (AI → t0t-w). Notice that in the latter case AI will depend just on the 
proportion of the corresponding elapsed times. When the time tolerance constant is set low 
compared to t
0
 the same t
w
t
-0
 < 1 proportion will account for higher acceleration index values, 
which means that the time saving is much more appreciated at larger time scales. On the 
contrary, t
w
t
-0
 > 1 causes a rapid decrease of accelerating index. The overall performance 
index (PI) is defined in equation 32 as the multiplication of CMI and AI.
 
 
PI CMI AI            (eq. 32) 
 
Table 18 – Dependence of the accelerating index on the t0 and tw values at  = 1 h 
 
 
1 2 5 10 50 100 
0.1 5.50 7.00 8.50 9.18 9.82 9.91 
0.5 1.50 1.67 1.83 1.91 1.98 1.99 
1 1.00 1.00 1.00 1.00 1.00 1.00 
2 0.75 0.67 0.58 0.55 0.51 0.50 
3 0.67 0.56 0.44 0.39 0.35 0.34 
5 0.60 0.47 0.33 0.27 0.22 0.21 
10 0.55 0.40 0.25 0.18 0.12 0.11 
15 0.53 0.38 0.22 0.15 0.08 0.08 
20 0.53 0.37 0.21 0.14 0.07 0.06 
24 0.52 0.36 0.20 0.13 0.06 0.05 
 
Considering that in most of the cases in the literature (i) the rebinding studies are carried out 
overnight or 24 hours assuming that the equilibrium between the scavenger and the solution 
has been reached, and (ii) both the adsorption and kinetic isotherms are following a saturation 
curve, for practical reasons it is proposed to use the elapsed times until 90% of the total 
binding is reached to be compared. However, it cannot be foreseen whether a potential 
performance modification agent actually facilitates MIP performance, i.e. increases the MIP 
capacity and/or accelerates the adsorption process, or not. Furthermore, an agent may also 
cause adverse effects by competing with the analyte and promoting electronic and steric 
hindrance. Hence, a set of simulated adsorption and kinetic isotherms is shown in Figure 46 
representing different case scenarios and Table 19 demonstrates all the possible outcomes of 
the analysis of the novel indexes. 
 
 ht 0
0t
tw
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Figure 46 – Simulated adsorption (A) and kinetic (B) isotherm representing 
both elevated and hampered MIP performance where the lines represent 
Case 1 (-----), Case 2 (– – –), Case 3 (–––), Case 4 (---) and Case 5 (––––) 
 
Table 19 – Comparison of the performance indexes based on the simulated isotherms 
 
Case # 1 2 3 4 5 
Agent yes yes no yes yes 
AI 0.67 2 1 0.5 3 
CMI 0.6 0.9 1 1.3 1.4 
PI 0.4 1.8 1 0.65 4.2 
 
Adsorption isotherms of Case 1 and 2 featuring maximum surface coverage 1-2 represent 
scenarios where the agent impede the analyte uptake resulting in lower  values than 3 
where the MIP was applied without the agent. On the other hand, adsorption isotherms of 
Case 4 and 5 indicate higher MIP capacity in the presence of the agent. Note, that although 
the shape of the adsorption isotherm might be anomalistic – as in the case of IPU – only the 
saturation point of the curve is incorporated in the CMI. On the other hand, AI incorporates 
the shape of the kinetic isotherm to a certain extent, given the fact that it is calculated based 
on reaching 90% of saturation which is strongly dependent on the shape of the curve. Since 
t5(5)  t3(3) where no agent was applied, the AI is higher than 1 meaning that the agent has 
an accelerating effect on the analyte uptake by the scavenger. Furthermore, 5  3 indicting 
higher capacity when the agent is applied. Hence, both AI and CMI contribute to a higher PI 
value which means that the agent has an overall positive effect on the performance of the 
MIP. Following the same consideration, the case of t1-1 results in AI, CMI and PI < 1 
meaning that the agent has a negative, hampering effect both on the kinetics and adsorption 
behavior of the scavenger. On the other hand, t2-2 and t4-4 case scenarios represent 
opposite effects of the agent on the kinetics and adsorption. In case of t2-2 the AI and CMI 
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values are higher and lower than in the absence of the agent, respectively. The t4-4 case 
gives AI and CMI values lower and higher than in the absence of the agent, respectively. In 
these two cases the decision whether to use the agent during the MIP application depends on 
the objective of the work and one has to prioritize the importance of kinetics and adsorption. 
From an industrial application perspective – considering the example of IPU removal from 
APIs – both factors are crucial and especially in these cases the overall performance index can 
help to make a decision. 
 
After the introduction of MIP performance-modification indicators, the particular case of 
PMP deprotonating agent is discussed. The impact of PMP on MIP2 performance can now be 
numerically expressed by CMI, AI and PI being 1.359, 0.796, 1.082, respectively. The CMI 
value higher than 1 indicates an increased performance related to higher capacity of the 
scavenger, while the AI value less then 1 demonstrates retarding effect of PMP on IPU 
recognition kinetics by MIP2 which implies that the particular case of PMP-MIP2 system 
falls into Case 4 (Table 19). The overall performance index value of 1.082 demonstrates that 
the effect of PMP is still positive on the MIP performance despite of the fact that it takes more 
time to reach the equilibrium of the adsorption process. 
 
4.5. OSN-MIP hybrid process for API degenotoxification 
 
Meta and IPU, molecular weights 521 g.mol
-1
 and 144 g.mol
-1
 respectively, were selected, as 
model API and potential GTI for the evaluation of the hybrid process. Combining the results 
of previous OSN membrane screening studies (chapter 4.3) with the use of the novel MIP2 
developed specifically for IPU (chapter 4.4), a novel hybrid process for effective API 
degenotoxification was developed. The use of MIP2 resulted in efficient removal of IPU 
(80%) in a single stage of about 80% IPU removal, even in the presence of high API 
concentrations. However, under such conditions, a significant fraction of the API, about 15%, 
binds non-specifically to the MIP. Thus the next step was to develop an improved MIP 
washing procedure that allows (i) quantitative recovery of the API which is non-specifically 
bound to the MIP in the first elution steps and (ii) removal of the IPU in the second elution 
steps, avoiding back contamination of the API and allowing recovery of the scavenger. A 
second aim is to evaluate strategies for high removals of IPU, achieving consistent low values 
of IPU contaminant, essentially through the combination of OSN and MIP in a hybrid process 
for purification of the API. Combination of OSN with other purification techniques can 
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already be found in the literature
110,209,210,211
 but OSN-MIP hybrid processes have not been 
reported yet. 
 
Furthermore, the initial equilibrium studies using MIP2 show that removal is limited to a 
maximum of about 80% of the total IPU at concentrations of 100 ppm. Therefore, high IPU 
removal, using MIP2 alone, requires a multistage procedure, in which the number of steps 
depends on the initial and target threshold IPU concentration. Notice also that the previous 
results giving 80% IPU removal were obtained with loads of MIP2 at 50 g.L
-1
 in DCM at 
ratios of 2 mg-IPU/g-MIP2, in other words 100 ppm IPU contamination can be reduced only 
to 20 ppm. Note that the acceptable IPU limit depends on the daily dose of the API meaning 
that it is sufficient in certain cases to reduce the IPU limit to 20 ppm but more strict limits are 
expected for high-dose APIs. Furthermore, the initial IPU contamination of APIs can reach 
even 1,000 ppm which cannot be effectively lowered to the IPU threshold limit by MIP2. 
Therefore, a hybrid process consisting of OSN followed by a MIP stage was evaluated. The 
scheme of the hybrid process can be seen in Figure 47. In this approach, the larger fraction of 
IPU is removed in the OSN permeate using a low dilution ratio.  Thereafter, MIP2 is used to 
remove the IPU at lower concentrations from the retentate solution thus minimizing the load 
required of the relatively expensive MIP2 and featuring only one MIP extraction step. 
 
 
 
Figure 47 - Schematic principles of using OSN (stage 
1) and MIP (stage 2) to remove IPU from API solutions    
- 
First, the use of OSN is discussed with regard to membrane selection and the effect of using 
different solvents and applied pressures, as well as diafiltration dilution ratios. The 
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development of an elution procedure is then described to recover the API bound to the MIP2 
scavenger by non-specific interactions. The recovery of the MIP scavenger and the IPU 
washout efficiency was also evaluated. In the final chapter, the combination of OSN with MIP 
based purification is discussed. 
 
4.5.1. Stage 1 evaluation: organic solvent nanofiltration 
 
DCM is a solvent commonly used in industry and hence it was also used for developing and 
testing the novel MIP2 for IPU removal in previous studies. Therefore, DCM was used as the 
solvent in the preparation of model solutions for the evaluation of the MIP-OSN combinatory 
approach. Most OSN membranes are not compatible with DCM. The OSN membrane 
screening revealed that membrane rejection of IPU and Meta was dependent on both solvent 
and pressure. Therefore, Figure 48 compares the rejections obtained for IPU and Meta of the 
three thin film composite OSN membranes: SolSep NF010206, GMT-oNF-2 and MPF-44, 
tested in DCM at 10 bar and 20 bar in a cross-flow cell. 
 
 
 
Figure 48 – Rejection of IPU and Meta at 10 bar 
and 20 bar in DCM on various OSN membranes 
- 
 
4.5.1.1. Membrane selection and solvent impact 
 
The rejections obtained, show that when using DCM, not only the IPU (Mw 144 g.mol
-1
), but 
also a significant fraction of Meta (Mw 521 g.mol
-1
) crosses the Koch MPF-44 membrane, 
indicating that in DCM the MWCO should be significantly higher than the reported value of 
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250 Da
212
 for this membrane or that the membrane is actually not entirely compatible with 
DCM. Thus, the use of Koch MPF-44 for the intended separation was ruled out. On the other 
hand, IPU rejection by SolSep is significantly higher than expected based on the OSN 
membrane screening or the reported MWCO of 300 Da
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 for this membrane. Hence, in order 
to push a higher fraction of IPU into the permeate, a higher dilution ratio is needed, which 
leads to higher API loss. The results indicate that the GMT membrane is the most suitable for 
separating Meta from IPU when dissolved in DCM, with a lower IPU rejection and a high 
Meta rejection. The use of a lower applied pressure, at a value of 10 bar can further be 
exploited to increase GTI permeation. 
 
 
 
Figure 49 – Rejection of Meta (A) and IPU (B) on the GMT 
and SolSep membranes in THF, MEK and DCM solvents    
- 
The differences in rejections found for the same solute, but different solvents (Figure 49), is 
most probably due to the extent of membrane swelling. In order to further explore the effect 
of solvents on the rejections of the tested solutes, the rejections of SolSep and GMT 
membranes obtained for IPU and Meta in DCM, THF and MEK were compared. The 
rejection of Meta is around 99% for the two membranes and three solvents tested. However, 
IPU rejections are greatly altered by the solvent system used. The polarity index for MEK, 
THF and DCM are 4.7, 4.0 and 3.5, respectively. Both SolSep and GMT have lower 
rejections (10-15%) in THF than in MEK (30-45%), which could be explained by an increase 
of free volume as the more apolar solvent, THF, can cause slight swelling of the OSN 
membrane active layer. However, such correlation is not corroborated by the data for DCM 
(the most apolar solvent of the three), which drives rejections at intermediate values (20-25%) 
for GMT and significantly higher values (70-80%) for the SolSep membrane. It could be 
speculated that these results are due to DCM effects on transport mass transfer resistance in 
the active layers, the supporting layer of the membrane or interface between support and 
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active layer. Nevertheless, the data collected is important for process development confirming 
the use of GMT membrane for removal of IPU from Meta post reaction DCM stream by OSN 
diafiltration. 
 
4.5.1.2. Organic solvent nano diafiltration 
 
Continuous addition of fresh DCM allows the operation of OSN in diafiltration mode and 
washing out of IPU from the system through the permeate whilst the API is retained by the 
membrane. Therefore, an experimental evaluation of this approach was performed. The mass 
balances close well within a 3% error. Figure 50 shows experimental results against the values 
calculated on the basis of mass balances and previously estimated IPU and Meta rejection 
values of 19.8% and 99.0%, respectively. The detailed description of the calculations can be 
found in chapter 3.4. It is to be noted that the experimental results on IPU removal diverge 
from those calculated for lower IPU concentrations, which may indicate that rejection is 
concentration dependent and that IPU retention due to adsorption phenomena in the 
membrane becomes significant for lower IPU concentrations. 
 
 
 
Figure 50 – Experimental results and calculated values of OSN diafiltration 
 
Overall, the results show that significant amount of IPU can be removed using the OSN 
diafiltration approach. However, such removal is more significant for the initial 
concentrations at the beginning of the cycle. As the IPU content decreases the efficiency of its 
removal also decreases. The rate of the API loss is sustained throughout the diafiltration, and 
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achieves a value of 2.5% at a dilution ratio of 3. At this dilution ratio, a value of 100 ppm IPU 
content, corresponding to 90% removal, was achieved. Therefore, based on the diafiltration 
results, a dilution ratio 3 is judged to be a possible optimum end point for OSN diafiltration.  
Further treatment of the retentate by MIP2 for the additional removal of IPU is discussed in 
the next chapter. 
 
4.5.2. Stage 2 evaluation: molecularly imprinted polymer phases 
 
4.5.2.1. IPU removal from APIs by the novel scavengers 
 
First of all, in search for the optimal phase ratio for removal of IPU from a solution at a fixed 
concentration (100 ppm) a polymer titration was carried out as described in chapter 3.7, in 
which the removal efficiency was investigated, using different amounts of MIP2. The 
percentages of IPU binding obtained, shown in Figure 51, led to the following conclusions: up 
to 50 mg polymer the uptake increases proportionally to the amount of polymer to reach 80% 
removal beyond which point the curve levels off to reach a maximum depletion level of 90% 
at 500 mg polymer. The level of depletion at the point of 50 mg polymer corresponds to an 
uptake of 13 mol-IPU/g-MIP2 and remaining free concentration of 0.07 mM. Hence, adding 
more polymer to a solution where the free concentration is as low as 0.07 mM IPU will not 
increase significantly the degenotoxification of the solution. Hence, 50 mg scavenger was 
used for each rebinding assays discussed in this chapter. 
 
 
 
Figure 51 – Polymer titration: 100 ppm IPU solution in DCM 
was titrated with increasing amount of MIP2 scavenger           
- 
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The solute binding percentage was investigated for binary model mixtures of IPU and APIs in 
the presence of the MIPs and the corresponding NIPs using DCM as solvent (Figure 52). It is 
interesting to note that the selectivity and capacity of IPU were higher for the polymers 
prepared in presence of the PMP base than for those where PMP was not used. This 
observation is valid for polymers prepared in the presence of a template (MIP2 vs. MIP1, 
80% vs. 55%), but also for the corresponding reference polymers prepared in the absence of 
IPU (NIP2 vs. NIP1, 50% vs. 35%). The results are consistent with the measured and 
calculated association constants (Table 16 in chapter 4.4.3.3.). 
 
 
 
Figure 52 – Specific binding of IPU and non-specific binding of APIs in 
API post-reaction solutions (the brackets indicate the corresponding 
APIs). While the API binding is fairly constant at about 15% the IPU 
binding differs with the MIP scavengers. 1 mL DCM solution of 10,000 
ppm API spiked with 100 ppm IPU was loaded on 50 mg scavengers.    
- 
The percentage of IPU binding is higher for both imprinted polymers when compared with the 
respective non imprinted polymer for both series 1 (MIP1 vs. NIP1, 55% vs. 25%-45%) and 
series 2 (MIP2 vs. NIP2, 80% vs. 45%-60%), showing that the introduction of the template 
molecule, IPU, during the preparation of the MIP samples have a significant impact not only 
on the selectivity but also on the capacity. Additionally, it should be noted that the percentage 
of IPU binding for the MIPs in the different tests was quite consistent with small standard 
deviation (2% for both MIP1 and MIP2), but the variation in IPU binding to the non-
imprinted scavengers was larger (11 and 7% for NIP1 and NIP2, respectively). 
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The percentage of binding of the APIs, in spite of being present in a 100 fold excess over the 
GTI, were significantly lower with values around 15%, when compared with the values for 
IPU. The template and the base hence induce enhanced affinity for the GTI only, with no 
significant effect on the affinity for the APIs. The observed binding of APIs is low compared 
to the binding of IPU (~84%) where Roxi and Meta is bound at the same level (~15%) while 
KP has a slightly higher binding value (~19%). From the APIs tested, KP is the molecule 
most similar to the target IPU, both in terms of size and structure, since it includes an amide 
group able to interact with the carboxyl groups of the scavengers. Nevertheless, high 
specificity was achieved by the use of IPU as template during the preparation of the 
scavengers, proven by low KP binding. A larger fraction of the API remain free in solution, 
regardless of API size, chemical family and functional group; indicating that API binding to 
MIPs was non-specific. 
 
It is interesting to note that the polymers are capable of efficient removal of the potentially 
genotoxic IPU from APIs of similar molecular sizes (e.g. KP, 170 g.mol
-1
 versus IPU, 144 
g.mol
-1
). Such a level of discrimination is extremely challenging using other separation 
techniques, particularly those relying on molecular weight differences such as OSN. As 
mentioned, similarities between IPU and KP are not only size based, but KP also contains a 
quasi-urea substructure, thus the amide group can be considered a close analog of the template 
molecule, IPU (Figure 53). The selectivity displayed by the MIPs for IPU in this case 
illustrates the potential of the novel molecular imprinted polymers as specific scavengers for 
GTI removal. Given the superior performance of MIP2, further investigations were carried 
out using this polymer. 
 
 
 
Figure 53 – Analogy between the target IPU and the KP drug substance 
 
An additional binding experiment was performed in order to study the effect of API 
concentration on binding. Using an equimolar concentration of IPU (100 ppm, 0.7 mM) and 
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one of the APIs (Meta, 362 ppm, 0.7 mM) in DCM the percentage of IPU binding was 81.6 ± 
0.6 % -  in the same range as in the previous experiment - whereas the non-specific binding of 
API was now significantly lower (1.3 ± 0.4 %). Since the API concentration is now 
significantly lower (10,000 ppm → 362 ppm; about 30x), the results demonstrate that the 
binding of IPU to MIP2 is essentially independent of the API concentration.  
 
From a trial planning and industrial point of view, it is important to have information on the 
dynamics of IPU and API binding to the polymer. Therefore, an experiment was performed in 
which samples of supernatant were collected over time to evaluate binding kinetics. The 
experiment was repeated twice with coefficients of variation lower than 1.2% and the average 
values are presented in Figure 54. It is noteworthy that the binding of the API (Meta) to MIP2 
is virtually instantaneous and does not vary significantly over the 22 hours. However, IPU 
binding progresses overall more slowly – somewhat faster when it is the only solute dissolved 
(no API present) and more slowly in the presence of the API. This observation can be 
explained by the high amount of API, which covers part of the specific binding sites, slowing 
down the recognition of IPU. Experiments were stopped at 22 hours, when about 80% of the 
IPU was bound to MIP2. The data obtain do not fit zero or first order kinetics towards the IPU 
concentration, but do fit a second order reaction with a correlation factor of 0.99 and a kinetic 
constant of 9 x 10
-6
 h
-1
ppm
-1
. For a kinetic order of two, one can speculate that, for the 
recognition mechanism, the simultaneous binding of two molecules is required due to size or 
stabilization of MIP2-IPU bonds. 
 
 
 
Figure 54 – Binding of IPU and Meta over time as a mixture and IPU-only 
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The imprinted polymers displayed superior recognition for IPU in comparison with different 
APIs. Regardless of the nature of the API in terms of size, chemical family and functional 
groups, the non-specific binding to API remains fairly constant. Even in typical industrial 
scenarios, where the IPU is present in low concentrations compared to high amounts of API, 
the experimental results indicate effective degenotoxification of about 80% at 2 mg-IPU/g-
MIP2 with initial IPU concentration of 100 ppm. This resulted in a loss of about 15% API 
when present in a 100 fold excess to the potentially genotoxic impurity, due to non-specific 
binding. 
 
For direct comparison of one single MIP2 step with OSN diafiltration, an additional 
experiment was performed with MIP2 and Meta loadings as above, but with a higher IPU 
concentration of 1,000 ppm. The results indicate that the percentage of IPU binding to the 
MIP2 was 49.9±0.4%, corresponding to about 495±4 ppm of IPU equilibrium concentration 
in solution. In other words, the results show that (i) MIP2 is capable of effectively removing 
IPU at lower concentrations and on the contrary (ii) the OSN diafiltration approach is superior 
to remove IPU at higher concentrations: IPU in solution is reduced from 1,000 pm to about 
100 ppm (vs. about 500 ppm for MIP2 system) with only 2.5% loss of API (vs. 15% in the 
MIP2 system) at dilution ratio of 3. 
 
MIP systems could be explored for further removal of IPU using a cascade type methodology 
where the supernatant of the first step is submitted to additional steps for sequential removal 
of further IPU. However, if this approach were to be applied other issues such as 
minimization of API loss and regeneration of MIP2 had to be addressed. Since a significant 
amount of API ends up bound to the MIP in the first step, a proper recovery step for such 
bound API – without back contamination of the IPU – would be crucial to improve the 
competitiveness of the MIP application. The recovery of used MIP2 is also an important 
consideration from a cost efficiency perspective. A single solvent or a mixed solvent system, 
able to wash off only the API in the first elution steps and then the specifically bound IPU in 
the following elution steps, would resolve this problem. The screening for such solvent 
systems is discussed in the following chapter. 
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4.5.2.2. Eluent selection: API recovery and MIP regeneration 
 
As discussed before, the MIP selectively binds IPU but also binds about 15% of the API in 
each step through non-specific interactions, which represents inacceptable loss of product. 
Several solvents were screened for their ability to dissolve API (Meta), but not the potential 
GTI (IPU), by exploring the different strengths of interactions between polymer with GTI and 
API in these solvents. The objective was to be able to remove easily the API in an initial 
elution step and significant IPU removal in additional elution steps. Polymer swelling was 
also tested in the solvents used in binding tests or solid phase extractions. Figure 55 shows the 
specific swelling volumes estimated for MIP2 (the polymer selected for the development of 
the hybrid process) and MIP1, as well as the respective non-imprinted polymers NIP1 and 
NIP2. It is interesting to note that the lowest swellings were observed in DCM, the solvent 
used for preparation and IPU removal tests, than for any of the other solvents. In particular, 
MIP2 which has the highest affinity towards IPU has the lowest swelling. Swelling leads to 
significant changes in the properties of the polymers, affecting accessibility of the binding 
sites, and thus the adsorption-desorption process. Therefore, removal of IPU in a solvent with 
low swelling properties, such as DCM, and desorption in solvents, such as MIBK and MeOH 
that swell the polymer significantly can actually be beneficial, since it promotes easier 
removal from the enlarged polymer pores
213
. 
 
 
 
Figure 55 – Specific swelling volumes of the IPU selective scavengers 
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DCM is the solvent in which the initial binding step takes place. Therefore, the use of DCM 
for further API elution would be ideal, avoiding solvent swap and allowing recovery of the 
API fraction in the original solvent. However, the experimental data shown in Figure 56 
indicates that the use of additional pure DCM results in back contaminating of the Meta, since 
DCM partly elutes IPU as well. This is an expected result, given the high solubility of IPU in 
this solvent. 
 
  
 
 
 
 
 
 
Figure 56 – Selective elution of 
Meta and IPU from MIP2: (A) 
eluent is DCM, (B) first eluent is 
MIBK and then DCM content is 
increased, (C) first eluent is 
MIBK and then the MeOH 
content is increased.     -         
 
 
Therefore, in order to recover Meta from the MIP2 scavenger, a strategy of using two elution 
solvents was evaluated. Following preliminary results, MIBK was selected as the first solvent 
to be used. Meta is highly soluble, but IPU is insoluble in this solvent. Thus, the use of pure 
MIBK allows recovery of non-specifically bound Meta in the first or first two washes (Figure 
56B) without significant cross contamination with IPU. This strategy has the drawback of 
recovering API in a solvent different from DCM, thus implying an undesirable solvent swap 
for the next processing step. Due to the high solubility of IPU in DCM and MeOH, these 
solvents were selected as secondary elution solvents to wash out the IPU, regenerating the 
MIP2. Methanol is a high polarity solvent, capable of disrupting the H-bonds in the host-guest 
interaction therefore, a faster IPU removal is possible with MeOH than with DCM (Figure 
56C). 99% IPU removal was achieved in the washing performed with MIBK:MeOH (30:70). 
Therefore the MIBK/MeOH solvent system was selected to regenerate the MIP2 scavenger. 
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This demonstrates that an appropriate selection of solvents makes it possible to efficiently 
recover the fraction of 15% of API non-selectively bound to the MIP2 scavenger without 
contamination with IPU, addressing one of the main challenges identified in the use of MIPs. 
 
4.5.2.3. Robustness of MIP recyclability 
 
A second challenge is that, as IPU binding percentage decreases for higher IPU 
concentrations, removal of IPU down to the required low levels implies a sequence of several 
steps of IPU binding and MIP2 recycling, which is time consuming and cumbersome. As an 
example, a MIP cascade simulation based on a one-stage MIP application is demonstrated in 
Figure 57. Therefore, the multi-steps strategy often followed in OSN protocols
214,215
 is not so 
often applied in MIP systems. Nevertheless, the novel MIP2 is particularly robust in terms of 
recyclability without loss of selectivity. Independently of operation mode, the option to 
recycle the MIP scavengers without any efficiency loss is crucial from an industrial point of 
view. Therefore, to illustrate the recyclability of the MIP2 scavenger, Figure 58 shows that the 
IPU binding values are between 80% and 85% for all the 18 assays performed sequentially 
using various polymer samples. These 18 assays were performed under identical conditions at 
50 g.L
-1
 of MIP2 in DCM featuring IPU concentration of about 100 ppm. 
 
 
 
Figure 57 – Schematic representation of MIP cascade including Meta 
recovery and MIP regeneration (values presented are based on one-
stage bulk rebinding experiments, thus they are only illustrative).      
- 
The results were assembled from several experiments reported throughout the project 
including the binding of IPU either alone or in the presence of different APIs, through kinetic 
and thermodynamic studies with a variety of elution solvents. In all these experiments the 
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final MIP2 regeneration employed was as follows: wash with 0.1 M HCl MeOH solution, dry 
in a vacuum oven and precondition with PMP base in DCM for further use. 
 
 
 
Figure 58 – IPU binding of MIP2 in the different 
experiments performed with MIP2 at 50 g.L
-1
 in 
DCM and IPU concentration of about 100 ppm.     
- 
 
4.5.3. Exploring OSN diafiltration and MIP polishing of the retentate 
 
Assessment of the OSN diafiltration and MIP2 systems independently was reported in the 
previous chapters, showing that the OSN diafiltration is more suitable for higher IPU 
concentrations being able to reduce IPU levels from 1,000 ppm to 100 ppm using a dilution 
ratio of 3 with only 2.5 %loss of Meta. However, IPU removal below 100 ppm by OSN was 
highly inefficient (see chapter 4.5.1). On the other hand, based on additional experiments of 
IPU binding to MIP2, the MIP approach suits the removal of IPU better from solutions where 
this solute is at low concentrations of about 100 ppm (see chapter 4.5.2.1). A suitable solvent 
system was selected to recover API, non-selectively bound to the MIP2 scavenger (see 
chapter 4.5.2.2). In this chapter a hybrid approach is suggested and evaluated experimentally. 
Diafiltration is first used to remove the greater part of the IPU and MIP2 is then used to polish 
the retentate stream resulting in ultra low levels of IPU content in the final Meta solution. The 
elution system developed in the previous section for the recovery of Meta and IPU was 
applied. A solution with 10,000 ppm Meta and 1,000 ppm IPU in DCM was submitted to 
diafiltration using the GMT-oNF-2 membrane and an applied pressure of 10 bar. The OSN 
diafiltration operation, run at an average solvent flux of 50 L.m
-2
.h
-1
 was stopped at a dilution 
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ratio of 3. The retentate was fed to MIP2 at a load of 50 g.L
-1
 in the same solvent, DCM, 
corresponding to ratio of 2 mg-IPU/g-MIP2. After equilibration, the MIP2 was collected from 
the purified Meta solution and MIP2 retained for further recovery of the non-specifically 
bound Meta. Pure MIBK was used in the two first washing steps, followed by MIBK/MeOH 
solutions with increasing MeOH content in washing steps 3 to 6. The results obtained are 
illustrated in Figure 59 and follow expectations with virtually all of the Meta being recovered 
in the first two wash steps thus increasing the recovery of Meta to 99.7 %. The IPU was 
efficiently washed out of the MIP2 in the following steps. 
 
 
 
Figure 59 – Cumulative recovery of Meta and regeneration 
of the MIP2 scavenger after polishing the OSN retentate    
- 
Figure 60 provides a detailed schematic diagram of the hybrid process including the 
quantification of Meta and IPU at the different phases. The bulk of the Meta, 97%, is retained 
by the membrane and 90% of the IPU is discharged in the permeate. At this point, there is still 
10% of IPU that remains in the retentate which corresponds to 10 mg-IPU/g-Meta (1 wt%). 
Therefore, the following MIP stage aims to decrease this level of contamination. 
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Figure 60 – Mass balance of the operation 
stages carried out during the hybrid process 
- 
The experimental data show that, using the appropriate system of eluting solvents, it is 
possible, without significant additional Meta loss (97 % yield of Meta), to bring down IPU 
levels to a value of 2 mg-IPU/g-Meta. Only one cycle using MIP was performed to obtain this 
level. Hence, assuming that in each cycle about 80% of the IPU is removed, by treatment of 
the supernatant I (Figure 60) it should be possible to reduced IPU content by about an order of 
magnitude per MIP cycle. However, this additional purification is achieved at the cost of the 
generation of a MIBK stream (supernatant II in Figure 60) in each cycle. The isolation of 
Meta therefore, involves a solvent swap back to the lower boiling point solvent, DCM. The 
removal of APIs from organic solvents by nanofiltration has been previously studied
216
 and 
several groups have suggested the use of membranes for solvent exchanges
217,218,219
 and for 
the recovery of solvents
220
 in the pharmaceutical industry when heat sensitive compounds are 
involved or when the solvent has a high boiling point, making distillation unsuitable. 
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5. Conclusions and future outlook 
 
In this chapter the conclusions of each projects of the thesis are presented, followed by a brief 
critical overview with the intention of both pointing out the limitations of the work and 
underlining where future work is recommended. 
 
Trace analysis of genotoxic impurities calls for sensitive analytical detectors such as mass 
spectrometry. Instead of the conventional trial and error approach, design of experiments was 
applied in the LC-MS/MS method development. The novel strategy considering LC and MS 
instrumentation in one single DoE design – rather than applying DoE consecutively to LC and 
then MS – has been successfully tested and led to a robust method allowing the trace analysis 
of the model potentially genotoxic impurity, DMAP at 0.5 ng.mL
-1
 absolute concentration 
which corresponds to 0.1 ppm limit of quantification in 5 mg.mL
-1
 Mometasone furoate 
glucocorticoid. In addition the robustness of the method so obtained was assessed via the DoE 
approach, which not only quantified the highest deviation of peak area to be 23%, meeting the 
acceptance criteria, but also revealed the most important factor causing fluctuations in peak 
area as being the collision energy. The method developed is determined to be robust since 
minor changes in the factor levels have negligible effect on the response values. The proposed 
LC-MS/MS method also meets criteria such as ease of use, low cost per analysis, ultra low 
LOQ and high sample throughput. It has been demonstrated that DoE provides a reliable basis 
for LC-MS/MS optimization and provides a framework for changing all the important factors 
systematically, while requiring only a limited number of experiments. The method was 
validated and found to be repeatable, linear, precise and accurate in the range of 0.1 to 2 ppm 
enabling the method to quantify DMAP at its threshold concentration of 0.75 ppm in Meta. 
The results obtained on the application of DoE to quantify the potentially genotoxic impurity 
are promising. However, it should be noted that the selection of the ranges of the DoE factors 
is based on qualitative FIA and if too broad ranges are selected then DoE responses cannot be 
accrued for all cases. Hence, further work is needed to establish a more justified approach for 
range selection. 
 
The comparative study of flash chromatography and recrystallization as conventional API 
purification technologies versus OSN proved the viability and sustainability of OSN as 
potential API purification technology. Degenotoxification of Mometasone furoate was 
successfully achieved for MeMS applying recrystallization, and for DMAP and MeMS by 
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flash chromatography and OSN. API losses during DMAP removal was 5% and 6.4% for 
OSN and flash chromatography, respectively. API losses during MeMS removal were 6.4%, 
11.9% and 16.4% for OSN, flash chromatography and recrystallization, respectively. The cost 
analysis of the three processes concluded that recrystallization is the cheapest process, with 
intermediate energy intensity (due the need of solvent exchanges by distillation) and lower 
mass and carbon intensity, although it is more labor intensive and time consuming. However, 
the cost analyses of the purification processes are dominated by the loss of revenue due to 
API loss which makes recrystallization the least cost effective process in the present study. 
Recrystallization is the purification process approved in the manufacture of many APIs, 
therefore the use of recrystallization should not be discarded without careful analysis. 
Although flash chromatography is an efficient process for degenotoxification, particularly for 
DMAP, it is the most difficult to scale-up and involves high loads of solid waste disposal. 
Comparing the case of DMAP and MeMS removal from the API, in the case of DMAP the 
API ends up in a large volume of solvent and is then isolated by distillation, hence presenting 
higher energy intensity. OSN requires the use of 7 diavolumes, achieving adequate final GTI 
levels with acceptable API losses at the cost of high solvent consumption. Therefore, from an 
investment perspective, the option of solvent recycle becomes economically feasible only for 
OSN. On the contrary, from an environmental perspective, solvent recycle (i) has a high 
impact in each process by reduction of mass intensity by two orders of magnitude (from 400-
1300 to 14-63 kg/kg-API depending on the process); and (ii) makes the three processes 
comparable with regard to their carbon intensity having reduced this to a range of 100-180 kg-
CO2/kg-API. The effect of solvent recycling also has a positive higher environment impact on 
OSN due to lower overall solvent consumption. OSN is a process easy to scale-up with low 
labor intensity and the processing time can be reduced by increasing the membrane area. 
However, in this case, when solvent recovery is included, the batch time increases 
significantly. Whilst considered green aspects it is worth mentioning that the post-reaction 
stream of Meta is in DCM, hence most of the work carried out during this PhD involves the 
use of DCM. Although after the approval of the API processing route, altering solvent is 
usually not an option for the manufacturers, it is highly recommended to replace DCM with a 
solvent featuring lower environmental, health and waste impacts. This solvent exchange 
requires large investment and tremendous work not only related to process chemistry but 
well-documented justification towards the authorities and new impurity profiling. 
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OSN was proven to be competitive in the process comparison assessment and hence various 
solvent resistant nanofiltration membranes were screened. The OSN diafiltration methodology 
proposed for API degenotoxification is based on commercial membranes, which are available 
in flat sheet or spiral wound modules enhancing the ease of scale-up. A large range of APIs 
and GTIs, covering different chemical families, were used as model compounds and 
rejections are provided, facilitating further process design and implementation. The applied 
membranes were examined with SEM, which suggests a thin film composite membrane 
configuration with an active layer of about 5 m thickness. During the membrane screening 
process two solvents, THF and MEK, both being difficultly compatibile with polymeric 
membranes, were selected and membrane stability was successfully assessed. However, in 
subsequent studies, including process comparisons and a hybrid process, an even more 
challenging solvent, DCM, was used successfully. The effect of hydrogen peroxide in THF on 
membrane stability was also assessed and a limit of 5 ppm for OSN application was 
established. This value is well above the usual content in commercial THF, however due to 
long and/or inappropriate storage peroxide can accumulate in the solvent and the post reaction 
solution may contain residual peroxide reagent. The recommendation for OSN 
degenotoxification processes is to select a membrane with high rejection for the API (>95%) 
and to extend the number of diavolumes according with the requirements for GTI removals. 
The effect of pressure change on solute rejection was also explored to improve 
degenotoxification without provoking an increase in API loss. It should be mentioned that 
membrane stability problems – partial dissolution of the active layer – occurred depending on 
the batch of the membrane used. This observation indicates that the production of OSN 
membranes is not perfectly uniform and their performance may vary, calling for 
improvements in membrane preparation techniques. 
 
Subsequently, IPU – representing an intermediate OSN case with higher GTI rejection – was 
chosen for investigation of molecular imprinting technology. ExploraSep
®
 Plate A was 
screened and a hit scavenger was found, which interestingly is not a MIP but a NIP. Current 
industrial needs in Hovione called for a solvent exchange, which significantly decreased the 
IPU uptake. Hence, novel scavengers had to be designed featuring IPU as a template. The 
results show that a slightly modified conventional imprinting procedure based on methacrylic 
acid and ethylene glycol dimethacrylate can result in potent scavengers for IPU. The 
imprinted polymers displayed superior recognition for IPU, when compared with common 
APIs. Regardless of the nature of the API in terms of size, chemical family and functional 
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groups, the non-specific binding to API remains fairly constant. Even in typical industrial 
scenarios, where the IPU is present in low concentrations compared to high amounts of API, 
the experimental results indicate effective removal of about 80% of IPU at 2 mg-IPU/g-MIP2 
with IPU concentration of 100 ppm in DCM. A notable improvement in MIP performance 
was achieved by addition of base in order to deprotonate the carboxylic moiety of the binding 
site. This promotes strong interactions between urea NH groups of the template and the 
negatively charged carboxylate groups of the scavenger. The quantum chemical investigation 
revealed a two-step complex formation mechanism in the absence of the deprotonating agent, 
whilst in its presence only the existence of 1:1 complexes were observed because the 1:2 
complex decomposes due to the high negative charge density associated with the two 
methacrylate anions. The binding strength was derived through both quantum chemical 
calculations and NMR titrations both for 1:1 and 1:2 complexes featuring methacrylic acid 
and for 1:1 complexes featuring methacrylate anion. The resulting binding constants were in 
good agreement with a reasonably high degree of certainty. Adsorption isotherms 
demonstrated increased capacity of the imprinted scavenger in the presence of the 
deprotonating agent which is in agreement with the observed (NMR) and calculated (DFT) 
higher association constants in the presence of such an agent. These results justify and 
validate the simplification of using the pre-polymerization solution, instead of the complete 
imprinting system (i.e. disregarding the cross-linker), to study molecular recognition of MIPs. 
It has been demonstrated through the example of a deprotonating agent that the presence of an 
additional component can enhance the performance of imprinted polymers. Consequently, the 
introduction of performance-modification indicators such as capacity modification index, 
accelerating index and overall performance index has been proposed. 
 
The methodology obtained based on OSN shows that OSN is an efficient process for removal 
of IPU from Meta at relatively high concentrations (~1,000 ppm) when using low diavolumes 
to avoid excessive loss of API. For diavolumes superior to 3, corresponding to IPU content in 
solution lower than 100 ppm, OSN becomes inefficient. On the contrary, the novel imprinted 
scavenger, MIP2, is more efficient when applied to IPU solutions in the lower concentrations 
ranges, with typical IPU removal efficiencies of 83%. Therefore, a hybrid process was 
developed which combines the advantages of molecular imprinting and organic solvent 
nanofiltration. An initial OSN stage is applied at a low dilution ratio, where the diafiltration 
process is efficient and then the retentate containing a low amount of IPU is submitted to the 
novel imprinted polymer for further IPU removal, The transition between OSN and MIP 
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stages takes place where the IPU concentration is approximately 100 ppm, a value particularly 
suitable for MIP2 operations. Meta with significantly lower contamination of by IPU was 
achieved using this hybrid approach. However, about 15% of Meta binds non-specifically to 
the scavenger. To address this challenge an elution system was developed using MIBK to 
recover Meta in the first two steps and mixtures of MIBK/MeOH in the 4 subsequent steps to 
recover the scavenger by eluting IPU. MIP2 was also efficiently recovered and reutilized over 
18 operations without loss of selectivity towards IPU. This methodology can be used to 
explore other cases where ultra low concentrations of contaminants must be reached. A 
limitation of this hybrid process lies in the fact that an undesirable solvent exchange is 
necessary in order to recover the API non-specifically bound to the scavenger. 
 
As a concluding remark, the close cooperation between Hovione as a pharmaceutical 
manufacturer and the Technical University of Dortmund as an academic institution provided a 
constant feedback between the research and market needs. In order to successfully complete 
the objectives of delivering nanofiltration and scavenging methodologies for API 
degenotoxification, commercially available solvent resistant nanofiltration membranes and 
specially developed imprinted scavengers were studied. Besides the contribution of the 
research presented on the implementation of both OSN and MIP technologies to 
pharmaceutical downstream processing, fundamental aspects of imprinting have also been 
investigated. Moreover, the findings during the PhD studies – funded by a Marie Curie ITN 
consortium – and carried out with a focus on the end user – laid the foundation for research by 
other colleagues within the consortium by identifying where further fundamental research is 
necessary to make the technologies more viable for the Pharmaceutical Industry. Based on the 
promising results, it is believed that the both nanofiltration and imprinting technologies have a 
significant role on the next generation of purification technologies for APIs. 
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6. Appendix 
 
6.1. Tables 
 
Table A1 – Model APIs of the OSN membrane screening 
C
la
ss
 
Name, source 
Abbrev., 
Mw 
(g.mol
-1
) 
Chemical 
structure 
Description 
A
m
id
es
 
Lacosamide 
UCB, Belgium 
LA 
250.2  
LA was developed by UCB for the 
adjunctive treatment of partial-onset 
seizuresand diabetic neuropathic pain 
marketed under the trade name Vimpat
221
. 
N
-h
et
er
o
cy
cl
es
 
Levetiracetam 
UCB, Belgium 
KP 
170.2 
 
KP is an anticonvulsant drug used to treat 
epilepsy
222
. 
Sumatriptan 
Hovione, 
Portugal 
Suma 
295.4 
 
Suma is structurally similar to serotonin 
(5HT), and is also a 5-HT receptor 
agonist used in the treatment of migraine 
disorders
223
. 
Irbesartan 
Jiacheng-Chem 
Enterprises Ltd., 
China 
Irb 
428.5 
 
Irb is an Angiotensin Receptor Blocker 
(ARB) used mainly for the treatment of 
hypertension
223
. 
 
S
te
ro
id
s 
Prednisolone 
Hovione, 
Portugal 
Pred 
361.2 
 
Pred is a corticosteroid drug with 
predominantly glucocorticoid and low 
mineralocorticoid activity, making it 
useful for the treatment of a wide range of 
inflammatory and auto-immune 
conditions such as asthma
224
. 
Betamethasone 
Hovione, 
Portugal 
Beta 
392.4 
 
Beta is particularly suitable for treating 
cerebral edema and congenital adrenal 
hyperplasia, due to its lack of 
mineralocorticoid properties
225
. 
Halobetasole 
propionate 
Hovione, 
Portugal 
Halo 
484.9 
 
Halo has an action similar to Meta. 
Mometasone 
furoate, 
Hovione, 
Portugal 
Meta 
521.4 
 
Meta is a glucocorticoids steroid used in 
the treatment of inflammatory skin 
disorders (such as eczema and psoriasis), 
allergic rhinitis (such as hay fever)
226
. 
M
ac
ro
li
d
es
 
Roxithromycin, 
Hovione, 
Portugal 
Roxi 
837.047 
 
Roxi is a semi-synthetic macrolide 
antibiotic preventing bacteria from 
growing, by interfering with their protein 
synthesis
223
. 
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Table A2 – Model GTIs of the OSN membrane screening 
 
C
la
ss
 
Name 
Abbrev, 
Mw (g.mol
-1
) 
Chemical Structure 
S
u
lf
o
n
ic
 e
st
er
s 
su
lf
at
e 
dimethylsulfate 
DMS 
126.1  
m
es
y
la
te
 
ethyl mesylate 
EtMS 
124.2 
 
to
sy
la
te
 methyl tosylate 
MeTS 
186.2  
ethyl tosylate 
EtTS 
200.3  
A
m
id
es
 
acetamide 
AA 
59.1  
thioacetamide 
TA 
75.1  
N,N-dimethylcarbamoyl-chloride 
DMCC 
107.5 
 
U
re
as
 1,3-diisopropylurea 
IPU 
144.2  
1,3-dicyclohexylurea 
CHU 
224.3 
 
O
th
er
s aldehide acrolein 
ACR 
56.1  
haloalcohol 2-bromo-ethanol 
BE 
124.9  
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Table A3 – DoE runs based on the CCF design 
 
# Ecol Econ Vinj F G 
1 20 35 12.5 0.35 60 
2 30 35 20 0.35 60 
3 30 35 12.5 0.35 60 
4 40 35 12.5 0.35 60 
5 40 50 5 0.2 70 
6 30 35 12.5 0.35 60 
7 20 20 5 0.5 50 
8 20 50 20 0.5 50 
9 40 20 5 0.2 50 
10 30 20 12.5 0.35 60 
11 30 50 12.5 0.35 60 
12 20 50 5 0.5 70 
13 30 35 12.5 0.35 50 
14 30 35 12.5 0.5 60 
15 30 35 12.5 0.35 70 
16 30 35 12.5 0.35 60 
17 30 35 5 0.35 60 
18 20 50 20 0.2 70 
19 40 20 20 0.5 50 
20 20 20 20 0.5 70 
21 20 20 20 0.2 50 
22 30 35 12.5 0.2 60 
23 40 20 5 0.5 70 
24 20 50 5 0.2 50 
25 40 50 5 0.5 50 
26 40 50 20 0.5 70 
27 40 50 20 0.2 50 
28 20 20 5 0.2 70 
29 40 20 20 0.2 70 
 
Table A4 – Descriptive statistics 
 
 S/N Sep Apeak Time 
Min 11.09 3.39 926 4.02 
Max 124.49 8.49 29046 10.00 
Mean 48.30 5.42 10162 6.42 
Q(25%) 19.60 4.48 3264 5.12 
Q(75%) 72.81 6.61 16163 8.18 
Median 46.19 4.87 7361 5.75 
Std. Dev. 28.80 1.61 7634 1.97 
Min/Max 0.08 0.40 0.03 0.40 
N 29 29 29 29 
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Table A5 – Generated DoE runs for robustness testing 
 
# Ecol Econ Vinj F G T Qres 
1 28 37 27 0.48 68 27 13 
2 28 33 25 0.52 72 27 13 
3 30 35 26 0.5 70 25 13.5 
4 28 37 25 0.48 72 23 14 
5 32 33 25 0.48 68 27 14 
6 32 37 25 0.52 68 23 13 
7 32 33 27 0.48 72 23 13 
8 30 35 26 0.5 70 25 13.5 
9 28 33 27 0.52 68 23 14 
10 32 37 27 0.52 72 27 14 
11 30 35 26 0.5 70 25 13.5 
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Table A6 – Scale-up assumptions and material inventory 
 
    
Lab Scale Industrial Scale  
Scale up 
factor 
 API 5 g 10 kg 2000 
 GTI 1 g 2 kg 2000 
 DCM 500 cm
3
 1 m
3
 2000 
Flash Chromatography 
C
o
lu
m
n
 s
p
ec
if
ic
at
io
n
s 
Silica 150.0 g 330 kg 2200 
Silica 300.0 cm
3
 0.6 m
3
 2000 
Silica/API 30 - 33 - 1.1 
diameter 5.0 cm 0.63 m  
section 19.6 cm
2
 0.31 m
2
  
H 15.3 cm 1.9 m  
H/diameter 3.1 - 3.1 - 1 
(a
) 
so
lu
ti
o
n
 c
o
n
ce
n
tr
at
io
n
s 
b
y
 d
is
ti
ll
at
io
n
, 
  
(b
) 
E
lu
ti
o
n
 
co
n
d
it
io
n
s 
an
d
 (
c)
 s
o
lv
en
t 
v
o
lu
m
es
  
(a) DCM distilled 450.0 cm
3
 0.900 m
3
 2000 
(b) Flow Rate 50.0 cm
3
.min
-1
 0.476 m
3
.h
-1
  
(b) Linear velocity 2.55 cm.min
-1
 1.53 m.h
-1
 1.0 
DMAP removal           
(c) Inlet DCM 1425 cm
3
 3.135 m
3
 2200 
(c) Inlet EtOAc 75 cm
3
 0.165 m
3
 2200 
(c) DMAP fraction 300 cm
3
 0.76 m
3
  
(c) META fraction 1200 cm
3
 2.64 m
3
  
(a) Distillate + filtered 1195 cm
3
 2.63 m
3
  
MeMes removal           
(c) Inlet DCM 1063 cm
3
 2.3386 m
3
 2200 
(c) Inlet EtOAc 137 cm
3
 0.3014 m
3
 2200 
(c) MeMs fraction 750 cm
3
 1.75 m
3
  
(c) META fraction 450 cm
3
 0.99 m
3
  
(a) Distillated+filtred 400 cm
3
 0.98 m
3
  
 
Table A6 continues on the next page 
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Continuation of Table A6 from the previous page 
 
  Crystallography    
Solvent 
exchange I 
DCM distilled 450 cm
3
 0.900 m
3
 0 
Inlet MeOH 100 cm
3
 0.200 m
3
 2000 
Inlet MeOH 100 cm
3
 0.200 m
3
 2000 
Distillate 200 cm
3
 0.400 m
3
   
Crystallization  I  
Initial temp 50 ºC 50 ºC  
Final Temp 10 ºC 10 ºC  
Cooling rate 30 ºC/h 30 ºC/h  
Initial time 1  1 h  
Final time 2 h 2 h  
MeOH washing 40 cm
3
 0.080 m3 2000 
Filtrated 85.0 cm
3
 0.170 m3   
Charcoal 
adsorption 
Charcoal 3 g 6 kg 2000 
Inlet DCM 100 cm
3
 0.200 m
3
 2000 
Inlet MeOH 100 cm
3
 0.200 m
3
 2000 
Operation time 2 h 3 h  
Recirculation flow rate -  1.5 m
3
/h  
DCM Washing 40 cm
3
 0.080 m
3
 2000 
Solvent 
exchange II 
Distillate 195 cm
3
 0.390 m
3
   
Inlet MeOH 100 cm
3
 0.200 m
3
 2000 
Distillate 100 cm
3
 0.200 m
3
   
Crystallization  
II 
Initial temp 50 ºC 50 ºC   
Final Temp 10 ºC 10 ºC  
Cooling rate 30 ºC/h 30 ºC/h  
Initial time 1  1 h  
Final time 2 h 2 h  
MeOH washing 40 cm
3
 0.080 m
3
 2000 
Filtrated 85 cm
3
 0.170 m
3
   
Organic Solvent Nanofiltration 
OSN diafiltration 
Membrane 105.6 cm
2
 20.0 m
2
 1894 
Solvent flux 5.5 cm
3
.cm
-2
.h
-1
 0.055 m
3
.m
-2
.h
-1
 1 
Diafiltration flow rate 581 cm
3
.h
-1
 1.100 m
3
.h
-1
 1894 
DCM Preconditioning 250 cm
3
 0.5 m
3
 2000 
DCM diafiltration 3500 cm
3
 7.0 m
3
 2000 
Permeate (GTI fraction) 3250 cm
3
 7.5 m
3
   
Retentate (Meta fraction) 500 cm
3
 1 m
3
   
Distillate + filtrated 450 cm
3
 0.990 m
3
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Table A7 – Measured IR spectrum of MAA in DCM and in CHCl3 
 
Wavenumber in 
DCM [cm
-1
] 
Wavenumber in 
CHCl3
 207
 [cm
-1
] 
Assignment  
951(m) 946 δrCH2, νC-C 
1009(w) 1010 δrCH3, δrCH2 
1122(m) - wCH3, wCCC 
1204(m) 1205 νC-O, βOH, δrCH3 
1221(w) -  
1258(w) - From solvent: CH2Cl2 
1300(m) 1300 βOH, δrCH2, νC-C 
1319(sh) 1320 νC-C, βOH, νC-O, δsciOCO 
1375(w) 1380 δsyCH3 
- 1410 δsciCH2, δasCH3, δsyCH3 
1431(w) 1435 δasCH3 
1454(m) 1458 δasCH3, δsciCH2 
1636(m) 1635 νC=C, δsciCH2 
1697(vs) 1697 νC=O 
1730(m) - overtone/combination 
2930(br) 2932 νsyCH3 
2963(br) 2964 νasCH3 
2990(br) 2988 νasCH3 
~3400 ~3400 νOH 
 
a
 The abbreviations s, as, ν, δ, β, sci, r, w  mean symmetric, asymmetric, 
stretch, deformation, bend, scissoring, rock and wag respectively. 
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6.2. Figures 
 
 
Figure A1 – Sweet spot plot of the CCF design 
 
 
 
Figure A2 – Regression coefficient plot for the FF design of robustness 
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Figure A3 – Summary of fit for the FF design of robustness 
 
 
 
Figure A4 – Microscopy image of MIP2 polymer particles 
 
 
 
Figure A5 – Intensity shift between the polymer particles 
synthesized in the presence and absence of PMP base.     
- 
 
50m 
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Figure A6 – IR spectra of IPU and the MAA-IPU complex 
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Figure A7 – Chemical shifts of all the protons during the titration of 10 mM IPU:PMP 
(1:1) with 0-5 equivalent MAA – the arrows indicate the increase of concentration           
- 
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Figure A8 – Rose-Drago plots of T1 and T2. The black line points the average intersection 
of the lines. The chosen lines are in agreement with the Weber criteria (vide infra)
227,228
.        
- 
Rose-Drago plot of H1 signal of the titration of 5mM IPU with MAA (T1) 
-
0.0100 
-
0.0050 
0.000
0 
0.005
0 
0.010
0 
0.015
0 
0.020
0 
0.025
0 
0.030
0 
0 0.2 0.4 0.6 0.
8 1 1.2 1.4 1.6 1.8 2 
Linear 
(eq=0.4) 
Linear 
(eq=0.6) 
Linear 
(eq=0.8) 
Linear 
(eq=1.0) 
1/K [1/M] 
Δδmax (ppm) 
Rose-Drago plot of H1 signal of the titration of 10mM IPU with MAA (T2) 
-0.0100 
-0.0050 
0.0000 
0.0050 
0.0100 
0.0150 
0.0200 
0 0.2 0.4 0.6 0.
8 1 1.2 1.4 1.6 
Δδmax (ppm) 
Linear (eq=1.5) 
Linear (eq=1.0) 
Linear (eq=0.8) 
Linear (eq=0.6) 
Linear (eq=0.4) 
1/K [1/M] 
 143 
7. Publications resulting from the work carried out in this thesis 
 
7.1. Articles 
 
“Unraveling the nature of recognition of genotoxin selective molecularly imprinted 
scavengers: binding characterization in the presence and absence of a deprotonating agent” 
Gy. Székely, P. Pogány, M. Gil, W. Heggie, B. Sellergren 
Chemistry - A European Journal (submitted) 
 
“Green process engineering for sustainable API manufacturing: purification considerations” 
Gy. Székely, M. Gil, B. Sellergren, W. Heggie, F.C. Ferreira 
Green Chemistry (under review) 
 
“Sources of genotoxic impurities in drug synthesis: a systematic review” 
Gy. Székely, M. Sousa, F.C. Ferreira, M. Gil, W. Heggie 
Chemical Reviews (under review) 
 
“Design of experiments as a tool for LC-MS/MS method development for the trace analysis 
of the potentially genotoxic 4-dimethylaminopyridine impurity in glucocorticoids” 
Gy. Székely, B. Henriques, M. Gil, A. Ramos, C. Alvarez 
Journal of Pharmaceutical and Biomedical Analysis (dx.doi.org/10.1016/j.jpba.2012.07.006) 
 
“Design, preparation and characterization of novel molecularly imprinted polymers for 
removal of potentially genotoxic 1,3-diisopropylurea from API solutions” 
Gy. Székely, J. Bandarra, W. Heggie, F.C. Ferreira, B. Sellergren 
Separation and Purification Technology 86 (2012) 190-198. 
 
“A hybrid approach to reach stringent low genotoxic impurity contents in active 
pharmaceutical ingredients: combining molecularly imprinted polymers and organic solvent 
nanofiltration for removal of 1,3-diisopropylurea” 
Gy. Székely, J. Bandarra, W. Heggie, B. Sellergren, F.C. Ferreira 
Separation and Purification Technology 86 (2012) 79-87. 
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“Removal of potentially genotoxic acetamide and arylsulfonate impurities from crude drugs 
by molecular imprinting” 
Gy. Székely, E. Fritz, J. Bandarra, W. Heggie, B. Sellergren 
Journal of Chromatography A 1240 (2012) 52-58. 
 
“Organic solvent nanofiltration: A platform for removal of genotoxins from active 
pharmaceutical ingredients” 
Gy. Székely, J. Bandarra, W. Heggie, B. Sellergren, F.C. Ferreira 
Journal of Membrane Science 381 (2011) 21-33. 
 
“Genotoxic impurities in pharmaceutical manufacturing” 
Gy. Székely, M. Gil, W. Heggie, B. Sellergren 
Hungarian Chemical Journal LXVII (2012) 34-37. 
 
Encyclopedia on Membranes (invited contributor by Springer-Verlag, Berlin, 2012) 
 
7.2. Patents 
 
“Polymers for drug purification”  
B. Sellergren, E. Fritz, Gy. Székely (inventors) – SE1100473-6 PCT patent application 
 
“Organic solvent nanofiltration for the removal of genotoxic impurities from active 
pharmaceutical ingredients” 
Gy. Székely, J. Bandarra, W. Heggie (inventors) – PT105601 patent application 
 
7.3. Posters 
 
“Investigation of molecular recognition phenomena of genotoxin selective, methacrylate 
based molecularly imprinted polymers” 
Gy. Székely, P. Pogány, M. Gil, W. Heggie, B. Sellergren 
MIP2012 – Science and Technology, Paris, France, 27-30/8/2012 
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“Implementation of molecular imprinting technology in pharmaceutical downstream 
processing” 
Gy. Székely, M. Gil, W. Heggie, B. Sellergren 
MIP2012 – Science and Technology, Paris, France, 27-30/8/2012 
 
“Molecularly imprinted polymers as polishing phases for degenotoxification of 
pharmaceuticals” 
Gy. Székely, M. Gil, F.C. Ferreira, W. Heggie, B. Sellergren 
HPLC2012 Conference, Anaheim, USA, 16-21/6/2012 
 
“Trace analysis of potentially genotoxic aminopyridine impurities in steroids by LC-MS/MS 
technique via design of experiments” 
Gy. Székely, B. Henriques, M. Gil, C. Alvarez, A. Ramos 
HPLC2012 Conference, Anaheim, USA, 16-21/6/2012 
 
„Molecularly Imprinted Polymers and Organic Solvent Nanofiltration – A hybrid process for 
removal of 1,3-diisopropylurea impurity from Active Pharmaceutical Ingredients” 
Gy. Székely, J. Bandarra, W. Heggie, F.C. Ferreira, B. Sellergren 
Affinity 2011, Tavira, Portugal, 16-19/6/2011 
 
„Organic Solvent Nanofiltration for Removal of Genotoxins from Active Pharmaceutical 
Ingredients” 
Gy. Székely, J. Bandarra, B. Sellergren, F.C. Ferreira 
ICOM2011, Amsterdam, Netherland, 23-29/7/2011 
 
„Integration of Organic Solvent Nanofiltration and Molecularly Imprinted Polymers for the 
removal of Genotoxic Impurities from Active Pharmaceutical Ingredients” 
Gy. Székely, J. Bandarra, F.C. Ferreira, B. Sellergren 
Marie Curie Conference 2010, Torino, Italy, 1-2/7/2010 
 
„Molecularly imprinted polymers for purification of crude pharmaceutical products” 
Gy. Székely, E. Fritz, J. Bandarra, B. Sellergren 
6th International Conference on Molecular Imprinting, New Orleans, USA, 9-12/8/2010 
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„Molecularly imprinted polymers for purification of crude pharmaceutical products” 
E. Fritz, Gy. Székely, B. Sellergren 
3rd EuCheMS Chemistry Congress, Nurnberg, Germany, 29.8-2.9/2010 
 
7.4. Lectures 
 
“A hybrid approach to reach stringent low genotoxic impurity contents in APIs” 
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 Graduate Student Symposium on Molecularly Imprinted Polymers 
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“Molecular imprinting and organic solvent nanofiltration as new technologies for the 
purification of active pharmaceutical ingredients” 
1
st
 IRMED Summer School on Molecularly Imprinted Polymers 
La Vieille Perrotine, Ile d'Oléron, France, 16-21/5/2011 
 
Various research progress presentations at NEMOPUR Marie 
Curie ITN consortium organized project meetings: 
 
Imperial College, London, UK, 12/7/2012 
Imperial College, London, UK, 27/9/2011 
Technical University of Dortmund, Dortmund, Germany, 8/2/2011 
Imperial College, London, UK, 16-17/9/2010 
Lonza, Visp, Switzerland, 16/4/2010 
Technical University of Dortmund, Dortmund, Germany, 19/11/2009 
GlaxoSmithKline, Stevenage, UK, 23/10/2009 
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